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Abstract
The process of programmed cell death (PCD) is a prevalent area of scientific research and is
characterized by a highly complex proteolytic cascade. PCD is involved in development, homeostasis and
the immune response. Further, unregulated PCD has been implicated in various, often, devastating
pathologies including cancer, autoimmune diseases and neurodegenerative disorders. The importance of
PCD in human health and disease has led to the widespread utilization of genetically encoded reporters
for the non-invasive imaging of PCD in vitro and in vivo; however, it is currently not well understood
whether the reporters themselves are susceptible to inactivation and/or degradation during PCD.
Molecular reporters that do exhibit an unexpected sensitivity to their environment could lead to
ambiguous findings and/or inaccurate conclusions. Interestingly, we have found that the commonly used
bioluminescent reporter protein, Firefly Luciferase (fLuc), exhibits a rapid loss in activity in cells
undergoing PCD. In contrast, a variant of Renilla Luciferase, RLuc8, demonstrated quite stable activity
under the same conditions. Following extensive inhibition analyses, it was determined that reactive
oxygen species (ROS), particularly hydrogen peroxide (H2O2), play a large role in the disparity between
fLuc and RLuc8 activity, in cells undergoing PCD. ROS are natural byproducts of oxygen metabolism that
are normally regulated by antioxidants; if the balance between ROS and antioxidants becomes skewed,
cells can enter a state of ‘oxidative stress.’ It has been reported that many cases of PCD are associated
with elevated levels of ROS. Consistent with these reports, when fLuc and RLuc8 were intracellularly
coexpressed, it was found that the bioluminescence ratio, RLuc8:fLuc, served as a useful metric to report
on caspase-dependent and –independent PCD in vitro and in vivo in an ROS-mediated manner. It is
envisioned that this ratiometric reporter could have widespread impact on research endeavors involving
the aforementioned maladies, including therapeutic development and evaluation.
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ABSTRACT

THE DEVELOPMENT, CHARACTERIZATION AND IMPLEMENTATION OF
A REACTIVE OXYGEN SPECIES-RESPONSIVE RATIOMETRIC
BIOLUMINESCENT REPORTER AND ITS USE AS A SENSOR FOR
PROGRAMMED CELL DEATH

Julie Czupryna

Advisor: Andrew Tsourkas, Ph.D.

The process of programmed cell death (PCD) is a prevalent area of scientific research and
is characterized by a highly complex proteolytic cascade.

PCD is involved in

development, homeostasis and the immune response. Further, unregulated PCD has been
implicated in various, often, devastating pathologies including cancer, autoimmune
diseases and neurodegenerative disorders. The importance of PCD in human health and
disease has led to the widespread utilization of genetically encoded reporters for the noninvasive imaging of PCD in vitro and in vivo; however, it is currently not well understood
whether the reporters themselves are susceptible to inactivation and/or degradation during
PCD. Molecular reporters that do exhibit an unexpected sensitivity to their environment
could lead to ambiguous findings and/or inaccurate conclusions. Interestingly, we have
found that the commonly used bioluminescent reporter protein, Firefly Luciferase (fLuc),
v

exhibits a rapid loss in activity in cells undergoing PCD. In contrast, a variant of Renilla
Luciferase, RLuc8, demonstrated quite stable activity under the same conditions.
Following extensive inhibition analyses, it was determined that reactive oxygen species
(ROS), particularly hydrogen peroxide (H2O2), play a large role in the disparity between
fLuc and RLuc8 activity, in cells undergoing PCD. ROS are natural byproducts of
oxygen metabolism that are normally regulated by antioxidants; if the balance between
ROS and antioxidants becomes skewed, cells can enter a state of ‘oxidative stress.’ It has
been reported that many cases of PCD are associated with elevated levels of ROS.
Consistent with these reports, when fLuc and RLuc8 were intracellularly coexpressed, it
was found that the bioluminescence ratio, RLuc8:fLuc, served as a useful metric to report
on caspase-dependent and –independent PCD in vitro and in vivo in an ROS-mediated
manner. It is envisioned that this ratiometric reporter could have widespread impact on
research endeavors involving the aforementioned maladies, including therapeutic
development and evaluation.
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Chapter 1: Introduction to bioluminescence imaging,
programmed cell death and reactive oxygen species
1.1 Introduction
Complete understanding of physiology and disease states requires the capability
to monitor specific cellular and molecular phenomena over biologically relevant time
scales. Molecular imaging technologies provide investigators with the ability to noninvasively examine a wide variety of biological processes, both in vitro and in animal
models.

Bioluminescence imaging (BLI) is a molecular imaging modality wherein

luciferase enzymes oxidize a substrate to produce light. Attributes of BLI include high
sensitivity, cost-effectiveness, simplicity, virtually non-existent background signals, highthroughput screening potential and ability to acquire temporal information in cells and in
live animal models. While safety concerns regarding transgene expression preclude BLI
usage in humans, it remains a powerful tool for pre-clinical in vivo imaging studies.
Luciferases and their substrates have been engineered to report on gene
expression levels, promoter activity and various other molecular processes, including
programmed cell death (PCD), which is known as an exquisitely regulated ‘cell suicide’
mechanism. PCD is the primary contributor to the removal of excessive and damaged
cells and plays a role in development, aging and the immune response. However, many
pathologies can result from unregulated PCD including cancer, Alzheimer’s disease and
autoimmune disorders. Thus, the ability to monitor aberrant PCD could have widespread
impact on the development of therapeutics for diseases characterized by this process.
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We have found that in cells undergoing PCD, the activity of wild-type Firefly
Luciferase (fLuc) is rapidly lost, and under the same conditions the activity of a Renilla
Luciferase variant (RLuc8) remains relatively stable (Chapter 3). Investigation into the
mechanism behind this disparity suggested that reactive oxygen species (ROS),
particularly hydrogen peroxide (H2O2), play a dominant role (Chapter 4). Therefore it
was hypothesized that when fLuc and RLuc8 were coexpressed in cells, their activity
differential could be used in a ratiometric manner (i.e. RLuc8:fLuc) to relay information
on intracellular ROS levels. It is well established that certain chemotherapeutic agents
can generate ROS in their induction of cell death and that ROS often serve as mediators
in caspase-dependent and –independent pathways. Consistent with these findings, we
have found that levels of intracellular H2O2 increased in multiple cell types treated with a
variety of PCD inducers and that this increase correlated well with RLuc8:fLuc ratios
(Chapter 5 and Chapter 6). The implementation of the ratiometric reporter in murine
models demonstrated that it was capable of detecting PCD in drug-treated tumors and
that this detection was related to intratumoral ROS levels (Chapter 7). In this chapter,
extensive background is provided on BLI, PCD and ROS.

1.2 Background
1.2.1 Bioluminescence Imaging
1.2.1a Overview
In order to obtain comprehensive knowledge regarding normal and pathological
physiology, it is important for biological processes related to these states to be monitored
2

in real-time and over biologically relevant time scales. Molecular imaging techniques
can facilitate the ability of investigators to non-invasively scrutinize the spatiotemporal
dynamics of specific biological processes without sacrificing cells or animals (see (1) for
extensive review).

The field of molecular imaging encompasses many modalities

including magnetic resonance imaging (MRI), optical imaging, signal photon emission
spectroscopy (SPECT), ultrasound, and positron emission tomography (PET).
Bioluminescence imaging (BLI) is an optical molecular imaging modality that harnesses
the light produced during enzyme (luciferase)-mediated oxidation of a substrate (e.g.
luciferin or coelenterazine) when the enzyme is expressed in cells, tissues or animals (see
(2) for review).

BLI has been utilized in studies examining tumor growth and

metastasis(3), gene therapy(4), cell tracking(5), infection progression(6), gene
expression(7) and toxicology(8), among others.
1.2.1b Types of luciferases and their substrates
Various types of luciferases have been identified across diverse phyla; however,
only a few of these have been characterized sufficiently for mammalian use. Even
though structures, sizes, substrates and emission wavelengths of these enzymes are quite
varied, their mechanisms of light production are generally similar: during the oxidation
of luciferin or coelenterazine by luciferase, an excited intermediate is generated and upon
its relaxation to ground state, it emits a photon of light(9). The most commonly used
luciferases and key attributes are highlighted in Table 1.1.
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Table 1.1. Common luciferases and selected characteristics. Adapted from (2).

Luciferase

Luciferin

Firefly
(fLuc)

D-luciferin

Peak
emission
(nm)
612

Click beetle
red (cbRed)
Click beetle
green
(cbGreen)
Renilla
reniformis
(RLuc)

D-luciferin

611

D-luciferin

Gaussia
princes
(gLuc)

Size
Comments
(kDa)

Reference(s)

61

(10)

61

Codon-optimized for
mammalian
expression; requires
ATP
Requires ATP

(10, 11)

544

61

Requires ATP

(10, 11)

Coelenterazine 480

36

(9, 11, 12)

Coelenterazine 480

36

Does not require
ATP; codonoptimized for
mammalian
expression
Does not require
ATP; naturally
secreted from cells

(12)

The luciferases from Firefly (fLuc) and Renilla reniformis (RLuc) are two of the
most widely used bioluminescent proteins in current research. Fluc emits light at ~600
nm making it more suitable for in vivo imaging compared with the ~480 nm light emitted
by RLuc, as fLuc photons are less absorbed by animal tissue. To produce light, fLuc
must react with its substrate, luciferin, in the presence of ATP, oxygen and magnesium.
RLuc requires its substrate, coelenterazine, and oxygen to produce light. The emission
spectra of the luciferases are depicted in Figure 1.1.
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Figure 1.1. Emission spectra of various bioluminescent proteins. Adapted from (10).

Despite the low emission wavelength of RLuc, both fLuc and RLuc are
commonly used together in both cell culture(13) and in vivo(14), with RLuc often serving
as a transfection control for studies involving fLuc under the control of a specific
promoter, and vice verse. The distinct substrates of these enzymes also allow for their
use in this manner since after washing or clearance of the substrate for the first enzyme
examined, a second substrate may be administered to specifically examine the second
enzyme (see Table I). An alternative to washing/clearance involves using spectral
separation to distinguish the signal from each protein. Each luciferase emits at a different
wavelength of light; thus if the imaging equipment possesses emission filters appropriate
for each enzyme, substrates can be administered at the same time, and each signal can be
spectrally separated.
1.2.1c BLI: general considerations
There are many advantages of utilizing BLI as a molecular imaging modality.
Since bioluminescent proteins are genetically encoded, once validated, they can be
employed in a range of vectors to investigate a wide variety of intracellular pathways(1517). A study using BLI to examine intracellular pathways involved heat shock proteins
(HSPs), which are proteins utilized in cellular heat shock response. Heat shock response
5

occurs in cells undergoing thermal and other stresses and can abrogate resulting cellular
damage and programmed cell death (see (18) for review). This group used transgenic
mice expressing fLuc under the control of an HSP promoter to assess spatiotemporal
patterns of HSP70 expression after thermal stress induced by laser irradiation(17). BLI
has been used to investigate many other promoters in addition to HSP, including βcatenin promoters(19), insulin promoters(20), ubiquitin promoters(21) and hepatitis B
virus promoters(22).
BLI has been used in conjunction with positron emission tomography (PET) to
examine tumor hypoxia and related molecular events (15).

Tumor hypoxia was

monitored using a hypoxia-sensitive PET tracer, followed by investigation of hypoxia
inducible factor (HIF), a transcription factor that helps tumor cells adapt to low oxygen
environments(23), using BLI. Specifically, a fusion protein of HIF-1α-luciferase was
monitored to assess the stability of HIF-1α, the subunit of HIF that is a target for
degradation under normoxic conditions and stabilization under hypoxic conditions(24).
In the same study, the gene encoding fLuc was placed downstream of a hypoxia response
element (HRE) promoter to monitor HIF-driven gene expression.
The optical properties of some bioluminescent proteins allow for depths of up to a
few centimeters to be imaged in vivo(25, 26). The emission wavelength of fLuc is ~600
nm, making it less likely than fluorescent light to be attenuated in animal tissue. Tumor
cells expressing fLuc have been imaged in rat colon(25) and mouse lungs(26), illustrating
the potential of BLI to image beyond superficial depths in vivo. Also, the intrinsically
low bioluminescence of tissues allows for greater signal-to-background ratios compared
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to fluorescence. For example, when using fluorescence imaging, the autofluorescence of
tissues causes unwanted background signal, effectively reducing this ratio.
In addition to its cost-effectiveness, robustness and simplicity, BLI has recently
proven to be quite useful in high-throughput screening assays(27-29). For example,
malignant cells expressing fLuc were co-cultured with non-fLuc stromal cells and this coculture was screened with anti-neoplastic candidates(27).

Here, it was possible to

specifically identify the effects of the compounds on malignant cells in an environment
more representative of in vivo conditions as tumor-stroma interactions play key roles in
tumor biology(30, 31). This ability to distinguish between cancerous and normal cells
using this method holds an advantage over traditional viability assays (discussed later)
where the high background of the stromal cells could skew information on malignant cell
viability.
However, like any imaging modality, BLI possesses certain disadvantages that
should be considered before its use in study design. Safety concerns preclude genetically
encoded reporters (including bioluminescent proteins) from being used in humans, with
the exception of gene therapy. Additionally, while the multi-centimeter depth penetration
of bioluminescent proteins is greater than that of fluorescent molecular reporters, it
nonetheless limits their in vivo application to small rodents.

Another consideration

regarding BLI is the potential for the proteins themselves to interfere with intracellular
processes and possible phenotypic changes. Notably, it has been shown that colon cancer
cells expressing fLuc were unable to grow into tumors in immunocompetent rats as
opposed to parental colon cancer cells(32); it was hypothesized that the high expression
levels of fLuc created unwanted immunogenecity and/or altered growth rates. Finally,
7

issues

with

substrate

administration

include

altered

substrate

catalysis

and

pharmacokinetics due to disease states and cellular transporters, respectively. The tumor
microenvironment is often hypoxic, and since the fLuc-luciferin reaction is oxygen
dependent, this reaction may be impeded and resulting light output diminished.
Additionally, the cellular membrane pumps ABCG2(29) and MDR1 P-glycoprotein(33)
have been shown to transport luciferin and coelenterazine, respectively, out of cells,
potentially hindering light output of the bioluminescent enzymes. Taken together, these
issues can lead to inaccurate findings and ambiguous conclusions.
1.2.2 Programmed Cell Death
1.2.2a Overview
Programmed cell death (PCD) is a major contributor to the removal of excessive
and damaged cells through an exquisitely regulated ‘cell suicide’ mechanism and is an
essential process that is involved in development(34), aging(35), homeostasis(36) and the
immune response(37). Apoptosis, or Type I PCD, is mechanistically characterized by a
proteolytic cascade involving cysteine-aspartic proteases (caspases)(38); these caspases
can be distinguished by the specific amino acid sequences wherein they cleave(39).
Many types of caspases can be activated during apoptosis, however, the activation of
caspase-3, an effector caspase, is required to complete the process (40); this necessity
makes caspase-3 an often utilized target in studies assessing PCD.

Additional

characteristics of apoptosis include membrane blebbing, chromatin condensation, and
nuclear fragmentation and the process ends with phagocytic engulfment of the dead cell
and debris(36).
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While apoptosis has been thoroughly characterized and is generally accepted as
the most prevalent form of PCD, a number of alternative cell death pathways have been
identified and are referred to as ‘caspase-independent cell death pathways’.

These

pathways serve many purposes in vivo including embryonic removal of interdigital
webs(41), the death of chondrocytes controlling bone growth(42), and the negative
selection of lymphocytes(34, 35).
One form of caspase-independent PCD involves the mitochondria. Under certain
stimuli the mitochondria release the apoptosis-inducing factor (AIF) from the
intermembrane space(43); AIF enters the nucleus and eventually causes the degradation
of chromatin into large (50 kb) chromatin fragments, in contrast to the oligonucleosomal
DNA fragments that are formed when certain DNase’s are activated by caspases(43, 44).
The exact mechanism behind chromatin degradation by AIF remains unknown. Another
mitochondrial-related PCD mechanism involves signaling from the tumor necrosis factor
receptor 1 resulting in mitochondrial production of reactive oxygen species (ROS) and
necrosis-like PCD(40).
Autophagy, or type II PCD, is a type of caspase-independent cell death that
mechanistically manifests cellular metabolism through the cell’s own lysosomal
machinery (see (45) for review). In cells undergoing type II PCD, autophagic vesicles
are formed to engulf various cytoplasmic components and these vesicles subsequently
fuse with lysosomes to form autophagolysosomes.

Various digestive enzymes are

present in the lysosomal machinery, including aspartate, zinc and cysteine proteases
(cathepsins), which are responsible for macromolecule breakdown. Autophagy can play
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multiple roles as it can be a method for cells to adapt to cellular stresses and avoid
apoptosis, or it can be an alternative method of PCD if apoptosis is inhibited(46).
Figure 1.2 illustrates pathways involved in both caspase-dependent and caspaseindependent cell death. Caspase-dependent PCD can result from various onslaughts;
however, regardless of induction method, this process is characterized by the activation
of initiator caspases (e.g., caspases-2 and –8), eventually leading to the activation of
effector caspases (e.g., caspase-3). Various stimuli can also induce caspase-independent
PCD, however this type of cell death is usually characterized by increased proteolysis.
ROS production and DNA damage can play prominent roles as well.
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Figure 1.2. Illustration of caspase-dependent and caspase-independent PCD pathways. Reprinted with
permission from (47).

Given the myriad processes in which PCD is involved, it is not surprising that
unregulated PCD can result in various devastating pathologies, including autoimmune
diseases, neurodegenerative disorders, and cancer (see (48) for review). Table 1.2 lists
conditions that may result from either increased or inhibited PCD. Accordingly, many
sensors have been developed to monitor and image PCD both in vitro and in vivo with the
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impression that these sensors will aid in the development and evaluation of therapeutics
designed to combat the many ailments associated with unregulated PCD.

Increased PCD

PCD inhibition

Table 1.2. Pathogenic conditions related to PCD.

Condition
Cancer
Carcinomas with p53 mutations
Hormone-dependent tumors
Breast
Prostate
Autoimmune diseases
Lupus
Viral Infection
Poxviruses
Adenoviruses
AIDS
Neurodegenerative disorders
Alzheimer’s disease
Huntington’s disease
Ischemic Injury
Myocardial Infarction
Stroke

Reference(s)
(49, 50)
(51)
(52)
(53)
(54)
(55, 56)
(49-51)
(52-54)
(55, 56)
(57, 58)
(57, 59)

1.2.2b Current Sensors for Apoptosis
Over the past decade, a large number of probes have been specifically developed
for assessing apoptosis in cell culture and animal model studies. Since apoptosis occurs
via a complex signaling cascade that is tightly regulated, these probes have been designed
to take advantage of a number of different molecular targets to identify apoptosis. Some
of the most commonly used agents involve measuring the level of caspase activity.
These probes can generally be categorized as fluorogenic peptide probes, fluorescent
molecular reporters, or bioluminescent reporters. However, not all sensors for apoptosis
12

rely on caspase activity. Phosphatidylserine (PS) targeting agents are designed to detect
PS phospholipids that have flipped from the inner-leaflet to the outer-leaflet of
membranes of cells undergoing apoptosis.

Also, various commercial sensors are

available to detect DNA fragmentation levels, dead-cell proteases and enzymes related to
cellular viability. The following subsections will expand upon each of these types of
sensors.
Fluorogenic Peptide Probes
Fluorogenic peptide probes for caspases are typically comprised of a peptidic
protease substrate, e.g. a caspase recognition motif, intervening between two
fluorophores or a fluorophore and a quencher(57-63). Peptidic cleavage by the target
enzyme separates the fluorescent/quenching moieties and the subsequent change in the
fluorescent emission spectrum is used to indicate enzymatic activity.

Figure 1.3

represents a schematic of fluorogenic peptide probes for caspase-3; a quencher is attached
to a fluorophore via a DEVD amino acid linkage, effectively quenching the fluorescence
of the excited fluorophore.

After caspase-3 cleavage of DEVD (its recognition

sequence), the quencher is removed and the fluorophore emission is restored.
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Figure 1.3. Schematic of a fluorogenic peptide probe for caspase-3. A fluorophore is conjugated to a
quenching molecule via the DEVD amino acid sequence. Thus when excited, the fluorophore’s emission is
quenched. However upon caspase-3 mediated cleavage of its target sequence, DEVD, the quencher is
released and the fluorophore emits light.

While fluorogenic peptide probes represent an important breakthrough in caspase
activation detection, their sensitivity can be less than ideal, due to incomplete quenching
before cleavage or spectral overlap of the two fluorophores in fluorescence resonance
energy transfer (FRET)-based assays. Additional problems are manifested in vivo where
autofluorescence of the living subject and/or pharmaceuticals can further reduce
sensitivity. As both caspase activity and the biodistribution/pharmacokinetics of these
probes affect the fluorescence intensity over time, imaging the temporal dynamics of
apoptosis using these sensors can be challenging. Finally, cytoplasmic delivery of these
probes can present additional issues as they may become non-specifically trapped and
degraded in the lysosomes.
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Fluorescent Molecular Reporters
Another category of fluorescent imaging sensors for apoptosis consists of
fluorescent molecular reporters (64-66). These probes are defined by two fluorescent
proteins with overlapping emission-excitation wavelengths that are linked by a proteasespecific recognition sequence. For example, the emission spectrum of cyan fluorescent
protein (CFP) significantly overlaps the excitation spectrum of yellow fluorescent protein
(YFP). When these two proteins are in close proximity (i.e., connected by the amino acid
sequence DEVD), the excitation of CFP results in emission from YFP, as a result of
FRET. This phenomenon is depicted in Figure 1.4A. The tethering of YFP to CFP with
DEVD effectively creates an activatable sensor for caspase-3; with increasing caspase-3
activation, the DEVD sequence is cleaved, the proteins separate, YFP emission decreases
and CFP emission increases with CFP excitation(66). A summary of this mechanism is
illustrated in Figure 1.4B.
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Figure 1.4. Schematic of FRET and its use in a reporter for caspase-3 activity. (A) In an activatable
reporter for caspase-3 activity, CFP and YFP are fused together via the DEVD sequence, resulting in
FRET. (B) Upon caspase-3 activation, its target DEVD sequence is cleaved, and CFP emission increases
as the distance between the fluorophores increases (i.e., FRET is no longer occurring).

Fluorescent molecular reporters are genetically encoded, thus their synthesis costs
are typically less than fluorogenic peptide probes. Another advantage of these reporters
is their constitutive expression reduces their chances of lysosomal degradation and
endosomal entrapment, two concerns of fluorogenic peptide probes.

However

fluorescent molecular reporters still suffer from similar background and autofluorescence
issues, especially given the dearth of highly fluorescent near-infrared (NIR) molecular
reporters available. It should be noted that very recently, an NIR fluorophore has been
developed that could allow for much improvement on these sensors in regards to in vivo
imaging capability(67).
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Bioluminescent Reporters
To avoid sensitivity issues commonly associated with fluorogenic sensors, several
groups have recently employed bioluminescent caspase reporter systems for PCD
detection. One of these sensors utilized a recombinant Firefly luciferase (fLuc) reporter
protein that was flanked on both sides by an estrogen receptor regulatory domain protein
(ER)(68).

The presence of these two large ER proteins (35 kDa each) effectively

silenced the enzymatic activity of fLuc by ~90%. Additionally, a DEVD sequence was
included between fLuc and each ER protein, which allowed for caspase-3 mediated
removal of the silencing ER domains and thus restoration of fLuc activity.

An

illustration of this sensor is shown in Figure 1.5.

Figure 1.5. Schematic of ER-fLuc-ER sensor for caspase-3. Under normal cellular conditions, the large
ER proteins flank the fLuc protein via DEVD linkages, hindering its enzymatic activity. When caspase-3 is
activated in PCD inducing conditions, the DEVD sequences are cleaved, the ER proteins are released and
fLuc activity is restored.
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A number of drawbacks to this design exist, including that two proteolytic events
are required to completely restore luciferase activity, the protease cleavage sites may be
inaccessible due to the large flanking ER proteins, and that the usage of ER proteins
themselves, which are endogenously expressed in mammalian cells, could provoke overly
complex intracellular localization/dynamics, potentially leading to alternative proteolytic
pathways and ambiguous bioluminescent signals. Furthermore, it should be noted that
although the fLuc bioluminescence increases with increasing caspase-3 activity, this may
be abrogated by accelerated degradation of functional enzyme under apoptotic
conditions, as observed in this thesis.
Another bioluminescent approach for imaging apoptosis via caspase-3 activation
in vivo made use of a split fLuc reporter strategy (69). In this sensor, fLuc is expressed in
two parts, NH2- and COOH-terminal sections, rendering it functionally inactive. When
the two halves are brought into close enough proximity, enzymatic activity is restored,
producing a bioluminescent signal in the presence of proper substrate. In the apoptotic
probe design, small, yet strongly interacting, peptides and the DEVD sequence were
incorporated to create a caspase-3 activatable sensor(70).

Specifically, strongly

interacting peptides, peptide A and peptide B (71, 72), were fused to the N- and Cterminal halves of fLuc, respectively, creating ANLuc and BCLuc (Figure 1.6). These
fusions are positioned sequentially with and intervening DEVD sequence.

Under

apoptotic conditions, active caspase-3 cleaves at the DEVD site, which allows peptide A
and peptide B to interact, effectively bringing the fLuc halves into favorable proximity,
and the bioluminescence activity of fLuc is restored.
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Figure 1.6. Schematic of split fLuc reporter for caspase-3. Under normal conditions, the NH2- and
COOH-terminal sections of fLuc (NLuc and CLuc, respectively) are attached to small, strongly
interacting peptides (PePA and PepB) with and intervening DEVD sequence.

Under apoptotic

conditions, caspase-3 is activated and cleaves the DEVD sequence. The fLuc fragments are separated
and PepA and PepB interact to bring the fragments into close enough proximity to reconstitute the
activity of the fLuc enzyme.

Although this probe exhibits improvements over previous split reporter
technologies, where drawbacks can include high-background and non-ideal signal-tonoise ratios (73), the requirement of two explicit events (i.e., DEVD cleavage and
peptideA-peptideB interaction) to generate a functionally indicator of cell death, and the
potential for an accelerated rate of enzyme degradation in cells undergoing PCD may
present unforeseen difficulties in the utilization of this sensor.
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Another activatable bioluminescent sensor for apoptosis that has found success in
vivo makes use of the DEVD sequence conjugated to aminoluciferin(74, 75). This
conjugation renders the luciferin unable to act as a proper substrate for fLuc until the
peptide sequence is cleaved off upon caspase-3 activation. This method allowed for the
detection of caspase-3 in murine tumor models, however some potential limitations must
be addressed.

First, it has been reported that the DEVD-luciferin is toxic to the

animals(74, 75), forcing all imaging experiments to be ceased 2 hours after DEVDluciferin injection, thus limiting the temporal dynamic range of this sensor significantly.
Additionally, extraneous background signal due to nonspecific degradation in serum,
extracellular space, lysosomes and non-apoptotic cells may decrease the sensitivity of this
approach.

Also, the peptide conjugation may affect the biodistribution and

pharmacokinetics of the caged aminoluciferin and this reagent can be quite costinefficient.

Phosphatidylserine Targeting Agents
Phosphatidylserine (PS) is a phospholipid that is typically found in the innerleaflet of cell membranes. In apoptotic cells, PS is often flipped to the outer leaflet of the
cell membrane(76). This biological phenomenon has brought about the use of PS as a
molecular marker for apoptotic cells, most commonly with Annexin V, a naturally
occurring protein with avid binding affinity for PS(77). It has been found that apoptotic
cells can be detected in vivo by labeling Annexin V with various contrast agents,
including fluorescent dyes(78), iron oxide nanoparticles(79), technetium 99m(80) and
PET agents(81). The cost-effectiveness of the fluorescently labeled Annexin V make
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them an attractive choice for the routine imaging of apoptosis; however autofluorescence
remains a concern, as does the non-specific localization of the labeled Annexin V agents
in untreated tumors due to the enhanced permeability and retention (EPR) effect.
Commercial Sensors for Apoptosis
Many commercial sensors have been developed to investigate apoptosis and its
related molecular processes. The terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay, first developed in 1992(82), detects DNA strand breaks after
terminal deoxynucleotidyl transferase (TdT) incorporates labeled dUTP at break sites;
DNA fragmentation is a hallmark of cells undergoing PCD(83). CytoTox Glo is a
bioluminescent assay that measures the activity of certain intracellular proteases (deadcell proteases) that are released from cells with compromised membranes. Additionally,
assays that measure the reduction of various tetrazolium salts, such as MTT(84),
XTT(85) and WST-1(86), by intracellular dehydrogenases which are active only in living
cells are commonly used. However, it is important to note that these reduction assays are
actually a measure of cell viability as opposed to cell death. Although all of these assays
clearly have utility in measuring PCD in cell culture, most of them are not appropriate for
real-time imaging/detection and/or imaging in animal models of disease.

These

limitations arise from the need for cell lysis, the use of membrane impermeable
substrates, and/or the use of green fluorescent dyes, which are generally masked by
autofluorescence in vivo.

21

1.2.2c Current Sensors for Caspase-Independent PCD
While caspase-3 activation is considered a gold standard for identification of cells
undergoing apoptosis, caspase-independent PCD has recently been attracting attention in
regards to cancer drug development. Anticancer drug resistance and tumorigenesis have
been linked to the ability of certain cancer types to evade caspase activation(87, 88); thus
it can be envisioned that therapeutics developed to induce caspase-independent PCD
could have widespread impact. To date, there exist no molecular imaging sensors to
specifically monitor caspase-independent PCD in vivo.

Certainly, some of the

aforementioned assays, namely TUNEL, CytoTox-Glo, MTT, and WST-1 have the
capability to provide information on caspase-independent cell death, but suffer from the
same previously mentioned limitations.
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1.2.3 Reactive Oxygen Species, Oxidative Stress and Cell Death
1.2.3a Overview
Reactive oxygen species (ROS) are natural byproducts of intracellular metabolic
processes, such as oxidation of xanthine by xanthine oxidase(89), uncoupling of the
mitochondrial transport chain(90, 91) and oxidation of NADPH by NADPH oxidase(92,
93), and have been shown to play a role in cell signaling and function(94-96). For
example, it has been shown that the growth factors tumor necrosis factor alpha (TNF
alpha) and basic fibroblast growth factor (bFGF) induce increases in ROS production in
chondrocytes(97). The ROS production seen here can stimulate the expression of early
response genes (e.g., c-fos and c-jun), which play roles in cell proliferation and
differentiation. Types of ROS include the hydroxyl radical (•OH), the superoxide radical
(O2•-), hydrogen peroxide (H2O2) and the peroxynitrite anion (ONOO-). In a balanced
cellular state, the level of ROS is typically controlled by various antioxidants that are
either expressed in cells (e.g. glutathione(98), superoxide dismutase(99) and
catalase(100)) or supplied through diet (e.g. vitamin E(101) and β-carotene(102)). When
unnecessary excesses of ROS are present, cells enter a state of ‘oxidative stress,’ wherein
various cellular components can be damaged, including DNA(103), RNA(104),
proteins(101-104) and lipids(105).

Pathological conditions that have been linked to

oxidative stress include atherosclerosis(106), cancer(107), cystic fibrosis(108), type-2
diabetes(109) and Alzheimer’s disease(110).
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1.2.3b Protein modification, damage and degradation by ROS
While ROS-mediated damage of DNA, RNA and lipids are significant topics for
discussion, the body of work included in this thesis focuses on the effects of oxidative
stress on proteins. A summary of common ROS and mechanisms of protein oxidation is
provided in Figure 1.7 and these mechanisms are described in more detail in subsequent
sections.

Figure 1.7.

Schematic representing potential pathways for intracellular protein modification and/or

degradation.

Superoxide
Superoxide (O2•-) is the primary free radical formed within the cell by the
reduction of molecular oxygen and it can act as either an oxidant or reductant. The
mitochondria produce a large fraction of this radical (see (111) for review) due to their
consumption of oxygen to produce energy for the cell. However, O2•- is not particularly
reactive in biological systems and does not itself cause much oxidative damage(112),
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rather it serves as a precursor to other oxidizing agents. The principal reaction of O2•- is
to react with itself to produce H2O2 and oxygen (O2), a reaction known as dismutation.
Superoxide dismutation can be spontaneous or can be catalyzed by superoxide dismutase
(SOD, (99)). Additionally, O2•- is important in the production of the highly reactive
hydroxyl radical (•OH). In this process, O2•- reduces metal ions (e.g. Fe3+  Fe2+) by
donating one electron, and these metal ions then act as catalysts to convert H2O2 into
•

OH.

Hydrogen Peroxide
Hydrogen peroxide (H2O2) is a natural byproduct of oxygen metabolism and is
necessary for the function of many enzymes in the intracellular environment (e.g. protein
tyrosine phosphatases and the lipid phosphatase PTEN)(113). An important attribute of
H2O2 is that it is small enough to pass through cell membranes and thus cannot be
excluded from cells. H2O2 is a powerful oxidizing agent that can directly and indirectly
modify many amino acids (see (114) for review), often creating hydroxyl- or carbonylderivatives. While the effect of protein oxidation can vary, it has been shown in some
cases that oxidation can destabilize a protein’s native structure and result in the
impairment of protein function and activity loss(115, 116). Loss of secondary structure
has also been shown to enhance the rate of protein degradation by the 20S
proteasome(117). In contrast, the presence of oxidized amino acids alone does not seem
to be a signal for degradation even though in vitro studies have suggested that proteins
oxidized by H2O2 may be more susceptible to proteolytic attack(118). It should also be
noted that in the presence of peroxidase (e.g. myeloperoxidase, lactoperoxidase and
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cyclooxygenase) H2O2 can also produce tyrosyl radicals, which can subsequently
dimerize to form dityrosine, which can further lead to protein cross-linking and
aggregation(119-121).

Hydroxyl Radical
The hydroxyl radical (•OH) is generally considered to be the most powerful
oxidizing species in biological systems, and similarly to H2O2, can also pass through
membranes and thus cannot be kept out of cells.

The oxidative attack of protein

backbones is initiated by the •OH-dependent abstraction of the α-hydrogen atom of an
amino acid residue to form a carbon-centered radical(122). Here, the •OH may be
created by the radiolysis of water or the metal-catalyzed cleavage of H2O2. In biological
systems, the majority of •OH radicals are produced when iron or copper react with H2O2,
commonly referred to as the Fenton reaction.
Once a carbon-centered radical is formed, it can give rise to protein cross-links,
peptide-bond cleavage (via diamide or α-amidation pathways), or direct oxidation of
amino acids(122). The direct oxidation of lysine, arginine, proline and threonine residues
may result in the formation of carbonyl derivatives (e.g. semialdehydes)(121, 122).
Alternatively, carbonyl groups may be introduced into proteins by reactions with
aldehydes produced during lipid peroxidation(123) or with other reactive carbonyls
generated by the reduction or oxidation of carbohydrates(109).

Lipid peroxidation

products can diffuse across membranes, thus allowing amino acids and proteins relatively
far from the initial site of peroxidation product formation to be modified(124).
Interestingly, protein carbonylation as a result of lipid-derived aldehydes is more
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prevalent than carbonylation from direct amino acid oxidation(125). The degradation of
carbonylated proteins typically occurs via the 20S proteasome; however, the 26S
proteasome has also been shown to play a role in the degradation of oxidatively modified
proteins(126, 127).
Besides the direct effect of •OH on proteins, they may also damage and
destabilize lysosomal membranes, causing the subsequent release of moderate amounts of
lysosomal hydrolytic enzymes into the cytosol(128, 129). The release of some of these
enzymes, namely cathepsins, has been implicated in PCD(130, 131). Recently, it has
been suggested that an intralysosomal pool of redox-active iron is also released upon
lysosomal permeabilization, which can lead to the further production of •OH if reacted
with intracellular H2O2(132).

Peroxynitrite
Peroxynitrite (ONOO-) is formed as a result of the reaction between O2•- and
nitric oxide (NO)(133). ONOO- can be cytotoxic through various mechanisms including
initiating lipid peroxidation(134), ssDNA cleavage(135) and glutathione depletion(136).
Methionine and cysteine residues are especially vulnerable to oxidation by ONOO-,
however tyrosine and tryptophan residues are also selective targets for nitration(122).
Tyrosine nitration is particularly damaging to cells because it can interfere with protein
phosphorylation, thus compromising intracellular signal transduction networks(122, 137).
As with previously mentioned ROS, mild ONOO- modification leads to the selective
recognition and degradation of proteins by the proteasome(138).
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1.2.3c Common Probes for Imaging ROS/Oxidative Stress
Leuco dyes and fluorescein derivatives
There currently exist a number of activatable fluorescent probes for detecting
ROS. Many of these sensors fall under the category of non-fluorescent leuco dyes, i.e.
‘dihydro’ derivatives of fluorescein, rhodamine and other dyes that are oxidized back to
the parent dye by some ROS. Even though these probes have been used to detect
oxidative activity in cells and tissue, their oxidation sometimes does not easily
discriminate between the various types of ROS.

It has been reported that

dihydrodichlorofluorescein (H2DCF) and dihydrorhodamine 123 (DHR) only react with
intracellular H2O2 in reactions mediated by peroxidase, cytochrome c or Fe2+, rather than
with H2O2 alone (139-141). Additionally, it has been reported that DHR can also be
rapidly oxidized by ONOO-(142). It has been shown that dihydroethidium (DHE) and,
more recently, the mitochondrial-targeted derivative of DHE, MitoSOX Red, can provide
a more specific signal for superoxide(143, 144); however, the need for these dyes to be
excited with a wavelength of 494-510 nm likely prevents their usage in animal models.
While not as commonly utilized as H2DCF, aminophenyl fluorescein (APF) and
hydroxyphenyl fluorescein (HPF) tend to show much more specific reactivity and greater
resistance to light-induced oxidation than leuco dyes(145). Until reaction with •OH or
ONOO-, these fluorescein derivatives are essentially non-fluorescent. Also, since APF
also reacts with the hypochlorite anion (-OCl), it is possible to use APF and HPF
concomitantly to selectively detect –OCl(145), an ROS not only well-known in
neutrophil killing of bacteria, but also in microvascular damage caused by plateletactivating factor(146).

As with the leuco dyes, the excitation wavelengths of these
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fluorescein derivatives (494 nm) likely limit their usage to in vitro assays. Table 1.3
summarizes the leuco dyes and fluorescein derivatives for ROS detection.

Table 1.3. Summary of leuco dyes and fluorescein derivatives for ROS detection.

Reporter
H2DCF
DHR
DHE
MitoSox Red
APF
HPF

ROS Detected
H2O2
H2O2
O2•O2••
OH, ONOO-, -OCl
•
OH, ONOO-

λEx/λEm (nm)
494/518
505/534
510/595
510/580
494/518
494/518

Luminol and lucigenin
Luminol and lucigenin are chemiluminescent compounds that have been used to
report the presence of ROS(147-149). However, a problematic characteristic of these
sensors is the requirement of two steps for light emission(150, 151). First, either luminol
must be oxidized by •OH(152), ONOO-(153), or peroxidase/H2O2(154) or lucigenin must
be reduced by xanthine oxidase(150), the mitochondrial electron transport chain(155) or
NADPH oxidase present in phagocytes(156). Then, the resulting radicals must react with
O2•- to generate a light-emitting product. The intermediate radicals present complicating
issues as they can themselves reduce oxygen to O2•-. Therefore, luminol and lucigenin
can be both sources and detectors of O2•-, which can obviously lead to ambiguous results.
Despite these complications, luminol was recently reported to be a successful method to
image myeloperoxidase activity in animal models(157).
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Electron Spin Resonance
Electron spin resonance (ESR) spectroscopy is an imaging technique for species
that have one or more unpaired electrons, analogous to the spins of atomic nuclei in
nuclear magnetic resonance. Theoretically ESR can be used to image ROS in living
subjects, however ROS generally do not accumulate enough to be detected(158). To
overcome this issue, ROS ‘traps’ have been developed to intercept reactive/unstable
radicals and react with them to form stable radicals that can thus be detected by ESR(159,
160). While initially promising, ROS traps suffer from numerous drawbacks including
loss of the ESR signal by enzymatic and/or molecular reductions, potential toxicity from
the high concentration of traps needed to generate an ESR signal and perturbations of the
traps on normal physiological function(158).

Luciferase-based sensors
The commercial assay GSH-Glo (Promega) is the only luciferase-based assay
designed to investigate oxidative stress; it detects intracellular glutathione (GSH) levels,
which generally tend to decrease in the presence of reactive species. This assay involves
the cleavage of an inactive luciferin derivative by GSH to render the native form of
luciferin. The luciferase provided in the assay can then catalyze the luciferin and produce
a bioluminescent signal. However there are currently no established luciferase-based
sensors designed to directly detect ROS. If achieved, luciferase-based sensors could offer
many advantageous attributes including cost-effectiveness, high sensitivity, simplicity
and ability to garner temporal information in cells and animal models. Given that current
ROS imaging techniques are quite limited in their ability to provide information in vivo,
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it is expected that a luciferase-based sensor would provide unique insight into the role of
ROS in disease progression and in response to therapy under natural biological
conditions.

Furthermore, the ability to image ROS in animal models would most

certainly be expected to facilitate the development and evaluation of new therapeutics,
assist with the development of strategies to improve the efficacy of current therapeutics,
or limit the unwanted side effects of current therapeutic agents.
1.2.4 The Role of ROS/Oxidative Stress in PCD
It is well established that certain chemotherapeutic agents, such as
rituximab(161), bortezomib(162) and adaphostin(163), among others(164-166), generate
ROS in their induction of malignant cell death. However, there is growing evidence that
ROS may be involved in the regulation of both apoptotic and non-apoptotic (caspaseindependent) cell death pathways(167, 168). Recent studies have suggested that various
cell death triggers can lead to the direct production of ROS or enhanced mitochondrial
outer membrane permeability (MOMP(169, 170)). The direct production of ROS can
induce lysosomal membrane permeabilization and the subsequent release of lysosomal
enzymes can either induce MOMP or cause lysosomal degradation-mediated autophagic
cell death(171, 172). If MOMP is induced, cytochrome c and other pro-apoptotic factors
are released into the cytosol; additionally, NADH dehydrogenase and reduced enzyme
Q10 divert electrons from the electron transport system to oxygen, and O2•- are
formed(169, 170). Illustration of these processes can be seen in Figure 1.1. These
findings suggest that there is substantial interplay between apoptotic and non-apoptotic
cell death signaling, and that ROS play significant roles within each mechanism(168). It
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is envisioned that ROS/oxidative stress can be used as robust, versatile markers for the
various morphologically distinct pathways of cell death.
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Chapter 2: Proposed Strategy and Experimental Methods
2.1 Proposed Strategy
Studies in our lab have shown that HeLa cells transiently expressing Firefly
Luciferase (fLuc) or Renilla Luciferase (RLuc) exhibited severely diminished
bioluminescence when treated with a PCD-inducing drug.

However, when stable

mutant variants of luciferase were utilized, bioluminescence measurements were less
sensitive to these treatment conditions.

Based on these observations, it was

hypothesized that the bioluminescent ratio (stable luciferase activity:wild-type
luciferase activity) could be used to report on the extent of intracellular stress associated
with PCD, inducing agents or other environmental factors.

A schematic of this

hypothesis is illustrated in Figure 2.1; bioluminescence from the stable luciferase
variant remains relatively constant over a range of drug dosages/treatment time while
wild-type luciferase bioluminescence declines(Figure 2.1A). The ratio of stable:wildtype luciferase activity thus increases over drug dosage or time course, accordingly
(Figure 2.1B). Coexpression of the mutant and wild-type luciferases would ultimately
create a Ratiometric Bioluminescent sensor (RBS) for cellular stress and PCD.
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Figure 2.1. Schematic of RBS. (A) Over increasing time or drug dosage it is expected that the mutant
luciferase bioluminescence will remain relatively stable while the wild-type luciferase bioluminescence
will decrease. (B) Over the same time or drug dosage increase, the ratio (mutant bioluminescence:wild-type
bioluminescence) will increase.

When considering which luciferases to incorporate into the RBS, it is necessary
that the bioluminescence from each of the proteins can be distinguished. This can be
accomplished by selecting stable and wild-type luciferase variants that catalyze different
substrates, e.g., luciferin and coelenterazine. Distinct signals can then be obtained from
each luciferase by adding one substrate first, measuring the signal, and either washing the
substrate out (in vitro) or allowing the substrate to clear (in vivo) before addition of the
second substrate. An alternative for in vitro assays involves the use of the Dual-Glo
Luciferase assay from Promega. This assay utilizes two proprietary solutions: the first
solution contains the substrate for fLuc and the second solution contains a reagent to
quench the bioluminescence of fLuc in addition to the substrate for RLuc.
As an alternative to using two different substrates to distinguish between stable
and wild-type luciferase variants, luciferase enzymes can also be selected that emit light
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at different wavelengths and thus can be differentiated optically.

In this scenario,

multiple emission filters can be applied during bioluminescence imaging in order to
obtain specific signals for each luciferase. For example, the emission wavelength of
RLuc is 480 nm and the emission wavelength of fLuc is 612; in this case, both substrates
can be administered during the same imaging session, and optically distinct emission
filters can be implemented to specifically obtain bioluminescent images from each
enzyme. Therefore, it is not necessary to wait for one substrate to clear before the second
can be administered and imaged.

2.2 Materials and Methods
2.2.1 Preliminary transient transfection studies
The DNA sequence encoding fLuc was PCR amplified from the pGL3-Basic
vector (Promega, Madison, WI) and inserted into the pCDNA3.1+ vector (Invitrogen,
Carlsbad, CA) between the BamHI and EcoRI restriction sites, creating fLucpCDNA3.1+. The fLuc-pCDNA3.1+ vector was modified with 5 amino acid mutations
(F14R, L35Q, V182K, I232K, F465R) using the QuikChange Multi Site Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions,
ultimately creating fLuc5.

The phRL-CMV vector (Promega) encoding Renilla

Luciferase was modified to contain eight amino acid mutations within the RLuc sequence
(A55T, C124A, S130A, K136R, A143M, M185V, M253L, and S287L) using the
QuikChange Multi Site Directed Mutagenesis Kit (Stratagene) according to the
manufacturer’s instructions, ultimately creating RLuc8. Cells were plated at a density of
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24,500 cells/well in a 48-well tissue culture plate (BD Biosciences, Franklin Lakes, NJ)
and transiently transfected with either the fLuc-pCDNA3.1+, phRL-CMV (encoding
Renilla Luciferase (RLuc)) (Promega), fLuc5 or RLuc8 vectors using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. After 24 hours, culture
medium was replaced and the transfected cells were allowed to recover for another 24
hours. Transfected cells were treated with 1 µM Staurosporine (Sigma, St. Louis, MO)
or PBS (pH 7.4) for indicated time periods. In certain assays, cells were treated with 20
µg/mL phenylbenzothiazole (PBT, Sigma) in addition to STS. At selected time points,
fLuc, RLuc and fLuc5 measurements were taken using a Dual-Glo Luciferase assay
system (Promega) according to the manufacturer’s instructions and an Infinite 200 plate
reader (Tecan, Mannedorf, Switzerland). To measure caspase-3 activity, the Caspase-3/7
Glo assay (Promega) was used according to the manufacturer’s instructions and
bioluminescence measurements were obtained from an Infinite 200 plate reader (Tecan).
2.2.2 RBS plasmid vector construction
The internal ribosome entry site (IRES) from the pIRES2-DsRed Express Vector
(Clontech, Mountain View, CA) was cloned into the pIRES vector (Clontech) using
restriction enzymes NheI and KpnI (New England Biolabs, Ipswich, MA), creating the
pIRES12 vector. The DNA sequence encoding Firefly Luciferase (fLuc) from the pGL3Basic vector (Promega) was PCR amplified and inserted into pCDNA3.1+ (Invitrogen)
between the BamHI and EcoRI restriction sites. The fLuc sequence was subsequently
cloned into pIRES12 using the NheI and XbaI restriction sites of fLuc-pCDNA3.1+ and
the XbaI site of pIRES12. RLuc8 was cloned into the pIRES12-fLuc vector at the NheI
56

and BglII restriction sites. The resulting RLuc8-IRES-fLuc sequence was cloned into the
pLENTI6/V-5 TOPO vector (Invitrogen) per the manufacturer’s instructions to create the
final vector necessary for the Ratiometric Bioluminescent Sensor (RBS). The final RBS
plasmid map is shown in Figure 2.2.

Figure 2.2. Plasmid map of the RBS. Image created using PlasMapper (1).

2.2.3 Reverse RBS plasmid vector construction
The RLuc8 sequence from the phRL-CMV vector (Promega) was PCR amplified
and cloned into pCDNA3.1+ (Invitrogen) between the BamHI and EcoRI restriction sites,
creating RLuc8-pCDNA2.1+. RLuc8 was subsequently cloned into pIRES12 using the
57

NheI and XbaI restriction sites of RLuc8-pCDNA3.1+ and the XbaI site of pIRES12,
creating pIRES12-RLuc8. The fLuc sequence was PCR amplified and inserted into
pCDNA3.1+ between the BamHI and EcoRI restriction sites. The fLuc sequence from
the pGL3-Basic vector (Promega) was subsequently cloned into the pIRES12-RLuc8
vector at the NheI and BglII restriction sites. The resulting fluc-pIRES-RLuc8 sequence
was cloned into the pLENTI6/V-5 TOPO vector per the manufacturer’s instructions to
create the final vector necessary for the reverse RBS.
2.2.4 Cell culture
Human cervical carcinoma (HeLa) and human breast adenocarcinoma (MCF7)
cells (ATCC, Manassas, VA) were grown in Eagle’s Minimum essential medium
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS, HyClone,
Logan, UT), 1.5 g/L sodium bicarbonate, 100 U/mL penicillin and 100 µg/mL
streptomycin (Invitrogen).

Human embryonic kidney (293T/17) cells (ATCC) were

grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech) supplemented with
10% FBS (Hyclone), 1.5 g/L sodium bicarbonate, 100 U/mL penicillin and 100 µg/mL
streptomycin (Invitrogen).

The genetically modified human embryonic kidney cells

(293FT, Invitrogen) for generating lentiviral particles were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM, Mediatech) supplemented with 10% fetal bovine
serum (FBS, HyClone, Logan, UT), 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate,
0.1 mM MEM non-essential amino acids (NEAA), 6 mM L-glutamine, 100 U/mL
penicillin and 100 µg/mL streptomycin (Invitrogen).

Cells that were genetically

engineered to stably express RBS (described below) also had Blasticidin (Invitrogen)
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added at a final concentration of 4 µg/mL. All cells were cultivated in a 37°C humidified
incubator with 5% CO2.

2.2.5 Lentiviral particle production and stable cell line creation
RBS lentiviral particles were produced using the Virapower Lentiviral Directional
TOPO Expression Kit (Invitrogen) according to the manufacturer’s instructions. Briefly,
293FT cells were transfected with viral packaging plasmids and the RBS lentiviral vector
using Lipofectamine 2000 (Invitrogen). Viral supernatant was harvested 48 hours after
transfection,

concentrated

using Peg-it

Virus

Concentration

Biosciences, Mountain View, CA) and the titer was assessed.

solution

(System

Concentrated viral

particles were added to HeLa, MCF7 and 293T/17 cells, which were subsequently
selected for stable genomic integration using Blasticidin (Invitrogen), resulting in RBSHeLa, RBS-MCF7 and RBS-293T/17 cells.

2.2.6 Cellular stress and inhibition assays
To induce cellular stress, RBS-cells were treated with various compounds listed in
Table I. Stressed and unstressed cells were also incubated with inhibitors that target
various intracellular protein degradation/modification pathways.

The specific

compounds/proteins that were utilized as inhibitors and the respective final working
concentrations are also listed in Table 2.1. Inhibitors were added to cells for 1 hour prior
to adding inducers of cellular stress and left in the media for the duration of the treatment.
Analogous controls were conducted in the absence of stress inducers.
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Table 2.1. Summary of reagents.

Inhibitors/Scavengers

Stress Inducers

Induces/Inhibits
Reagent
Manufacturer
PCD,
ROS/Staurosporine (STS)
Sigma
Hydrogen peroxide (H2O2) ROS/Fisher
ROS/Hypoxanthine (HX)
Sigma
Xanthine Oxidase (XO)
ROS/Sigma
PCD/Doxorubicin (DOX)
Sigma
PCD/Camptothecin (CPT)
Sigma
PCD/Sodium Selenite (SSe)
MP Biomedicals
Resveratrol (Res)
PCD/Enzo Life Sciences
-/proteasome
MG-132
Fisher
-/proteasome
Epoxomicin
Enzo Life Sciences
-/proteasome
Lactacystin
Sigma
-/calpains
Calpain Inhibitor III
Calbiochem
-/cathepsins
Pepstatin A
Enzo Life Sciences
Ammonium Chloride
-/autophagy
Alfa Aesar
-/caspases
z-vad-fmk
Sigma
Tiron
-/superoxide
Sigma
TEMPOL
-/superoxide
Sigma
-/superoxide
MnTMPyp
Enzo Life Sciences
Mannitol
-/hydroxyl radical Sigma
-/hydroxyl radical Calbiochem
DFO
-/hydroxyl radical Sigma
TEPA
Catalase
-/hydrogen peroxide Sigma
-/hydrogen peroxide MP Biomedicals
Allopurinol
Acetylsylic Acid (Aspirin) -/hydrogen peroxide Fisher
Uric Acid
-/peroxynitrite
Alfa Aesar

Working
Concentration
0 - 50 µM
0 - 10 mM
50 µM
25 mU/mL
1 µM
10 µM
0 – 55 µM
0 – 1 mM
20 µM
10 µM
10 µM
100 µM
100 µM
1 mM
1 µM
10 mM
10 mM
100 µM
100 mM
50 µM
50 µM
40 U/mL
100 µM
1 mM
1 mM

2.2.7 Cellular bioluminescence assays
Unless otherwise noted, bioluminescence assays were performed 24 hours after
plating 10,000 RBS-HeLa cells/well in a white-walled 96 well tissue culture plate (BD
Biosciences). The Dual-Glo Luciferase Assay System (Promega) was utilized according
60

to the manufacturer’s instructions to obtain both fLuc and RLuc8 bioluminescence
measurements from an Infinite 200 plate reader (Tecan). In the case of using MnTMPyP
as an inhibitor, the cell media was removed, cells were gently washed and the media was
replaced before using the Dual-Glo Luciferase Assay System as it was found that the
compound interfered with the bioluminescence measurements.

2.2.8 Cellular bioluminescence imaging
RBS-HeLa cells were plated at a density of 10,000 cells/well in a black-walled 96
well tissue culture plate (BD Biosciences). The Dual-Glo Luciferase Assay System
(Promega) was utilized according to the manufacturer’s instructions in order to obtain
bioluminescent images in an Omega 16vs imaging system (UltraLum, Claremont, CA).
It should be noted that the exact position of the 96 well plate was kept constant
throughout the imaging session in order for accurate ratiometric images to be calculated.

2.2.9 Cellular bioluminescence image analysis
Image analyses were performed using ImageJ (NIH, Bethesda, MD).

Image

background was determined by measuring 3 regions of interest (ROIs) surrounding the
bioluminescent ROI. After background subtraction, the RLuc8 image was divided by the
fLuc image using the ‘Math’ command under the ‘Process’ menu tab.

61

2.2.10 Cell death assays
Caspase Activity: PCD was induced (as described above) 24 hours after plating
10,000 cells/well in white-walled 96 well tissue culture plates (BD Biosciences). After
indicated treatment times, the Caspase 3/7-Glo Assay (Promega) was performed
according to the manufacturer’s protocol and bioluminescence measurements were
obtained from and Infinite 200 plate reader (Tecan). All values were normalized to
controls (i.e. pre-treatment values).
DNA Fragmentation: PCD was induced (as described above) 24 hours after
plating 300,000 cells/well in 6 well tissue culture plates (BD Biosciences).

After

indicated treatment times, TUNEL assays for DNA fragmentation were performed using
the TUNEL/ApoBRDU assay kit (Invitrogen) according to the manufacturer’s protocol.
Percent DNA fragmentation was determined using flow cytometry on a Guava EasyCyte
flow cytometer (Guava Technologies, Hayward, CA). Analysis of flow cytometry data
was performed using FlowJo software (Treestar, Ashland, OR).

2.2.11 Proteasome inhibition control assay
RBS-HeLa cells were plated at a density of 10,000 cells/well in a white-walled
96-well plate (BD Biosciences). 24 hours later, cells were treated with PBS (pH 7.4), 20
µM MG-132, 10 µM epoxomicin or 10 µM lactacystin for 1 hour. RBS-HeLa cells were
then treated with PBS (pH 7.4) or 10 µM Staurosporine (STS) in addition to the
inhibitors for 24 hours. Proteasome activity measurements were obtained using the
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Proteasome-Glo 3-Substrate Cell-Based Assay system (Promega) according to the
manufacturer’s instructions.

2.2.12 Protease inhibition control assays
Calpain Inhibitor III:

RBS-HeLa cells were plated at a density of 10,000

cells/well in a white-walled 96-well plate (BD Biosciences). 24 hours later, cells were
treated with either PBS (pH 7.4) or 100 µM Calpain Inhibitor III for 1 hour. PBS (pH
7.4) or 10 µM STS was subsequently added to the cells, and both compounds remained
on the cells for 24 hours.

Calpain activity measurements were obtained using the

Calpain-Glo Protease Assay (Promega) according to the manufacturer’s instructions.
Pepstatin A: RBS-HeLa cells were plated at a density of 10,000 cells/well in a
black-walled 96-well plate (BD Biosciences). 24 hours later, cells were treated with
either PBS (pH 7.4) or 100 µM pepstatin A for 1 hour, with either PBS (pH 7.4) or 10
µM STS added for another 24 hours. Cathepsin activity was assessed using the CVCathepsin B Detection Kit (Enzo Life Sciences) according to the manufacturer’s
instructions with one exception; after the final wash step, the plate was read on an Infinite
200 plate reader (Tecan) for fluorescence (550ex/610em), as opposed to microscopy.
Ammonium Chloride:

In lieu of a control assay for ammonium chloride

effectively inhibiting lysosome-phagosome fusion, we direct the reader to a seminal
paper regarding this phenomena in HeLa cells(2).
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z-vad-fmk: RBS-HeLa cells were plated at a density of 10,000 cells/well in a
white-walled 96-well plate (BD Biosciences). 24 hours later, cells were treated with
either PBS (pH 7.4) or 1 µM z-vad-fmk for 1 hour. PBS (pH 7.4) or 10 µM STS was
subsequently added to the cells, and both compounds remained on the cells for 24 hours.
Caspase activity measurements were obtained using the Caspase-Glo 3/7 Assay
(Promega) according to the manufacturer’s instructions.

2.2.13 Superoxide (O2•-) scavenger control assay
RBS-HeLa cells were plated at a density of 120,000 cells per well of a 12 well
tissue culture plate (BD Biosciences). 24 hours later, cells were treated with PBS (pH
7.4), 10 mM TEMPOL, 10 mM Tiron or 100 µM MnTMPyP for 1 hour. PBS (pH 7.4) or
10 µM STS was subsequently added to the cells, and both compounds remained on the
cells for 24 hours. Intracellular O2•- levels were then determined by incubating the cells
in 5 µM dihydroethidium (DHE, Invitrogen) for 30 minutes at 37°C and subjecting them
to flow cytometry using a Guava EasyCyte (Guava Technologies, Hayward, CA).
Analysis of flow cytometry data was accomplished using FlowJo software (TreeStar,
Ashland, OR).

2.2.14 Hydroxyl Radical (•OH) scavenger/inhibitor control assay
RBS-HeLa cells were plated at a density of 120,000 cells per well of a 12 well
tissue culture plate (BD Biosciences). 24 hours later, the cells were incubated with 10
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µM hydroxyphenylfluorescein (HPF, Sigma) for 30 minutes at 37°C. Cells were then
treated with PBS (pH 7.4), 100 mM Mannitol, 50 µM deferoxamine (DFO), 50 µM
tetraethylenepentamine (TEPA) or 50 µM DFO plus 50 µM TEPA for 1 hour. PBS (pH
7.4) or 10 µM STS was subsequently added to the cells, and all compounds remained on
the cells for 24 hours. Intracellular •OH levels were determined by subjecting the cells to
flow cytometry using a Guava EasyCyte (Guava Technologies).

Analysis of flow

cytometry data was accomplished using FlowJo software (TreeStar).

2.2.15 Hydrogen peroxide (H2O2)-related inhibitor control assays
Catalase and Allopurinol: RBS-HeLa cells were plated at a density of 120,000
cells per well of a 12 well tissue culture plate (BD Biosciences). 24 hours later, the cells
were incubated with 10 µM CM-H2DCFDA (Invitrogen) for 30 minutes at 37°C. Cells
were then treated with PBS (pH 7.4), 50 U/mL catalase or 100 µM allopurinol for one
hour.

PBS (pH 7.4) or 10 µM STS was subsequently added to the cells, and all

compounds remained on the cells for 24 hours.

Intracellular H2O2 levels were

determined by subjecting the cells to flow cytometry using a Guava EasyCyte (Guava
Technologies).

Analysis of flow cytometry data was accomplished using FlowJo

software (Treestar).
Aspirin: RBS-HeLa cells were plated at a density of 1.2 x 106 cells in 100 mM
tissue culture dishes (BD Biosciences). 24 hours later, the cells were treated with PBS
(pH 7.4) or 1 mM aspirin for one hour, followed by PBS (pH 7.4) or 10 µM STS for 24
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hours. Cyclooxygenase (COX) activity was determined by using the Cox Activity Assay
Kit (Cayman Chemical Company, Ann Arbor, MI).

2.2.16 Quantitative real-time PCR (qRT-PCR)
Cytoplasmic RNA from RBS-HeLa cells cultured under indicated conditions was
isolated using the High Pure RNA Isolation Kit (Roche, Mannheim, Germany) and
subsequently reverse-transcribed to single-stranded cDNA using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to each
manufacturer’s protocol. Quantitative RT-PCR was performed on an ABI PRISM 7300
Sequence detection system using FAM-labeled Taqman primer sets for RLuc8, fLuc and
β-actin (as a control) and the Taqman universal PCR Master Mix (Applied Biosytems)
according to the manufacturer’s protocol.

2.2.17 Western blot analysis
Following indicated culture conditions, RBS-HeLa cells were washed 3 times
with 1x PBS (pH7.4). Proteins were extracted using RIPA extraction buffer (50 mM Tris
HCL, pH 7.4, 1% Triton X-100, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA
and a Complete Mini Protease Inhibitor Cocktail Tablet (Roche)) at 4°C for 30 minutes
with constant agitation. Total protein concentrations were measured using a BCA assay
(Pierce, Rockford, IL). 30 µg of total protein from each sample were heated to 95°C in
Laemmli Sample buffer containing 2% (v/v) 2-mercaptoethanol (Bio-Rad, Hercules,
CA). After a 5 minute cooling period, the samples were quickly centrifuged and the
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supernatants were immediately run on a 4-15% Tris-HCl gel (Bio-Rad).

Proteins

separated by electrophoresis were transferred to nitrocellulose membranes in 1X Transfer
Buffer (Bio-Rad) at 15V for 30 minutes. Membranes were blocked in Blocking Buffer
for Fluorescent Western Blotting (Rockland Immunochemicals, Gilbertsville, PA) for 60
minutes. The membranes were incubated with anti-fLuc (Sigma), anti-rLuc (Millipore,
Billerica, MA) or anti-β-actin primary antibodies in blocking buffer overnight. After
washing 3 times with TBS-T, the membranes were incubated with either Anti-Mouse IgG
Antibody IRDye800 conjugated (fLuc, rLuc) or Anti-Rabbit IgG Antibody IRDye800
conjugated (β-actin) at a 1:10,000 dilution (Rockland Immunochemicals).

The

fluorescent signal from the membranes was imaged using the Odyssey Infrared Imaging
System (Li-Cor Biosciences, Lincoln, NE)

2.2.18 Intracellular hydrogen peroxide detection
Amplex Red: HeLa cells subjected to various treatment conditions, as indicated,
were lysed using RIPA buffer and the clarified lysate samples were used in the Amplex
Red Hydrogen Peroxide/Peroxidase assay kit (Invitrogen) to determine levels of H2O2.
Results were normalized to total protein content determined by the BCA assay (Pierce).
CM-H2DCFDA: Cells were plated at a density of 120,000 cells per well of a 12
well tissue culture plate (BD Biosciences). 24 hours later, the cells were incubated with
10 µM CM-H2DCFDA (Invitrogen) for 30 minutes at 37°C. The reagent was removed,
the cells were washed with PBS (pH 7.4) and PCD was induced as described above.
Cells were lifted using a rubber scraper, washed twice with PBS (pH 7.4) and
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intracellular H2O2 levels were determined by subjecting the cells to flow cytometry using
a Guava EasyCyte flow cytometer (Guave Technologies). Analysis of flow cytometry
data was accomplished using FlowJo software (TreeStar).

2.2.19 RLuc8 and fLuc protein purification
The DNA sequences encoding RLuc8 and fLuc were PCR amplified and inserted
into the pHAT 10 and pHAT 11 vectors (Clontech) between the BamHI and EcoRI
restriction sites. 50 mL of bacterial cultures were inoculated in LB medium containing
50 µg/mL ampicillin overnight, shaking at 37°C. Cultures were expanded into 500 mL
LB medium containing 50 µg/mL ampicillin for 1.5 hours, shaking at 37°C. Protein
expression was induced by adding 500 µM IPTG (Fisher Scientific, Pittsburgh, PA) and
shaking for 5 hours at 37°C. After centrifugation at 10,000 x g for 5 minutes, cell pellets
were resuspended in 35 mL wash/extraction buffer (50 mM Phosphate, 300 mM NaCl,
pH 7.0). Lysozyme (final concentration of 0.75 mg/mL) and PMSF (final concentration
of 1 mM) were added and the cells were frozen at -80°C overnight after standing at room
temperature for 20 minutes. Lysates were thawed in a 37°C water bath, sonicated and
centrifuged at 20,0000 x g for 20 minutes. Clarified cell lysates were applied to a
purification column loaded with TALON metal affinity resin (Clontech) and washed
several times with wash/extraction buffer. The RLuc8 and fLuc proteins were eluted
from the column using an imidazole gradient (10, 60, 150, 300, 450, 600, 700, 1000
mM). Samples from each imidazole concentration were subjected to SDS-PAGE in order
to identify the most pure protein samples. Aliquots were heated to 95°C in Laemmli
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sample buffer containing 2% (v/v) 2-mercaptoethanol (Bio-Rad).

After a 5 minute

cooling period the samples were immediately centrifuged and run on a 4-15% Tris-HCl
gel (Bio-Rad). Proteins were visualized using the Simply Blue stain (Invitrogen) and the
purest samples of each protein (i.e. the samples with the least amount of extraneous
bands) were further purified on Amicon Ultra Centrifugal Filtration Devices (Millipore,
Billerica, MA) of appropriate molecular weight cutoffs to remove the imidazole.

2.2.20 In vitro bioluminescence assays on purified proteins
For the xanthine/xanthine oxidase assay, equivalent concentrations of each protein
were resuspended in a sample buffer consisting of phosphate buffered saline (PBS,
Invitrogen), 1 mg/mL bovine serum albumin (BSA, Fisher Scientific) and a Complete
Mini protease inhibitor cocktail tablet (Roche).

Samples were treated with 50 µM

hypoxanthine, 25 mU/mL xanthine oxidase (Sigma) or a combination of each and
incubated at 37°C for indicated time periods. Luminescence measurements were made
on an Infinite 200 plate reader (Tecan) following the addition of Dual-Glo reagents
(Promega).
For the H2O2 assay, 650 nM of both purified fLuc and RLuc8 proteines were
used. Proteins were added to PBS containing a range of H2O2 concentrations (0-10 mM)
for up to 120 minutes at 37°C. At indicated times, 10 µL aliquots of each sample were
subjected to bioluminescence measurements on an Infinite 200 plate reader (Tecan),
following the addition of Dual-Glo reagents (Promega).
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2.2.21 SDS-PAGE gels on purified proteins treated with H2O2
Three protein conditions were used: fLuc alone (650 nM), rLuc alone (650 nM) or
fLuc and RLuc together (650 nM total protein). Proteins were added to PBS containing a
range of H2O2 concentrations (0-10 mM) for up to 120 minutes at 37°C. At indicated
times, 10 µL aliquots were removed and heated to 95°C in Laemmli sample buffer
containing 2% (v/v) 2-mercaptoethanol (Bio-Rad). After a 5 minute cooling period the
samples were immediately centrifuged and run on a 4-15% Tris-HCl gel (Bio-Rad).
Proteins were visualized using the Simply Blue stain (Invitrogen) according to the
manufacturer’s instructions.

2.2.22 Cellular protein carbonylation detection
To assay for protein carbonylation, the OxyBlot Protein Carbonlyation Detection
Kit (Millipore) was used according to the manufacturer’s instructions. Briefly, RBSHeLa cells were treated with PBS or STS for 24 hours. Proteins were extracted using
RIPA extraction buffer (50 mM Tris HCL, pH 7.4, 1% Triton X-100, 0.25% Nadeoxycholate, 150 mM NaCl, 1 mM EDTA and a Complete Mini Protease Inhibitor
Cocktail Tablet) at 4°C for 30 minutes with constant agitation.

Total protein

concentrations were measured using a BCA assay and 15 µg of total protein was treated
with a final concentration of 6% SDS to denature the proteins. The samples were then
treated with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups in the
protein side chains to 2,4-dinitrophenylhydrazone (DNP-hydrazone). Also, a second set
of samples was treated with Derivatization-Control solution, to serve as a negative
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control. The protein samples were run on a 4-15% Tris-HCl gel (Bio-Rad). Proteins
separated by electrophoresis were transferred to nitrocellulose membranes in 1X Transfer
Buffer (Bio-Rad) at 15V for 30 minutes.

The membrane was blocked in

blocking/dilution buffer (1%BSA/PBS-T (PBS, pH 7.4, 0.05% Tween-20)) for 1 hour
and then incubated with rabbit anti-DNP antibody (1:150 dilution in blocking/dilution
buffer) for one hour. After rinsing with PBS-T, the membrane was incubated with HRPconjugated goat anti-rabbit IgG antibody (1:300 dilution in blocking/dilution buffer) for
one hour and again rinsed. The Immun-Star HRP Chemiluminescent kit (Bio-rad) was
used and the signal was imaged on an Omega 16vs imaging system (UltraLum).
2.2.23 Purified protein carbonylation detection
To assay for protein carbonylation, the OxyBlot Protein Carbonylation Detection
Kit (Millipore) was used according to the manufacturer’s instructions. Briefly, 650 nM
of pure fLuc and RLuc8 proteins were treated with PBS or 5 mM H2O2 for 2 hours,
followed by denaturation with SDS (final concentration: 6%).

The samples were then

treated with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups in the
protein side chains to 2,4-dinitrophenylhydrazone (DNP-hydrazone).
samples were run on a 4-15% Tris-HCl gel (Bio-Rad).

The protein

Proteins separated by

electrophoresis were transferred to nitrocellulose membranes in 1X Transfer Buffer (BioRad) at 15V for 30 minutes. The membrane was blocked in blocking/dilution buffer
(1%BSA/PBS-T (PBS, pH 7.4, 0.05% Tween-20)) for 1 hour and then incubated with
rabbit anti-DNP antibody (1:150 dilution in blocking/dilution buffer) for one hour. After
rinsing with PBS-T, the membrane was incubated with Anti-Rabbit IgG Antibody
IRDye800 conjugated (β-actin) at a 1:10,000 dilution (Rockland Immunochemicals).
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The fluorescent signal from the membranes was imaged using the Odyssey Infrared
Imaging System (Li-Cor Biosciences, Lincoln, NE).
2.2.24 Animal imaging
Five week old female nude mice (Charles River Laboratories International LLC,
Wilmington, MA) were obtained and given free access to food and water.

All

experiments conformed to animal care protocols approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Pennsylvania.

For tumor

induction, 2.5 x 106 RBS-HeLa cells were resuspended in PBS (pH 7.4) and
subcutaneously implanted in the lower right flank of lightly anesthetized mice (1%
isoflurane/oxygen mixture). Once the tumors reached ~ 1 cm in diameter, each group
was imaged prior to any inhibitor/drug treatment. Briefly, the animals were i.v. injected
with 100 µL of 500 µg/mL sterile coelenterazine (NanoLight, Pinetop, AZ) in a 20/20/60
mixture of USP grade ethanol/propylene glycol/PBS and imaged using an IVIS Lumina II
(Caliper Life Sciences, Hopkinton, MA) under anesthesia (2.5% isoflurane/oxygen
mixture). The substrate was allowed to clear for 3 hours before the animals received an
i.p. injection of 200 µL of sterile 15 mg/mL luciferin (Biosynth, Itasca, IL) in PBS (pH
7.4) and imaged using an IVIS Lumina II under anesthesia (2.5% isoflurane/oxygen
mixture). Immediately following the second imaging session animals were divided into 4
groups (PBS/PBS, PBS/STS, Allo/PBS, Allo/STS) and the inhibitor (1 mM Allopurinol)
or control (PBS, pH 7.4) was intratumorally injected. After 1 hour, the cell death inducer
(500 µM STS) or control (PBS, pH 7.4) was intratumorally injected. All intratumoral
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injections were of a volume of 25 µL. 24 hours later, the animals were imaged in the
same manner as stated previously.
2.2.25 Animal image analysis
Image analysis was performed using Living Image Software (Caliper Life
Sciences). Images were first background subtracted (treating the animal body as the
background) and automatic (5% threshold) ROIs were generated around each tumor.
Average bioluminescent counts were recorded and used in the ratio calculations. For each
group, data was normalized to the day 1 ratio values.
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Chapter 3: Development of the Ratiometric Bioluminescent
Sensor (RBS) and its response to cellular stress in HeLa cells

3.1 Abstract
The use of bioluminescent proteins as optical reporters for PCD and other cellular
stress states is advantageous owing to their sensitivity, non-invasiveness, and in vivo
imaging capability.

However, the possibility of reporter degradation during these

biological processes must be accounted for. In this chapter, we show that wild-type
bioluminescent proteins (luciferases) exhibit a marked decrease in activity in cells
undergoing PCD and that certain chemical treatments and mutations can rescue activity.
Wild-type fLuc and a stable variant of RLuc (RLuc8) were incorporated into a
Ratiometric Bioluminescent Sensor (RBS) and when expressed in HeLa cells, the RBS
was capable of detecting PCD in a ratiometric manner.

3.2 Introduction
There are many optical sensors designed to image and/or report on programmed
cell death (PCD). Many of these sensors are based on the specific proteolytic cleavage of
the amino acid sequence DEVD by caspase-3, the cysteine-aspartic protease that is
considered to be absolutely required for apoptotic PCD(1). Some of these caspase-3
dependent sensors are fluorescent in nature and typically involve the separation of a
fluorophore and a quencher or overlapping FRET-pairs after DEVD cleavage by caspase3. The fluorescent molecular reporters(2-4) hold an advantage over fluorogenic peptide
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probes(5-11) in their synthesis costs and cellular delivery methods; however both
categories of PCD sensors suffer from drawbacks, including autofluorescence and poor
light penetration of tissue, making them less than ideal for in vivo applications.
To circumvent the issues surrounding fluorescent probes for PCD, several groups
have recently utilized bioluminescent proteins as optical reporters for PCD.
Bioluminescent proteins are highly sensitive as they emit no light until a specific
substrate is present and one of the most prominently used bioluminescent proteins,
Firefly luciferase (fLuc), emits a wavelength of light (610 nm) that is much less
attenuated in tissues than many fluorescent molecules, making it a promising candidate
for in vivo studies. Generally, these PCD sensors utilize the cleavage of the caspase-3
recognition sequence, DEVD, as a catalyst for luciferin (substrate) recognition(12, 13),
removal of steric hindrance(14), or protein fragment complementation(15).
While the bioluminescent sensors for PCD seem to be superior to fluorescent
sensors for in vivo imaging purposes, the design of any genetically encoded or peptidic
sensor for PCD should take into account the possibility of sensor degradation and
modification in cells undergoing PCD. It has been shown that certain proteases (e.g.,
calpains(16, 17) and cathepsins(18, 19)) can be upregulated during PCD, in addition to
the oxidative modifications that can result from increases in various reactive oxygen
species (ROS)(20-22). Thus, information garnered from these types of sensors should be
highly scrutinized.
In this chapter, we show that wild-type luciferases do indeed suffer from activity
loss in cells undergoing PCD.

Pretreatment with phenylbenzothiazole (PBT), a

compound shown to prevent the intracellular degradation of fLuc(23), abrogated fLuc
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activity loss in cells undergoing PCD. Additionally, certain mutant forms of luciferase
were analyzed under the same conditions; a fLuc (fLuc5) mutant exhibited slightly more
activity than wild-type fLuc while an RLuc mutant (RLuc8) retained significant activity
in cells undergoing PCD.

Based on these observations, RLuc8 and fLuc were

incorporated into one sensor to explore whether the ratio (RLuc8 bioluminescence:fLuc
bioluminescence) could be used to report on PCD. It was found that the Ratiometric
Bioluminescent Sensor (RBS) was capable of detecting PCD in STS-treated HeLa cells
over ranges of time and dosage.

3.3 Results
In order to investigate the sensitivity of bioluminescent proteins to intracellular
stresses incurred during PCD, we examined the effects of staurosporine (STS), a PCDinducing drug(24) that has also been shown to increase intracellular ROS(25), on HeLa
cells transiently expressing Firefly and Renilla luciferases (fLuc and RLuc, respectively).
The normalized bioluminescence measurements of fLuc and RLuc decreased
significantly over time with 1 µM STS treatment as shown in Figure 3.1. By 8 hours,
fLuc activity was reduced by ~85% and RLuc activity was reduced by ~95%.
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Figure 3.1. Effect of staurosporine on fLuc and RLuc bioluminescence. HeLa cells were transiently
transfected with either fLuc or RLuc vectors and treated with 1 µM staurosporine (STS) for a time period
of 24 hours. Bioluminescence measurements were taken at various time points and each point was
normalized to time 0.

Under the same treatment conditions of 1 µM STS for 24 hours, caspase-3
activity in HeLa cells increased over the course of 12 hours before reaching a plateau and
slowly decreasing (Figure 3.2), indicative of PCD.

Caspase-3 activity was clearly

elevated at time points where fLuc and RLuc bioluminescence was nearly completely
diminished.

Thus, the use of wild-type luciferases in sensors for PCD must be

scrutinized carefully since their signals can be nearly completely abrogated before the
appearance of the apoptotic markers (i.e., caspases) they are supposed to detect.
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Figure 3.2. Caspase-3 activity during a time course of STS treatment. HeLa cells were treated with 1
µM STS for 24 hours. At selected time points, cells were assayed for caspase-3 activity using
Caspase-3/7 Glo and each point was normalized to time 0.

To circumvent the issue of diminished bioluminescence during PCD, we
investigated the potential use of a chemical stabilizer to prevent the loss of fLuc activity.
Phenylbenzothiazole (PBT) has been shown to prevent the intracellular degradation of
fLuc(23) when added to cell cultures. HeLa cells transiently expressing fLuc were
treated with either 1 µM STS or 1 µM STS + 20 µg/mL PBT for 24 hours. Figure 3.3
shows that the bioluminescence of the cells treated with PBT in addition to STS was
slightly higher and more stable than cells treated with STS alone.
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Figure 3.3. Response of fLuc to STS or STS + PBT treatment. HeLa cells transiently expressing fLuc
were treated with either 1 µM STS or 1 µM STS + 20 µg/mL PBT for 24 hours. Bioluminescence
measurements were taken at various time points and each point was normalized to time 0.

While the in vitro utilization of PBT to stabilize fLuc activity exhibited positive
results, the use of this chemical may not translate well into in vivo models. Thus, we
investigated the potential use of bioluminescent proteins that have been mutated to
enhance their stability in our PCD sensor. Table 3.1 summarizes some of these proteins
and the purported effects of the mutations.
Table 3.1. Luciferase mutations and their reported effects.

Enzyme Mutations
FLuc5
F14R, L35Q, V182K, I232K,
F465R
RLuc8 A55T, C124A, S130A, K136R,
A143M, M185V, M253L, and
S287L

Effects
Reference
↑
pH
tolerance, (26)
thermostable up to 45°C
200x serum inactivation (27)
resistance and 4x brighter
than WT

When HeLa cells were transiently transfected with a vector encoding either wildtype fLuc or fLuc5 and treated with 1 µM STS for a time course of 24 hours, the
80

normalized bioluminescence from the fLuc5 cells was slightly higher and more stable
than that of fLuc (Figure 3.4).

Figure 3.4. Effect of STS on fLuc5 compared to wt fLuc. HeLa cells were transiently transfected with
fLuc or fLuc5 and treated with 1 µM STS for a time course of 24 hours.

Bioluminescence

measurements were taken at various time points and each point was normalized to time 0.

Similarly, when HeLa cells were transiently transfected with a vector encoding
either wild-type RLuc or RLuc8 and treated with 1 µM STS for a time course of 24
hours, the normalized bioluminescence from the RLuc8 cells was higher and more stable
than that of RLuc (Figure 3.5). RLuc8 clearly exhibits less activity loss than fLuc5,
therefore it would ultimately be included in our bioluminescent sensor for PCD.
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Figure 3.5. Effect of STS on RLuc8 compared to wt RLuc. HeLa cells were transiently transfected with
RLuc or RLuc8 and treated with 1 µM STS for a time course of 8 hours. Bioluminescence measurements
were taken at various time points and each point was normalized to time 0.

We have shown the fLuc and RLuc bioluminescence decreases significantly under
PCD-inducing conditions while the bioluminescence of PBT/fLuc, fluc5, and RLuc8
remains more stable. These observations led us to hypothesize that we could incorporate
an unstable luciferase and a stable luciferase into one sensor and that the bioluminescent
ratio (stable bioluminescence:unstable luminescence) could be used to report on the
extent of intracellular stress associated with PCD. We chose to incorporate fLuc and
RLuc8 into this Ratiometric Bioluminescent Sensor, or RBS, for multiple reasons.
RLuc8 exhibited the highest level of activity/stability under PCD-inducing conditions.
Also, the emission wavelength of fLuc (~600 nm) makes it more suitable for in vivo
imaging.

Further, each of these enzymes utilizes a different substrate, effectively

simplifying the distinction between the bioluminescence of fLuc and RLuc8. The fLuc
and RLuc8 coding sequences flank an internal ribosomal entry site (IRES) in the plasmid
construct, allowing both proteins to be translated from one bicistronic mRNA(28, 29);
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this ensures that protein levels (and the thus the ratio) would be unaffected by any
changes in promoter activity.
HeLa cells constitutively expressing the RBS (RBS-HeLa cells) were subjected to
STS time course and dosage treatments. As seen in Figure 3.6A, upon treatment with 10
µM STS, the fLuc bioluminescence decreases while the RLuc8 bioluminescence remains
relatively stable over the time course of 24 hours. This can be presented as an increase in
the RLuc8:fLuc ratio (right-hand axis). Representative bioluminescent images obtained
from RBS-HeLa cells under the same conditions are shown in Figure 3.6B. The resulting
ratiometric images generated from the RLuc8 and fLuc images exemplify similar trends
to the ratiometric measurements in Figure 3.6A. When RBS-HeLa cells were treated
with a dosage range of STS (0-50 µM) for 6 hours, the RLuc8 bioluminescence remained
stable, fLuc bioluminescence decreased and the RLuc8:fLuc ratio increased (Figure
3.6C). Consistent with these findings, bioluminescent images acquired under the same
treatment conditions, and the corresponding ratiometric measurements, exhibited similar
trends (Figure 3.6D).
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Figure 3.6. Response of RBS-HeLa cells to STS. (A) Bioluminescent measurements of RLuc8 and fLuc
were acquired at various times during the course of 10 µM STS treatment. All measurements were
normalized to values at time 0. The RLuc8:fLuc ratio was subsequently calculated for each time point
(right axis). (B) A representative bioluminescent image of RLuc8 and fLuc activity in STS-treated cells
throughout the time course is shown as well as the calculated ratiometric image, RLuc8:fLuc. (C)
Bioluminescent measurements of RLuc8 and fLuc activity in cells treated with various doses of STS.
The RLuc8:fLuc ratio is also shown (right axis). (D) Representative bioluminescent images of RLuc8
and fLuc activity in cells treated with various doses of STS. The calculated ratiometric image of
RLuc8:fLuc is also shown.

To confirm that the RLuc8:fLuc ratio was independent of cell number, RBS-HeLa
cells were plated at a range of 0 – 20,000 cells/well and bioluminescence measurements
of RLuc8 and fLuc were taken 24 hours later. As shown in figure 3.7A, the RLuc8:fLuc
ratio remained constant regardless of the cell seeding density. Additionally, little to no
increase in the RLuc8:fLuc ratio was observed in cells that were not treated with STS
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over a period of 24 hours (Figure 3.7B).

The slight increase in RLuc8 and fLuc

bioluminescence that was observed with time likely reflects cell proliferation.

Figure 3.7. Analysis of RLuc8:fLuc ratio as a function of cell number and time. (A) RBS-HeLa cells
were plated at various cell densities and the RLuc8:fLuc ratio was measured. (B) For a fixed cell
seeding density, the RLuc8 and fLuc bioluminescent signal that was elicited by RBS-HeLa cells (PBStreated) was detected over the course of 24 hrs (left axis) and the RLuc8:fLuc ratio was calculated at
each time point (right axis).

Similar changes in the RLuc8:fLuc ratio were seen regardless of whether the
coding sequences for fLuc and RLuc8 were interchanged, relative to the IRES sequence
(Figure 3.8). Further, it should be noted that similar bioluminescent measurements were
obtained from live and lysed cells. All measurements of fLuc and RLuc8 activity that are
shown were acquired using the in vitro assay kit, Dual-Glo (Promega).

85

Figure 3.8. Response of reverse RBS-HeLa cells to STS. Reverse RBS-HeLa cells were treated with PBS
or 10 µM STS for 24 hours and characterized by measurements of RLuc8:fLuc bioluminescence.
Statistical significance: * (p<0.01).

To determine the extent of PCD in STS-treated RBS-HeLa cells, TUNEL assays
for DNA fragmentation and Caspase-3/7 Glo assays for caspase-3 activation were
performed.

As shown in Figure 3.9A, the percent of DNA fragmentation over the

course of 24 hours with 10 µM STS treatment rises, while untreated control cells exhibit
no such increase. Additionally, caspase-3 activation rises initially (up to 8 hours) but
then decreases at later time points under the same conditions; untreated control cells
show little increase in caspase-3 activation (Figure 3.9B). RBS-HeLa cells treated with a
dosage range of STS (0 – 50 µM) for 6 hours experience an increase in percent DNA
fragmentation with increasing dose (Figure 3.9C), and an increase in caspase-3 activation
(Figure 3.9D).

86

Figure 3.9. Commercial PCD assays on STS-treated RBS-HeLa cells. (A) A TUNEL assay for DNA
fragmentation was performed at various times during the course of 10 µM STS or PBS (untreated control)
treatment. (B) A Caspase-3/7 Glo assay was performed at various times during the course of 10 µM STS
or PBS (untreated control ) treatment. (C) A TUNEL assay for DNA fragmentation was performed after 6
hours of 0 – 50 µM STS treatment. (D) A Caspase-3/7 Glo assay was performed after 6 hours of 0 – 50
µM STS treatment.
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3.4 Discussion
Preliminary studies on the stabilities of wild-type bioluminescent proteins
demonstrated that both RLuc and fLuc exhibit decreased bioluminescence under PCDinducing conditions. Additionally, caspase-3 activity is markedly elevated under the
same conditions, indicative of PCD. The disparity between high caspase-3 activity and
nearly completely diminished fLuc and RLuc bioluminescence suggests that the
utilization of these proteins in sensors for PCD must be done with caution.
These observations led us to investigate methods of increasing the stabilities of
fLuc and RLuc. The application of PBT, a chemical reported to increase the stability of
fLuc by preventing its intracellular degradation(23), abrogated the decrease in fLuc
bioluminescence in HeLa cells treated with STS. However, the usage of this chemical
may not translate well into in vivo models. HeLa cells expressing mutant luciferases,
fLuc5 and RLuc8, and treated with STS also demonstrated increases in stability,
compared to wild-type luciferases.
These results led to the hypothesis that if a stable and unstable luciferase were
incorporated

into

one

sensor,

the

resulting

bioluminescence

ratio

(stable

bioluminescence:unstable bioluminescence) could be used to report on the extent of
intracellular stress associated with PCD. RLuc8 was chosen as the stable luciferase for
the sensor because it remained the most stable out of all of the proteins tested. Wild-type
fLuc was chosen as the unstable luciferase for the sensor because its emission wavelength
(~600 nm) is better suited for in vivo imaging. Additionally, each of these enzymes
utilizes a different substrate, effectively simplifying the distinction between the
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bioluminescence of fLuc and RLuc8. The sensor incorporating RLuc8 and fLuc was
termed the Ratiometric Bioluminescent Sensor, or RBS.
Studies involving STS-treated RBS-HeLa cells indicated that fLuc activity was
rapidly lost, while RLuc8 exhibited significantly prolonged functionality. Accordingly,
the bioluminescent ratio (RLuc8 activity):(fLuc activity) correlated well with TUNEL
and Caspase-3/7 Glo assay results, indicating that the RBS could provide information on
cells undergoing PCD.
The RLuc8 and fLuc coding sequences flanked an IRES site in the final plasmid
construct of the RBS in order to allow for protein translation from a single, bicistronic
mRNA(28, 29). In having both genes under the control of a single (CMV) promoter and
expressed as a single mRNA, the RLuc8:fLuc ratio at the transcript level is unaffected by
altered promoter activity. However, previous studies have shown that in healthy cells,
proteins translated from sequences downstream of the IRES site can be expressed at
lower levels compared with upstream sequences(30).

Therefore, to ensure that the

position of the fLuc and RLuc8 coding sequence with respect to the IRES sequence (i.e.,
before or after the IRES sequence) was not responsible for the observed correlation
between the ratio RLuc8:fLuc and cellular stress, the coding sequences for fLuc and
RLuc8 were interchanged. It was found that similar changes in the RLuc8:fLuc ratio
were seen regardless of the position of each luciferase relative to the IRES sequence.
Additionally, the RLuc8:fLuc ratios remained unchanged in untreated cells
regardless of cell number or incubation time. This highlights the potential transitional
use of the RBS, from high-throughput screening where very small samples are used all
the way to animal models, where large numbers of cells are usually necessary.
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There was an interesting disparity present between caspase-3 activity and percent
DNA fragmentation when cells were treated with 10 µM STS over a time course of 24
hours. The caspase-3 activity peaked at 8 hours, while the percent DNA fragmentation
continued to increase. Even though caspase-3 activation is considered to be absolutely
necessary for apoptosis to occur(1), a hallmark trait for cells undergoing any type of PCD
is increased DNA fragmentation(31). Given that the RBS seems to correlate better with
the TUNEL assay for DNA fragmentation, it is expected that it will be able to monitor
various biochemically and morphologically distinct pathways that lead to PCD.
While the discrepancy between RLuc8 and fLuc bioluminescence in cells
undergoing PCD is quite explicit, the mechanism behind this difference remained
unknown. There have been various reports indicating that the proteasome plays an
essential role in PCD(32-34) and that calpain(16, 17) and cathepsin(18, 19) protease
activity is upregulated during PCD. Additionally, increases in ROS that can occur in cells
undergoing PCD broach the possibility of potentially damaging oxidative modifications
to proteins(20-22). In the subsequent determination of the RBS mechanism, the roles of
these proteases and ROS, among others were investigated.
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Chapter 4: The RBS mechanism relies on hydrogen peroxide
4.1 Abstract
The molecular processes involved in PCD are undoubtedly complicated, however
it is generally accepted that protein degradation is readily involved in this phenomenon.
Given the complex nature of the cytosol, there are naturally many avenues that can
eventually lead to protein degradation. Some of the most prominent mechanisms for
protein degradation involve the proteasome, caspases, lysosomal proteases and
oxidatively damaging reactive oxygen species (ROS). In this chapter, comprehensive
inhibition/scavenging studies were performed to determine the cause of the disparity seen
between fLuc and RLuc8 in the RBS. It was shown that this disparity stems from H2O2mediated oxidative damage that preferentially affected fLuc over RLuc8.

4.2 Introduction
Intracellular proteases play various, sometimes complicated, roles in the process
of programmed cell death (see (1), for review). The 26S proteasome is a proteolytic
complex that is present in all mammalian cell types and is responsible for most of the
protein degradation that occurs in cells.

Proteins that are covalently conjugated to

ubiquitin are targeted for rapid proteolysis by the proteasome(2). Ubiquitin production
has been shown to increase in γ-irradiated thymocytes (3) and proteasome inhibition can
result in abrogation of apoptosis (4, 5).
Calpains are cytosolic proteins that depend on Ca2+ for activation(6).

They

typically degrade cytoskelatal proteins(7-9), but do not cleave a specific target sequence
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within proteins(10). Increases in intracellular Ca2+ during apoptosis have previously been
reported (11, 12) and calpains have been shown to be active during apoptosis in many
different cell types(13-15). Additionally, calpain inhibitors have reportedly resulted in
the inhibition of apoptosis in response to certain apoptotic stimuli(16, 17).
Cathepsins are cysteine, zinc and aspartyl proteases that are present primarily in
lysosomes and endosomes, but have been shown to be secreted into the cytosol under
certain conditions(18, 19). Additionally, damage to lysosomal membranes via hydroxyl
radicals (•OH) can result in the release of cathepsins into the cytosol(20, 21). Cathepsin
B and D mRNA and protein levels have been shown to be upregulated in cells
undergoing apoptosis(22, 23) and inhibition studies have shown that when these
proteases are inhibited, apoptosis may also be inhibited(24, 25). Following synthesis,
cathepsins need to be proteolytically processed(26, 27); further, they may be activated in
a cascade-like manner(25), similar to caspases, as it has been reported that cathepsin B is
directly cleaved by cathepsin D to become activated(28, 29).
Perhaps the most thoroughly characterized proteases involved in programmed cell
death are the caspase family of proteases (see (30) for review). Caspases are defined by
the specific amino acids sequences they cleave(31) and caspase-3 is required in order for
a cell to fully complete the apoptotic process(32).
In addition to proteases, ROS can contribute to the degradation or damage of
proteins in dying cells. The superoxide radical (O2•-) does not cause much damage on its
own(33), but it can react with other radicals (•OH)(34) or intracellular iron, leading to the
production of •OH which is highly reactive. The hydroxyl radical (•OH) is generally
considered to be the most powerful oxidizing species in biological systems; the oxidative
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attack of protein backbones is initiated by the •OH-dependent abstraction of the αhydrogen atom of an amino acid residue to form a carbon-centered radical(35). Once a
carbon-centered radical is formed, it can give rise to protein cross-links, peptide-bond
cleavage (via diamide or α-amidation pathways), or direct oxidation of amino acids(35)
The direct oxidation of lysine, arginine, proline and threonine residues may result in the
formation of carbonyl derivatives (e.g. semialdehydes)(36, 37).

Hydrogen peroxide

(H2O2) is a powerful oxidizing agent that can directly and indirectly modify many amino
acids (see (38) for review), often creating hydroxyl- or carbonyl-derivatives. While the
effect of protein oxidation can vary, it has been shown in some cases that oxidation can
destabilize a protein’s native structure and result in the impairment of protein function
and activity loss(39, 40).
In this chapter, after eliminating mRNA as a source of RLuc8 and fLuc activity
discrepancy, we employed a series of inhibition studies on the aforementioned proteases
and ROS on RBS-HeLa cells treated with STS. We have found that the disparity in fLuc
and RLuc8 activity is likely directly related to intracellular H2O2 levels.

4.3 Results
Quantitative RT-PCR revealed that the relative expression of fLuc and RLuc8
mRNA within RBS-HeLa cells did not significantly change regardless of whether being
treated with STS or PBS (Figure 4.1A). In contrast, Western blot analysis revealed that
fLuc protein levels decreased over the time course of STS treatment, while RLuc8 protein
levels remained relatively stable (Figure 4.1B).

Notably, some fLuc staining was

observed at higher than expected molecular weights at later time points, particularly at 24
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hours.

Based on these findings, we began to investigate various cellular pathways

involved in protein degradation and/or modification.

Figure 4.1. Assessment of mRNA and protein levels in STS-treated RBS-HeLa cells. (A) Normalized
RLuc8 and fLuc mRNA levels in RBS-HeLa cells treated with PBS (control, C) or 10 µM STS (STS) for
24 hours. mRNA levels were determined by qRT-PCR. (B) Western blot of RBS-HeLa cells treated with
PBS (-) or 10 µM STS (+) over a time course of 24 hours. β-actin is shown as a loading control.

To investigate pathways related to protein degradation and modification, a
comprehensive series of inhibition studies were performed. It was expected that certain
inhibitors would rescue fLuc activity, resulting in a decrease in the RLuc8:fLuc ratio in
STS-treated RBS-HeLa cells. Since the proteasome is a prominent source of intracellular
protein degradation, it was naturally one of the first molecular entities we investigated for
the inhibition studies. Three proteasome inhibitors were tested, and all three inhibit the
chymotryptic, peptidylglutamic peptidase and tryptic proteasome activity of the
proteasome. MG-132 acts as a ‘suicide substrate’(41), epoxomicin covalently binds to
and modifies specific proteasomal subunits(42) and lactacystin covalently binds to and
irreversibly modifies all β-subunits of the proteasome(43).

When the proteasome

inhibitors were employed (Figure 4.2A), the RLuc8:fLuc ratio increased, i.e.

fLuc
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activity was even further reduced relative to RLuc8. The efficacy of the proteasome
inhibitors was confirmed by performing analogous studies with Proteasome-GLO (Figure
4.2B).

Figure 4.2. RBS response to proteasome inhibition. (A) RBS-HeLa cells were pretreated with PBS
(control), 20 µM MG-132, 10 µM Epoxomicin or 10 µM Lactacsytin for 1 hour before the addition of 10
µM STS or PBS for 24 hours. RLuc8 and fLuc bioluminescence measurements were taken and the
RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in
(A) for 1 hour prior to the addition of 10 µM STS for 24 hours. Proteasome activity was assayed using
Proteasome-Glo and the inhibited bioluminescence values were normalized to uninhibited controls.
Statistical significance: **p<0.01.

Next, inhibitors for various proteases associated with apoptosis and lysosomal
degradation were evaluated, namely calpain Inhibitor III (inhibits calpains), Pepstatin A
(inhibits aspartyl proteases), ammonium chloride (inhibits phagosome-lysosome fusion),
and z-vad-fmk (pan caspase inhibitor).

As shown in figure 4.3A, none of these

inhibitors significantly affected the RLuc8:fLuc ratio of STS-treated cells. The efficacy
of the various protease inhibitors was confirmed by appropriate commercial assays
(Figure 4.3B). As noted in Chapter 2, in lieu of a control assay for ammonium chloride
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effectively inhibiting lysosome-phagosome fusion, we direct the reader to a seminal
paper regarding this phenomenon in HeLa cells(44).

Figure 4.3. RBS response to various protease inhibitors. (A) RBS-HeLa cells were pretreated with PBS
(control), 100 µM Calpain Inhibitor III, 100 µM Pepstatin A, 1 mM ammonium chloride or 1 µM z-vadfmk for 1 hour before the addition of 10 µM STS or PBS for 24 hours. RLuc8 and fLuc bioluminescence
measurements were taken and the RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with
PBS or the inhibitors mentioned in (A) for 1 hour prior to the addition of 10 µM STS for 24 hours.
Protease activity was assayed using appropriate commercial assays and the inhibited values were
normalized to uninhibited controls. Statistical significance: **p<0.01.

Once the proteasome and various proteases were shown to have insignificant
effects on the mechanism responsible for the increase in the RLuc8:fLuc ratio in STStreated cells, focus was shifted to three oxygen byproducts associated with oxidative
stress: superoxide (O2•-), hydroxyl radical (•OH) and hydrogen peroxide (H2O2). Three
O2•- scavengers were tested - Tiron, TEMPOL (both cell-permeable O2•- scavengers) and
MnTMPyP (a cell-permeable superoxide dismutase (SOD) mimetic) - for their ability to
reduce the RLuc8:fLuc ratio by rescuing fLuc activity. Figure 4.4A indicates that none

100

of these scavengers had any significant effect on the RLuc8:fLuc ratio. The efficacy of
the O2•- scavengers was confirmed by performing a dihydroethidium assay (Figure 4.4B).

Figure 4.4. RBS response to O2·- scavengers. (A) RBS-HeLa cells were pretreated with PBS (control), 10
mM Tiron, 10 mM TEMPOL or 100 µM MnTMPyP for 1 hour before the addition of 10 µM STS or PBS
for 24 hours. RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc ratio is
reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in (A) for 1 hour prior
to the addition of 10 µM STS for 24 hours. O2•- scavenging capability was tested using a dihydroethidium
assay and inhibited values were normalized to uninhibited controls. Statistical significance: *p<0.05,
**p<0.01.

Next, three •OH scavengers/inhibitors, namely mannitol (specific •OH scavenger),
deferoxamine (DFO, iron chelator) and tetraethylenepentamine (TEPA, copper chelator)
were examined.

The two metal chelators, alone and in combination, were used to

effectively reduce the amounts of metals available for the Fenton reaction (Fe2+ + H2O2
→ Fe3+ + •OH

+ OH−).

Interestingly, none of the •OH scavengers/inhibitors

significantly affected the RLuc8:fLuc ratio observed in STS-treated cells (Figure 4.5A).
The effective reduction of intracellular

•

OH following the addition of each
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scavenger/inhibitor was confirmed by a decrease in hydroxyphenyl fluorescein
fluorescence (Figure 4.5B).

Figure 4.5. RBS response to ·OH scavengers. (A) RBS-HeLa cells were pretreated with PBS (control),
100 mM Mannitol, 50 µM DFO, 50 µM TEPA or 50 µM DFO + 50 µM TEPA for 1 hour before the
addition of 10 µM STS or PBS for 24 hours. RLuc8 and fLuc bioluminescence measurements were taken
and the RLuc8:fLuc ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors
mentioned in (A) for 1 hour prior to the addition of 10 µM STS for 24 hours. •OH scavenging capability
was tested using a hydroxyphenyl fluorescein assay and inhibited values were normalized to uninhibited
controls. Statistical significance: *p<0.05.

The next group of inhibitors/scavengers that was examined was associated with
reducing intracellular H2O2 levels: catalase (scavenger), allopurinol (xanthine oxidase
(XO) inhibitor), and acetylsalicylic acid (aspirin, cyclooxygenase (COX) inhibitor).
Catalase converts H2O2 to water, allopurinol inhibits XO, an enzyme that catalyzes the
oxidation of hypoxanthine and xanthine, creating H2O2 as a byproduct, and aspirin
inhibits COX enzymes, which possess peroxidase activity. The addition of all three of
these reagents resulted in significant reduction (p<0.01) in the RLuc8:fLuc ratio, as seen
in Figure 4.6A. A reduction in intracellular H2O2 following the addition of each
inhibitor/scavenger was confirmed by a decrease in CM-H2DCFDA fluorescence (Figure
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4.6B). Given these results, catalase, allopurinol and aspirin were subjected to additional
dosing studies and a Western blot to further characterize their behavior.

Figure 4.6. RBS response to H2O2 related scavengers. (A) RBS-HeLa cells were pretreated with PBS
(control), 50 U/mL catalase, 100 µM allopurinol or 1 mM aspirin for 1 hour before the addition of 10 µM
STS or PBS for 24 hours. RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc
ratio is reported. (B) RBS-HeLa cells were pretreated with PBS or the inhibitors mentioned in (A) for 1
hour prior to the addition of 10 µM STS for 24 hours. H2O2 scavenging capability was tested using
appropriate commercial assays and inhibited values were normalized to uninhibited controls. Statistical
significance: *p<0.05, **p<0.01.

The final ROS-related inhibitor tested was uric acid, a peroxynitrite (ONOO-)
scavenger. When RBS-HeLa cells were pretreated with 1 mM uric acid for one hour
prior to 10 µM STS for 24 hours, a slight but insignificant increase in the RLuc8:fLuc
ratio was exhibited compared to cells without this pretreatment (Figure 4.7). As there are
currently no commercial assays available that specifically detect ONOO- only, we
referred to previously published reports indicating that this concentration of uric acid
effectively reduced intracellular ONOO-(45-47).
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Figure 4.7. RBS response to an ONOO- scavenger, uric acid. (A) RBS-HeLa cells were pretreated
with PBS (Control) or 1 mM uric acid for 1 hour before the addition of 10 µM STS or PBS for 24
hours. RLuc8 and fLuc bioluminescence measurements were taken and the RLuc8:fLuc ratio is
reported after normalization to PBS/PBS treated controls.

Catalase, allopurinol and aspirin were explored further since they had the greatest
effect on the RLuc8:fLuc ratio of RBS-HeLa cells treated with STS. RBS-HeLa cells
were pretreated with increasing doses of catalase (Figure 4.8A), allopurinol (Figure 4.8B)
or aspirin (Figure 4.8C) for 1 hour prior to the addition of 10 µM STS. After a 24 hour
incubation period with the various H2O2 inhibitors/scavengers and STS, the
bioluminescent ratio was measured.

It was found that each inhibitor/scavenger

effectively reduced the RLuc8:fLuc ratio in a dose-dependent manner. A Western blot
was also performed (using the same pretreatment conditions from Figure 4.6A) to
directly determine the effect of the various H2O2 inhibitors/scavengers on bioluminescent
protein levels. Consistent with the observed recovery in fLuc activity, STS treated RBSHeLa cells that were pretreated with catalase, allopurinol, and aspirin exhibited higher
levels of fLuc protein (Figure 4.8D, column 3-5) compared to cells treated with STS in
the absence of inhibitor (i.e. PBS, column 2).
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Figure 4.8. Dose response and Western blot analysis of STS-treated cells to H2O2-related scavengers.
RBS-HeLa cells were pretreated with a dosage range of (A) catalase, (B) allopurinol, or (C) aspirin for 1
hour prior to 24 hours of 10 µM STS. The RLuc8:fLuc ratio was calculated and reported. (D) Western
blot on RBS-HeLa cells pretreated for 1 hour with PBS, 50 U/mL catalase, 100 µM allopurinol or 1 mM
aspirin (columns 2-5) before 10 µM STS for 24 hours. β-actin is shown as a loading control.

Having shown that inhibitors/scavengers of H2O2 affected the signal elicited by
the RBS, additional studies were performed that dealt with H2O2 more directly. First,
RBS-HeLa cells that were treated with 10 µM STS for up to 24 hours were analyzed for
H2O2 production using the Amplex Red assay. Figure 4.9A shows that the intracellular
H2O2 concentration increased nearly three-fold under these conditions, compared with
PBS-treated controls. The H2O2 levels in RBS-HeLa cells also increased with STS dose
(6 hour incubation, Figure 4.9B). These trends mirror the increase in the RLuc8:fLuc
ratio that was observed with the RBS (Figure 4.1). To further evaluate the effect of H2O2
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on the RBS, we investigated the response of RBS-HeLa cells to 1 mM H2O2 in serum, for
incubation times ranging from 0 to 24 hours.

Interestingly, it was found that the

bioluminescent ratio increased dramatically, reaching levels that were drastically higher
than what was observed previously with STS treatment (Figure 4.9C). Treating RBSHeLa cells with a range of exogenous H2O2 concentrations for 6 hours also resulted in a
more striking increase of RLuc8:fLuc when compared with the STS dosage study (Figure
4.9D). Additionally, it was found that exposing purified RLuc8 and fLuc proteins to the
HX-XO reaction led to a significant increase (p<0.01) in the RLuc8:fLuc ratio over all
controls.

These findings suggest that the RBS may be specifically responsive to

intracellularly produced H2O2 alone, and not other upstream or downstream reactions
involving other oxygen radicals or enzymes.
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Figure 4.9. Analysis of intracellular H2O2, exogenous application of H2O2, and the hypoxanthine-xanthine
oxidase reaction. RBS-HeLa cells treated with (A) 10 µM STS over a course of 24 hours or (B) a dosage
range of STS for 6 hours were assayed for H2O2 concentrations using the Amplex Red Hydrogen
Peroxide/Peroxidase assay. RBS-HeLa cells were treated with (C) 5 mM H2O2 in serum over a course of
24 hours or (D) a dosage of H2O2 for 6 hours and the normalized RLuc and fLuc bioluminescence
measurements (left axis) and the RLuc8:fLuc ratio (right axis) were determined. (E) RBS-HeLa cells were
subjected to PBS (Control) or the HX-XO reaction (50 µM HX, 25 mU/mL XO) for 24 hours. The
RLuc8:fLuc ratio was calculated and reported. (F) Purified RLuc8 and fLuc proteins were treated in vitro
with PBS (Control), 50 µM HX, 25 mU/mL XO or 50 µM HX + 25 mU/mL XO for 4 hours. The
RLuc8:fLuc ratio was calculated and reported.
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To investigate whether reductions in the level of H2O2, specifically through the
use of allopurinol pretreatment, protected STS-treated RBS-HeLa cells from cell death, a
TUNEL assay was performed. As can be seen in Figure 4.10A, allopurinol had no effect
on DNA fragmentation levels, indicating that it had no effect on cell death.
Bioluminescence measurements from HeLa cells pretreated with allopurinol before STS
indicated a significant (p<0.01) decrease in the RLuc8:fLuc ratio compared to cells
pretreated with PBS (Figure 4.10B). A CM-H2DCFDA assay was performed to assess
intracellular H2O2 levels under the same conditions, and as shown in Figure 4.10C, these
levels were significantly reduced (p<0.01) by allopurinol pretreatment compared to PBS
pretreatment. These results provide further support that changed in the RLuc8:fLuc ratio
that are observed in apoptotic cells are likely mediated by H2O2.
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Figure 4.10. Summary of RBS-HeLa responses to allopurinol pretreatment.

RBS-HeLa cells were

pretreated with either PBS or 100 µM allopurinol for 1 hour prior to PBS or 10 µM STS for 24 hours. (A)
DNA fragmentation levels from a TUNEL assay. (B) RLuc8:fLuc bioluminescence ratios from fLuc and
RLuc8 bioluminescence measurements. (C) Intracellular H2O2 levels as measured by CM-H2DCFDA. For
(B) and (C), measurements were normalized to PBS/PBS controls. Statistical significance: *(p<0.05),
**(p<0.01).

In order to obtain a more definitive understanding of the role of H2O2 in the
mechanism of the RBS, we exposed purified RLuc8 and fLuc to increasing
concentrations of H2O2 (0, 1, 5 and 10 mM) for 2 hours. Each well contained 650 nM
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fLuc or 650 nM RLuc8. Aliquots from each reaction were removed every 30 minutes
and subjected to SDS-PAGE.

When fLuc was treated with H2O2, protein levels

decreased with increasing time and dose, compared to untreated controls as can be seen
in Figure 4.11 (first lane of each panel). Smearing of the fLuc band is seen from 30-90
minutes for 5 and 10 mM H2O2, indicative of possible degradation. In the case of RLuc8
treated with H2O2, little change was observed over either time or dose (Figure 4.11,
second lane of each panel).

Figure 4.11. Response of purified fLuc and RLuc8 proteins to H2O2 visualized with SDS-PAGE.
Proteins (650 nM fLuc or 650 nM RLuc8) were treated with 0-10 mM H2O2 for up to 120 minutes.
Every 30 minutes, aliquots were removed and subjected to SDS-PAGE. For every panel, Lane 1: fLuc,
Lane 2: RLuc8.

During the same study, aliquots from each reaction were removed and analyzed
for bioluminescence. A dose and time dependent decrease in fLuc bioluminescence was
demonstrated when fLuc was treated with H2O2 (Figure 4.12A), while RLuc8
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bioluminescence remained quite stable under the same conditions (Figure 4.12B). The
resulting RLuc8:fLuc ratio is presented in Figure 4.12C, and this ratio increases over both
time and dose.

Figure 4.12. Bioluminescence response of purified fLuc and RLuc8 proteins to H2O2. Proteins (650 nM
fLuc or 650 nM RLuc8) were treated with 0-10 mM H2O2 for up to 120 minutes. Every 30 minutes,
aliquots were removed and subjected to bioluminescence measurements using Dual-Glo. (A)
Bioluminescence measurements of fLuc treated with 0-10 mM H2O2 for up to 120 minutes. (B)
Bioluminescence measurements of RLuc8 treated with 0-10 mM H2O2.

(C) Bioluminescence ratios

(RLuc8:fLuc) of measurements from (A) and (B).

When fLuc was treated with H2O2, fLuc bioluminescence appeared to decay at a
faster rate than protein levels for all H2O2 concentrations tested.

For example,

bioluminescence values were less than 1% of control values after 120 minutes (Figure
4.12A), but fLuc protein levels were clearly higher when compared to control (Figure
4.11). These observations indicate that H2O2 may have oxidatively modified or damaged
the fLuc proteins, rendering them inactive, prior to degradation/protein loss.
A possible mechanism causing the modification and subsequent degradation of
fLuc is protein carbonylation, as this modification can damage/inactivate enzymes and
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serve as a trigger for protein degradation (see (48) for review).

Proteins can become

carbonylated directly through oxidative attack on amino acid side chains as well as
indirectly through reaction with lipid radicals, carbohydrate radicals and nucleic acid
radicals(38). Interestingly, a recent study has suggested that protein carbonylation caused
by lipid radicals is actually more common than carbonylation caused by direct amino acid
side chain oxidative attack(49). Our studies on RBS-HeLa cells treated with STS for 24
hours have shown increased protein carbonylation compared to PBS treated control cells
as shown in Figure 4.13A. The carbonylation assay uses DNP antibodies to detect
protein carbonyls that have been derivatized to DNP using DNPH. Lanes 1 and 3
represent RBS-HeLa cells treated with PBS or STS and a derivatization control solution,
while lanes 2 and 4 represent PBS or STS and DNPH treated cells. A marked increase
can be seen in carbonylated proteins between lanes 2 and 4.
To further investigate carbonylation levels specifically in fLuc and RLuc8,
purified samples of these proteins were treated with either PBS or 5 mM H2O2 for 2 hours
and then subjected to the same carbonylation assay. As seen in Figure 4.13B, fLuc
proteins treated with H2O2 exhibit a striking increase in carbonylation levels compared to
PBS-treated controls (lanes 3 and 1, respectively). In contrast, very little difference in
carbonylation is seen between PBS- and H2O2-treated RLuc8 proteins (lanes 2 and 4,
respectively). Further, the relatively higher levels of carbonylation seen in PBS-treated
fLuc proteins (lane 1) compared to PBS-treated RLuc8 proteins (lane 2) may explain the
decrease in fLuc bioluminescence seen in PBS-treated fLuc in Figure 4.12A at the 120
minute time point.
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Figure 4.13. Analysis of protein carbonylation in STS-treated RBS-HeLa cells and H2O2-treated
fLuc and RLuc8 proteins. (A) Proteins from RBS-HeLa cells treated with PBS (columns 1 and 2)
or STS (columns 3 and 4) were extracted and treated with Derivatization-Control solution (C,
columns 1 and 3) or DNPH (columns 2 and 4). The resulting proteins were subsequently analyzed
by Western blot. (B) Purified fLuc and RLuc8 proteins were treated with either PBS (columns 1
and 2) or 5 mM H2O2 for 2 hours. After treatment with DNPH, the samples were analyzed by
Western blot.
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4.4 Discussion
Quantitative RT-PCR and western blot analyses were performed to determine
whether changes in RNA or protein levels were responsible for the loss of fLuc activity,
but not RLuc8 activity. Previous studies have shown that oxidative stress can trigger the
degradation of both mRNA (50) and proteins(38). If RNA was degraded, we would
expect to see a drastic difference in the relative level of fLuc and RLuc8 mRNA
expression after STS treatment, compared with PBS-treated controls; however, this was
not the case.

In contrast, western blot analysis revealed that the fLuc protein levels

decreased over time, while the RLuc8 protein levels remained relatively stable.
Additionally, several higher molecular weight bands were observed after fLuc staining at
the later time points, introducing the possibility of protein cross-linking and/or posttranslational modification. These results indicated that ‘activation’ of the RBS can be
attributed to the susceptibility of the bioluminescent proteins themselves to cellular
stresses.
To explicate the root cause responsible for the loss in fLuc activity in STS-treated
cells

and

the

corresponding

increase

in

the

RLuc8:fLuc

ratio,

systematic

inhibition/scavenger studies were performed to individually silence key pathways known
to cause protein degradation/modification. It was expected that certain inhibitors would
rescue fLuc activity, resulting in a decrease in the RLuc8:fLuc ratio in STS-treated RBSHeLa cells.

Since the proteasome is a prominent source of intracellular protein

degradation, it was naturally one of the first molecular entities we investigated for the
inhibition studies. Surprisingly, employment of the proteasome inhibitors MG-132,
epoxomicin and lactacystin did not rescue fLuc activity and actually demonstrated an
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increase in the RLuc8:fLuc ratio. These results provided strong evidence that enhanced
proteasomal degradation was not responsible for the loss of fLuc activity in STS-treated
cells. Since proteasome inhibitors have previously been shown to increase intracellular
ROS levels(51-54) these findings hinted at ROS as a potential cause for the loss of fLuc
activity.
Next, various proteases associated with the apoptotic and lysosomal pathways
were inhibited to examine their effects on the RBS sensor. None of the inhibitors tested
(Calpain Inhibitor III, Pepstatin A, ammonium chloride and z-vad-fmk) significantly
affected the RLuc8:fLuc ratio, indicating the unlikelihood of the related proteases’
involvement in the RBS mechanism.

While the increase in the RLuc8:fLuc ratio

observed upon use of the Calpain Inhibitor III on untreated (–STS) cells requires further
exploration, one possible explanation may involve the decrease of intracellular
antioxidant glutathione (GSH) levels and the associated increase in oxidative stress that
has been shown to occur with the addition of this inhibitor(55).
After eliminating the proteasome and various proteases as primary candidates
responsible for the increase in the RLuc8:fLuc ratio in STS-treated cells, we began
examining the effects of scavengers for oxygen byproducts to determine the role of
oxidative stress on the RBS. The three O2•- scavengers that were tested (Tiron, TEMPOL
and MnTMPyP) showed no significant change in the RLuc8:fLuc ratio, concluding that
O2•- alone is likely not responsible for the trends observed in STS-treated RBS-HeLa
cells. This was somewhat expected given the short half-life of O2•- and its function as a
precursor to other oxidizing agents. The three scavengers/inhibitors of •OH (mannitol,
DFO and TEPA) also did not significantly reduce the RLuc8:fLuc ratio in STS treated
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RBS-HeLa cells, effectively eliminating the likelihood that •OH as a direct contributor to
the loss in fLuc activity. It may be argued that the slight increase in RLuc8:fLuc ratio
that was observed following the addition of TEPA to the RBS-HeLa cells could be a
result of excess H2O2 buildup from the prevention of the Fenton reaction, however further
studies are warranted especially since the combination of DFO + TEPA did not yield an
additive effect.

In

contrast to the previous inhibition studies, all three

inhibitors/scavengers of H2O2 tested (catalase, allopurinol and aspirin), yielded a
significant reduction (p<0.01) in the RLuc8:fLuc ratio, suggesting that fLuc activity can
be recovered in STS-treated RBS-HeLa cells through removal of H2O2. It should be
noted that catalase cannot cross cell membranes, but our results are consistent with
previous studies reporting that extracellularly added catalase is effective at removing
intracellular H2O2 (56, 57).
The final ROS investigated was ONOO-, by employing uric acid, an intracellular
antioxidant that scavenges and becomes nitrosated by ONOO-(58). Pretreatment of RBSHeLa cells with 1 mM uric acid prior to 10 µM STS for 24 hours had no effect on the
RLuc8:fLuc ratio. Interestingly, ONOO- has been reported to deplete intracellular GSH
levels(59); therefore it would be expected that the scavenging of ONOO- by uric acid
would alleviate this depletion, effectively reducing ROS and the RLuc8:fLuc ratio.
However, the RLuc8:fLuc ratio did not decrease with uric acid pretreatment, suggesting
that GSH may not be a primary target for ONOO-.
Dosing studies of the three H2O2 related inhibitors on STS-treated RBS-HeLa
cells revealed a reduction in the RLuc8:fLuc ratio in a dose-dependent manner,
confirming that fLuc activity could be recovered by reducing H2O2 levels in STS-treated
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cells. Additionally, a Western blot performed on STS-treated RBS-HeLa pretreated with
each inhibitor/scavenger resulted in the rescue of fLuc protein levels when compared to
STS treatment alone. Therefore, H2O2 inhibitors/scavengers were able to significantly
reduce the degradation and/or modification of fLuc. The increase in H2O2 levels of STStreated RBS-HeLa cells over time further supports the intrinsic involvement of H2O2 on
the RBS mechanism, as does the striking increase in the RLuc8:fLuc ratio of these cells
when treated directly with H2O2 in serum.
Since the highest level of fLuc rescue was seen when RBS-HeLa cells were
pretreated with allopurinol, an XO inhibitor, an additional cellular assay was performed
with HX and XO added to the media of RBS-HeLa cells. Here, the RLuc8:fLuc ratio
also increased significantly (p<0.01) after 24 hours. While it has been thought that this
reaction produces the superoxide anion in addition to H2O2, recent studies have shown
that H2O2 is the dominant oxidant produced in this reaction(60). The magnitude of the
increase was above that of STS treatment, but lower than H2O2 treatment, which was
expected given that this reaction is expected to produce H2O2 more directly than STS but
is obviously not as harsh as direct H2O2 application.
Additionally, it was found that exposing purified RLuc8 and fLuc proteins to the
HX-XO reaction led to a significant increase (p<0.01) in the RLuc8:fLuc ratio over all
controls.

These findings suggest that the RBS may be specifically responsive to

intracellularly produced H2O2 alone, and not other upstream or downstream reactions
involving other oxygen radicals or enzymes.
Interestingly, when RBS-HeLa cells were pretreated with allopurinol for 1 hour
prior to STS, no change in DNA fragmentation levels were seen. In parallel assays, this
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pretreatment significantly reduced both the RLuc8:fLuc ratio and intracellular H2O2 level
compared to cells pretreated with PBS. The correlation between the RLuc8:fLuc ratio
and intracellular H2O2 levels supports the notion that the RBS is specifically responsive
to H2O2 and not other processes associated with cell death. Further, the inability of
allopurinol to affect cell death suggests that H2O2 production is a consequence of cell
death, not a catalyst for cell death.
To investigate the specific effects of H2O2 on fLuc and RLuc8, these proteins
were treated with 0-10 mM H2O2. SDS-PAGE gels and bioluminescence measurements
of each reaction were obtained throughout the course of 120 minutes and it was found
that fLuc bioluminescence and protein levels decreased when it was treated alone, while
both of these metrics remained relatively stable for RLuc8 under the same conditions.
Interestingly, fLuc bioluminescence appeared to decay more rapidly than fLuc protein
levels at all H2O2 concentrations tested. These observations indicate that H2O2 may have
oxidatively modified or damaged the fLuc proteins, rendering them inactive, prior to
degradation/protein loss.
It is hypothesized that H2O2 may differentially affect the proteins of the RBS
through protein carbonylation prior to degradation, as an increase in this phenomenon
was seen in STS treated cells versus PBS treated cells. Additionally, purified fLuc
proteins exhibited higher levels of carbonylation versus RLuc8 when treated with H2O2.
Protein carbonylation is irreversible(61), can cause protein aggregates to form(62, 63)
and targets the damaged proteins for degradation(64).
In summary, we have shown that the bioluminescent ratio (RLuc8 activity):(fLuc
activity) could be used to report on the extent of intracellular stress. Through various
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inhibition assays, it has been determined that the likely candidate causing the discrepancy
between fLuc and RLuc8 activity in STS-treated cells is H2O2. The specific affect that
H2O2 has on fLuc compared to RLuc8 has yet to be determined. An initial theory
involved specific amino acid modifications on the proteins by H2O2. For example, H2O2
can modify certain amino acids, including but not limited to methionine (M), cysteine
(C), histidine(H), tyrosine (Y) and phenylalanine (F), (see(38), for review), often creating
hydroxyl- or carbonyl-derivatives. The proposed active site for fLuc is 244H-H-GlycineF-247 (65) while the proposed active site for rLuc is a catalytic triad composed of
aspartic acid (D) 120, glutamic acid (E) 144, and H285(66). Given that both of these
active sites contain amino acids that are commonly oxidatively modified, it is not clear
whether the differential sensitivity of fLuc and RLuc8 to H2O2 can be attributed to this
alone.
We have determined that the RBS has the potential to relay important information
regarding hydrogen peroxide in HeLa cells undergoing cell death. Given that caspases
did not influence the RBS (Figure 3A), we anticipate that the RBS may be quite useful in
studies examining caspase-independent cell death, especially since these pathways
generally involve an increase in ROS (67, 68). Caspase-independent cell death has
recently been garnering attention in terms of cancer drug development since anticancer
drug resistance and tumorigenesis have been linked to the ability of certain cancers to
circumvent caspase activation(69, 70).

It is envisioned that the in vitro findings

presented here will correlate well with in vivo work, potentially opening doors for
advances in therapeutic and antioxidant research.
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Chapter 5: The RBS can detect caspase-dependent PCD in
multiple cell lines using multiple inducers
5.1 Abstract
Many imaging sensors currently utilized to investigate PCD rely on the cleavage
of the amino acid sequence DEVD by caspase-3.

However, caspase-3 activity is

transiently activated and thus does not always directly correlate with the extent of cell
death. Further, since caspase-7 can also cleave DEVD, PCD sensors based on caspase-3
activity may lead to ambiguous findings and inaccurate conclusions. In this chapter, we
show RBS measurements consistently correlate with the extent of cell death, even in
cases where caspase-3 probes fail. The RBS was used to detect PCD in MCF7 and
293T/17 cells treated with STS and in HeLa cells treated with DOX and Cpt to
demonstrate the robustness of this approach.

5.2 Introduction
According to the American Cancer Society, cancer remains one of the most
devastating diseases in the United States with over 500,000 deaths and 1.5 million new
cases in 2009.

Although great strides have been made in the pursuit of cancer

therapeutics, the vast array of cancer phenotypes makes it an elusive target for definitive
cures. As a result, there remains much to be discovered in terms of improving treatment.
Many therapies that have been developed to treat cancer involve inducing
apoptosis, a type of programmed cell death (PCD), that is mechanistically characterized
by a proteolytic cascade involving caspases (See (1) for comprehensive review).
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Accordingly, a variety of sensors have been developed to image and monitor apoptosis,
or more specifically caspase activity, to further assist in the discovery, development, and
evaluation of apoptosis-inducing agents. Most of these sensors are based on fluorescence
resonance energy transfer (FRET) or ground-state quenching, whereby removal of an
acceptor fluorophore or quenching moiety, respectively, following cleavage of a caspasespecific recognition sequence results in detectable change in fluorescence(2-11).
Bioluminescence is an appealing alternative to fluorescence due to its sensitivity,
cost-effectiveness, simplicity, virtually non-existent background signals, high-throughput
screening potential and ability to acquire temporal information in cells and in live animal
models.
developed.

Recently, several bioluminescent sensors for apoptosis have also been
In general, these sensors have utilized the cleavage of the caspase-3

recognition sequence, DEVD, as a catalyst for luciferin (substrate) recognition(12, 13),
removal of steric hindrance(14), or protein fragment complementation(15). However,
many drugs that induce PCD act through a caspase-independent mechanism (see (16) for
review), which would render caspase-specific sensors futile. Another confounding factor
in regarding sensors for caspase-3 is that caspase-7 recognizes and cleaves the same
amino acid sequence (DEVD) as caspase-3. Thus, sensors designed specifically for
caspase-3 activity as a biomarker for apoptosis may not accurately report on intracellular
mechanisms associated with cell death or the extent of cell death when used alone.
We have previously determined that the RBS is activated in HeLa cells
undergoing apoptosis and that the response correlates with intracellular H2O2 levels. In
this chapter, we show that the RBS also functions in MCF7 and 293T/17 cell lines treated
with STS and in HeLa cells treated with doxorubicin (DOX) and camptothecin (Cpt), two
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drugs known to induce apoptosis in HeLa cells(17, 18). The capability of the RBS to
detect PCD induced in multiple cell types and with different drugs demonstrates its
versatility and robustness.

5.3 Results
When RBS-MCF7 cells were treated with the apoptosis inducing drug
staurosporine (STS) for 6 hours, the fLuc bioluminescence decreased by up to 90% in a
dose-dependent manner. In contrast, the RLuc8 bioluminescence was much less sensitive
to the treatment, only decreasing by 20% at the maximum dosage (Figure 5.1A). The
resulting bioluminescent ratio RLuc8:fLuc increased accordingly with dosage. It was
previously shown in Chapter 4, with purified bioluminescent proteins and in living cells,
that changes in the ratio RLuc8:fLuc correlate with the level of H2O2. Consistent with
this assessment, the intracellular H2O2 levels in MCF7 cells also increased with STS
dose, as determined by a CM-H2DCFDA assay (Figure 5.1B). To confirm that the STS
treatment was causing apoptosis, two cell death assays were performed in parallel. As
can be seen in Figures 5.1C and 5.1D, both caspase 3/7 activity and DNA fragmentation,
well-known hallmarks of apoptosis(19, 20), increased under the same treatment
conditions.
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Figure 5.1. Response of RBS-MCF7 cells to increasing STS dosage. RBS-MCF7 cells were treated with a
dosage range of STS (0-50 µM) for 6 hours. (A) Bioluminescent measurements of RLuc8 and fLuc were
acquired for each STS concentration after 6 hours (left axis). The RLuc8:fLuc ratio was subsequently
calculated for each STS concentration (right axis). (B) Intracellular H2O2 levels were assessed using CMH2DCFDA at each STS concentration. (C) A Caspase 3/7 Glo assay was performed to measure caspase
activity at each STS concentration. (D) A TUNEL assay for DNA fragmentation was performed at each
STS concentration.
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As described in Chapter 4, fLuc bioluminescence in STS-treated RBS-HeLa cells
can be rescued by pretreatment with allopurinol, resulting in a corresponding reduction in
the ratio RLuc8:fLuc. Allopurinol is a xanthine oxidase (XO) inhibitor that is known to
reduce the intracellular level of H2O2(21). To investigate the effects of this pretreatment
on RBS-MCF7 cells, 100 µM of allopurinol was added to the cells one hour before
treatment with 1 µM STS for 6 hours. As expected, this resulted in a significant decrease
in the RLuc8:fLuc ratio (p < 0.05) compared to STS treatment alone (Figure 5.2A).
Interestingly, pretreatment with allopurinol had no effect on cell death, as shown by
unchanged caspase 3/7 activity and DNA fragmentation in Figures 5.2B and 5.2C.
However, a significant (p < 0.05) decrease in intracellular H2O2 was seen when MCF7
cells were pretreated with allopurinol before the addition of STS (Figure 5.2D).
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Figure 5.2. Response of STS-treated RBS-MCF7 cells to allopurinol pretreatment. RBS-MCF7 cells were
pretreated with 100 µM allopurinol for 1 hour prior to 1 µM STS for 6 hours (A) RLuc8:fLuc ratios were
acquired for cells exposed to PBS pretreatment followed by PBS as drug treatment (i.e. PBS/PBS),
PBS/STS or Allo/STS. (B) Caspase 3/7 activity was acquired for cells exposed to PBS/PBS, PBS/STS or
Allo/STS.

(C) TUNEL assays for DNA fragmentation were performed on cells exposed to PBS/PBS,

PBS/STS or Allo/STS. (D) Intracellular H2O2 measurements were acquired for cells exposed to PBS/PBS,
PBS/STS or Allo/STS. In all studies (except TUNEL assays, which provide an absolute measure of cell
death), measurements were normalized to control (0 µM STS). Statistical significance: * (p<0.05), **
(p<0.01).
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The STS treatment studies were expanded over a time course of 24 hours using 10
µM STS on RBS-MCF7 cells. As shown in Figure 5.3A, the RLuc8:fLuc ratio increased
dramatically over this time course while the PBS treated controls exhibited little change.
Consistent with the RBS measurements, the intracellular H2O2 levels continually
increased from 0 to 24 hours with STS treatment and exhibited little change with only
PBS treatment (Figure 5.3B).
Interestingly, caspase activity did not continuously increase with time following
the addition of STS, but rather reached a peak at the 6 hour time point and returned to
control values by 24 hours (Figure 5.3C). In contrast, the TUNEL assay revealed that
cell death remained elevated for the entire 24 hours after STS treatment (Figure 5.3D).
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Figure 5.3. Response of RBS-MCF7 to treatment with PBS (untreated control) or 10 µM STS over the
course of 24 hours. (A) Bioluminescent measurements of RLuc8 and fLuc were acquired at various times
following treatment with STS or PBS (left axis) and the RLuc8:fLuc ratios were subsequently calculated
(right axis). (B) Intracellular H2O2 levels were measured during the course of treatment. (C) Caspase
activity measurements were acquired at various time points. (D) The percent DNA fragmentation was
determined at various time points using a TUNEL assay. In all studies (except TUNEL assays, which
provide an absolute measure of cell death), measurements were normalized to control (time = 0).

The versatility of the RBS was tested further in 293T/17 cells. When RBS293T/17 cells were treated with a dosage range of STS (0-50 µM) for 6 hours, fLuc
bioluminescence decreased and RLuc8 bioluminescence remained relatively stable with
increasing dosage (Figure 5.4A, left axis); thus an increase in the RLuc8:fLuc ratio was
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observed (Figure 5.4A, right axis).

Under the same treatment conditions, a rise in

intracellular H2O2 was exhibited (Figure 5.4B). The two control assays for cell death
revealed that caspase-3 activity increased (Figure 5.4C) along with DNA fragmentation
(Figure 5.4D), indicating that increasing STS dosage led to a corresponding increase in
PCD.

Figure 5.4. Response of 293T/17 cells to increasing STS dosage. RBS-293T/17 cells were treated with a
dosage range of STS (0-50 µM) for 6 hours. (A) Bioluminescence measurements of RLuc8 and fLuc were
acquired for each STS concentration after 6 hours (left axis). The RLuc8:fLuc ratio was subsequently
calculated for each STS concentration (right axis). (B) Intracellular H2O2 levels were assessed using CMH2DCFDA at each STS concentration. (C) A Caspase 3/7 Glo assay was performed to measure caspase
activity at each STS concentration. (D) A TUNEL assay for DNA fragmentation was performed at each
STS concentration.
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The effects of 10 µM STS over the course of 24 hours were also examined in
RBS 293T/17 cells. As expected, the RLuc8:fLuc ratio increased with time, as shown in
Figure 5.5A, while the PBS treated control remained unchanged. Similarly, intracellular
H2O2 (Figure 5.5B) levels increased when treated with 10 µM STS for up to 24 hours
compared to PBS treated controls. The two control assays for cell death indicated that
caspase-3 activity increased (Figure 5.5C) and DNA fragmentation (Figure 5.5D), also
increased with time.
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Figure 5.5. Response of RBS-293T/17 to treatment with PBS (untreated control) or 10 µM STS over the
course of 24 hours. (A) Bioluminescent measurements of RLuc8 and fLuc were acquired at various times
following treatment with STS or PBS (left axis) and the RLuc8:fLuc ratios were subsequently calculated
(right axis). (B) Intracellular H2O2 levels were measured during the course of treatment. (C) Caspase
activity measurements were acquired at various time points. (D) The percent DNA fragmentation was
determined at various time points using a TUNEL assay. In all studies (except TUNEL assays, which
provide an absolute measure of cell death), measurements were normalized to control (time = 0).

Similar to RBS-MCF7 and RBS-HeLa cells, RLuc8:fLuc ratio and intracellular
H2O2 levels in STS-treated RBS-293T/17 cells (10 µM STS for 24 hours) could be
significantly reduced (p<0.05) by the application of 100 µM allopurinol for one hour
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prior to STS, as shown in Figure 5.6A and 5.6B, respectively. These results further
support the notion that the PCD detection of the RBS is related to H2O2 levels.

Figure 5.6. Effect of allopurinol on PBS (-STS) and STS treated RBS-293T/17 cells.

100 µM

allopurinol or PBS was added to the cells for 1 hour prior to PBS or 10 µM STS application for 24 hours.
(A) RLuc8 and fLuc bioluminescence measurements were obtained and the RLuc8:fLuc ratio is calculated
and reported. (B) Intracellular H2O2 levels were measured using CM-H2DCFDA. For both assays, values
were normalized to PBS/PBS treated controls. Statistical significance: *(p<0.05).

Further investigation of the capabilities of the RBS involved treating RBS-HeLa
cells with doxorubicin (DOX) and camptothecin (Cpt). RBS-HeLa cells treated with 1
µM DOX exhibited an increase in the RLuc8:fLuc ratio over the time course of 48 hours,
compared to control (Figure 5.7A). In addition, intracellular H2O2 levels also increased
in DOX-treated cells compared to controls (Figure 5.7B). The application of 10 µM Cpt
for up to 48 hours elicited similar results for the RLuc8:fLuc ratio (Figure 5.7C) and
intracellular H2O2 levels (Figure 5.7D).
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Figure 5.7. Effects of DOX and Cpt on RBS-HeLa cells. RBS-HeLa cells were treated with PBS (i.e.
untreated control), 1 µM DOX or 10 µM Cpt over the time course of 48 hours.

RLuc8 and fLuc

bioluminescence measurements were taken at various time points following treatment with (A) DOX or (C)
Cpt or PBS and the RLuc8:fLuc ratio was calculated. Intracellular H2O2 levels were measured in cells
treated with (B) DOX, (D) Cpt or PBS. All reported values were normalized to time 0.

When RBS-HeLa cells were treated with 1 µM DOX over a time course of 48
hours, caspase-3 activity increased, compared to PBS treated control (Figure 5.8A).
Under the same treatment conditions, DNA fragmentation percentage increased
predominantly from 24 to 48 hours (Figure 5.8B). The application of 10 µM Cpt on
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RBS-HeLa cells for 48 hours yielded a similar increase in caspase-3 activity (Figure
5.8C). The percent of DNA fragmentation increased earlier in the Cpt treated cells
(Figure 5.8D) compared to DOX-treated cells, but the kinetic profile was similar between
24 and 48 hours.

Figure 5.8. Response of commercial cell death assays in RBS-HeLa cells treated with DOX or Cpt.
Caspase activity measurements were taken at various time points using Caspase-3/7 Glo after (A) 1 µM
DOX , (C) 10 µM Cpt or PBS treatment on RBS-HeLa cells. Values were normalized to PBS (untreated)
control at time 0. TUNEL assays for DNA fragmentation were performed on cells treated with (B) DOX,
(D) Cpt, or PBS. In all studies (except TUNEL assays, which provide an absolute measure of cell death),
measurements were normalized to control (time = 0).
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To investigate the role of H2O2 in the mechanism of the RBS in HeLa cells treated
with DOX and Cpt, RBS-HeLa cells were pretreated with 100 µM allopurinol for 1 hour
prior to drug treatment. Allopurinol pretreatment prior to 1 µM DOX application yielded
a significant (p<0.05) decrease in the RBS ratio compared to PBS pretreated control
(Figure 5.9A).

Intracellular H2O2 levels also decreased significantly (p<0.01) with

allopurinol pretreatment before DOX application (Figure 5.9B).

Similar significant

decreases (p<0.01) in the RLuc8:fLuc ratio and intracellular H2O2 levels were
demonstrated in RBS-HeLa cells treated with allopurinol prior to 10 µM Cpt (Figure
5.9C and 5.9D, respectively).
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Figure 5.9. Response of DOX and Cpt treated RBS-HeLa cells to allopurinol pretreatment. RBS-HeLa
cells were treated with PBS or 100 µM allopurinol for 1 hour prior to 1 µM DOX or 10 µM Cpt for 48
hours. RLuc8 and fLuc bioluminescence measurements were taken at various time points following
treatment with (A) DOX or (C) Cpt and the RLuc8:fLuc ratio was calculated. Intracellular H2O2 levels
were measured in cells treated with (B) DOX, (D) Cpt or PBS. All reported values were normalized
PBS/PBS treated controls.

5.4 Discussion
It was shown in chapter 3 that the RBS is responsive to cell death induced by STS
in HeLa cells. To begin to investigate the span of cell types in which the RBS could
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function, RBS-MCF7 and RBS-293T/17 cells were also subjected to STS dosage and
time course studies. The RBS exhibited an increase in the RLuc8:fLuc ratio in both cell
lines with an increase in STS dosage (6 hour treatment); additionally, the RLuc8:fLuc
ratio increased with time in RBS-MCF7 and RBS-293T/17 cells treated with 10 µM STS
for up to 24 hours. Corresponding assays for cell death demonstrated that both cell lines
were undergoing PCD under these conditions, which was expected based on previous
reports of STS inducing PCD in MCF7 (22) and 293T/17 cells(23). The ability of the
RBS to relay information on cell death in MCF7 and 293T/17 cells in addition to HeLa
cells indicates its versatility and potential for utilization over a wide range of cellular
research endeavors.
Similar to HeLa cells, when MCF7 and 293T/17 cells are treated with STS, cell
death was accompanied by an increase in H2O2. These findings suggest that H2O2 levels
are increased in a wide range of cell lines as a consequence of STS-induced PCD,
consistent with previous reports(24, 25). As shown in chapter 4, the RLuc8:fLuc ratio
can be reduced in STS-treated RBS-HeLa cells by pretreatment with allopurinol, and this
reduction is due to the rescue of functional fLuc protein levels. Allopurinol, a xanthine
oxidase (XO) inhibitor(21), prevents the oxidation of xanthine or hypoxanthine by XO,
thereby reducing production of the dominant oxidant of H2O2(26). The treatment of
RBS-MCF7 cells with allopurinol for 1 hour prior to STS effectively reduced the RBS
ratio and intracellular H2O2 levels, while leaving caspase-3 activity and DNA
fragmentation unchanged. The correlation between the decrease in intracellular H2O2 and
the reduction in the RLuc8:fLuc ratio further supports the notion that the RBS is
specifically responsive to H2O2 during cell death. However, the inability of allopurinol to
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affect the extent of cell death suggests that H2O2 production is a consequence of cell
death, not a catalyst for cell death.
The STS time course studies on RBS-MCF7 cells introduced an interesting
disparity between caspase-3 activity and DNA fragmentation, RBS ratio and intracellular
H2O2 levels; namely, caspase-3 activity returned to near-control levels while the
remaining three parameters continued to increase. These results highlight how the use of
caspase-3 activity as a biomarker for cell death could potentially lead to ambiguous
findings, due to the transient nature of its activation. Here, the RBS may hold an
advantage over traditional cell death assays, since it is capable of detecting cell death
when caspase activity assays cannot and it possesses real-time detection ability.
Additionally, the RBS can be used for in vivo assays, an ability that is not characteristic
of the TUNEL assay. The correlation between the TUNEL assay and the RBS, even in
the absence of caspase activity, suggests that the RBS may be able to provide insight on
cells undergoing caspase-independent PCD. This would not be entirely surprising
considering that many previous studies have shown that caspase-independent cell death
pathways can involve ROS(27-32).
Inducing caspase-dependent cell death (apoptosis) in tumor cells remains a topic
of interest regarding cancer therapeutics, and DOX and Cpt are two well-established
therapeutics (see (33, 34) for reviews, respectively). The overall increasing trend in
RLuc8:fLuc ratio, DNA fragmentation and H2O2 levels following DOX- and Cpttreatment suggests that the RBS will likely detect cell death under a vast array of
induction methods. Many other drugs have also been shown to result in an increase in
H2O2 levels. For example, it has been shown that murine epidermal cells treated with
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vanadate undergo apoptosis and exhibit an increase in intracellular H2O2 cells(35). Also,
apoptosis induced by erbstatin (36), vinblastine and inostamycin (37) in human small cell
lung carcinoma cells is accompanied by increased intracellular H2O2 levels.
In summary, we have determined that the RBS is capable of detecting PCD in
multiple cell lines using multiple inducers. It is envisioned that the RBS will prove to be
useful for investigations of any death-inducing conditions that are accompanied by an
increase in H2O2 levels.

Given that the RBS does not rely on caspases for its

functionality, it is hypothesized that it may perform well during instances of caspaseindependent PCD as well.
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Chapter 6: The RBS can detect caspase-independent PCD
through pathways involving ROS production, Bcl-2
downregulation and mitochondrial membrane
permeabilization
6.1 Abstract
A variety of cancer phenotypes possess the ability to evade caspase activation and
this can result in both tumorigenesis and anticancer drug resistance, especially if the
drugs are designed to induce caspase-dependent PCD. Accordingly, the development of
drugs that induce caspase-independent PCD has been garnering much attention in the
scientific community. It is envisioned that the ability to monitor caspase-independent
PCD through molecular imaging would undoubtedly lead to both novel and improved
cancer therapeutics. In this chapter, we show that the RBS is capable of detecting
caspase-independent PCD induced by different compounds that act through distinct
pathways.

6.2 Introduction
While caspase-3 activation is considered a gold-standard for the identification of
cells undergoing programmed cell death (PCD), caspase-independent PCD has recently
been attracting attention in regards to cancer drug development.

Anticancer drug

resistance and tumorigenesis have been linked to the ability of certain cancer types to
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evade caspase activation(1, 2). Thus, it is envisioned that cancer therapeutics that induce
caspase-independent PCD could have widespread impact.
In one study, caspase-independent PCD was induced in HeLa cells treated with
sodium selenite (SSe)(3).

Here, it was deduced that p53 and p38 were activated

independently of caspases through an oxidative stress mediated process. It has also been
shown that resveratrol induces caspase-independent PCD in MCF7 cells through Bcl-2
downregulation, mitochondrial membrane permeabilization and ROS production without
caspase 3 activation, PARP cleavage or cytochrome c release(4). In another study,
various microtubule stabilizing agents (MSAs) induced caspase-independent PCD in nonsmall cell lung carcinoma (NSCLC) cells and it was found that cathepsin B played a
pivotal role(5). Additionally, paclitaxel, a type of MSA(6), has been shown to induce
caspase-independent PCD in ovarian cancer cells through an apoptosis inducing factor
(AIF) mechanism(7). Other groups have reported caspase-independent PCD in arsenic
trioxide-treated myeloma cells(8), vitamin D-treated breast cancer cells(9, 10), and
flavopiridol-treated glioma cells(11).
The therapeutic need for agents that induce caspase-independent PCD gives rise
to the necessity of assays that can detect this phenomenon. Additionally, current studies
involving these types of agents will likely warrant assays that can be extended to animal
models. Currently, not all PCD sensors rely on caspase activity as a metric for PCD. The
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, first
developed in 1992(12), detects DNA strand breaks after terminal deoxynucleotidyl
transferase (TdT) incorporates labeled dUTP at break sites; DNA fragmentation is a
hallmark of cells undergoing PCD(13). CytoTox Glo is a bioluminescent assay that
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measures the activity of certain intracellular proteases (dead-cell proteases) that are
released from cells with compromised membranes. Additionally, assays that measure the
reduction of various tetrazolium salts, such as MTT(14), XTT(15) and WST-1(16), by
intracellular dehydrogenases active only in living cells are commonly used. However, it
is important to note that these reduction assays are actually a measure of cell viability as
opposed to cell death. Although all of these assays clearly have utility in measuring PCD
in cell culture, most of them are not appropriate for real-time imaging/detection and/or
imaging in animal models of disease. These limitations arise from the need for cell lysis,
the use of membrane impermeable substrates, and/or the use of green fluorescent dyes,
which are generally masked by autofluorescence in vivo.
Notably, many instances of caspase-independent PCD involve an increase in the
intracellular level of reactive oxygen species (ROS)(1-3, 17). Therefore, imaging agents
that specifically detect ROS could potentially be used to identify cells undergoing
caspase-independent cell death. In this chapter, we show that the RBS is able to detect
caspase-independent PCD with inducers that involve distinct pathways, and that this
detection corresponds with intracellular H2O2 levels.

6.3 Results
To test the hypothesis that the RBS may be able to provide insight into cells
undergoing caspase-independent PCD, RBS-HeLa cells were treated with sodium selenite
(SSe). This compound has been shown to induce caspase-independent PCD in HeLa cells
through oxidative stress mediated activation of p53 and p38(3). When RBS-HeLa cells
were treated with a dosage range of SSe for 24 hours, the RLuc8:fLuc ratio increased
153

(Figure 6.1A), while caspases 3 and 7 remained relatively inactive (Figure 6.1B). Under
the same conditions, the intracellular H2O2 levels also rose appreciably (Figure 6.1C).
Additionally, to examine whether or not SSe caused cell death, a TUNEL assay was
performed. As seen in Figure 6.1D, DNA fragmentation increased with SSe treatment.

Figure 6.1. Response of RBS-HeLa cells to increasing doses of sodium selenite. Sodium selenite (SSe)
was added to RBS-HeLa cells at a concentration range of 0-55 µM for 24 hours. (A) RLuc8:fLuc ratios
were calculated for treated RBS-HeLa cells. (B) Caspase activity in treated RBS-HeLa cells was measured
using Caspase 3/7 Glo. (C) Intracellular H2O2 measurements in treated RBS-HeLa cells were obtained
using CM-H2DCFDA. (D) A TUNEL assay for DNA fragmentation was performed on treated RBS-HeLa
cells.

In all studies (except TUNEL assays, which provide an absolute measure of cell death),

measurements were normalized to control (0 µM SSe).
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Parallel studies were performed on RBS-MCF7 cells using SSe; the pathway in
which SSe induces PCD in MCF7 cells remains unknown, however it has been shown to
decrease viability in these cells(18). With increasing SSe dosage (0 – 55 µM), the
RLuc8:fLuc ratio of the RBS increased (Figure 6.2A), caspase-3 activation was not
observed (Figure 6.2B), and intracellular H2O2 and DNA fragmentation levels (Figure
6.2C and 6.2D, respectively) increased.
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Figure 6.2. Response of RBS-MCF7 cells to increasing doses of sodium selenite. Sodium selenite (SSe)
was added to RBS-MCF7 cells at a concentration range of 0-55 µM for 48 hours. (A) Bioluminescent
measurements of RLuc8 and fLuc were acquired at each SSe concentration and the RLuc8:fLuc ratios were
subsequently calculated. (B) A Caspase 3/7 Glo assay was performed to measure caspase activity at each
SSe concentration.

(C) Intracellular H2O2 levels were assessed using CM-H2DCFDA at each SSe

concentration. (D) A TUNEL assay for DNA fragmentation was performed at each STS concentration. In
all studies (except TUNEL assays, which provide an absolute measure of cell death), measurements were
normalized to control (0 µM SSe).
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To further examine the detection of caspase-independent PCD by the RBS,
resveratrol was used as a cell death inducer in RBS-MCF7 cells. Resveratrol has been
shown to induce caspase-independent PCD in MCF7 cells through Bcl-2 downregulation,
mitochondrial membrane permeabilization and ROS production without caspase 3
activation, PARP cleavage or cytochrome c release(4). As shown in Figure 6.3A, when
RBS-MCF7 cells were treated with increasing dosages of resveratrol for 24 hours, the
RLuc8:fLuc ratio increased. Similarly to the SSe studies, caspases remained relatively
inactive while intracellular H2O2 and DNA fragmentation levels increased (Figure 6.3BD).
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Figure 6.3. Response of RBS-MCF7 cells to increasing doses of resveratrol. Resveratrol (Res) was added
to RBS-MCF7 cells at a concentration range of 0-1000 µM for 24 hours. (A) RLuc8:fLuc ratios were
calculated for treated RBS-MCF7 cells. (B) Caspase activity in treated RBS-MCF7 cells was measured
using Caspase 3/7 Glo. (C) Intracellular H2O2 measurements in treated RBS-MCF7 cells were obtained
using CM-H2DCFDA. (D) A TUNEL assay for DNA fragmentation was performed on treated RBS-MCF7
cells.

In all studies (except TUNEL assays, which provide an absolute measure of cell death),

measurements were normalized to control (0 µM Res).
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As with previous studies with cell death inducers, allopurinol was used as an
inhibitor of xanthine oxidase in order to reduce intracellular H2O2 on both RBS-HeLa and
RBS-MCF7 cells treated with 55 µM SSe and RBS-MCF7 cells treated with 1 mM Res.
RBS-HeLa cells pretreated with 100 µM allopurinol for 1 hour prior to 55 µM SSe
treatment for 24 hours exhibited significant decreases (p<0.05) in both RLuc8:fLuc ratio
and intracellular H2O2 levels (Figure 6.4A and 6.4B, respectively), compared to PBS
pretreated controls. Similarly, when RBS-MCF7 cells were pretreated with 100 µM STS
for 1 hour before the addition of 55 µM SSe, there was a significant (p<0.05) decrease in
the RLuc8:fLuc ratio and intracellular H2O2 levels compared to PBS pretreated controls
after 48 hours, as seen in Figure 4C and 4D, respectively.

Finally, Res-treated RBS-

MCF7 cells that were subjected to allopurinol pretreatment also demonstrated significant
(p<0.01) reductions in both RLuc8:fLuc (Figure 6.4E) and intracellular H2O2 levels
(Figure 6.4F) after 24 hours.
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Figure 6.4. Effect of allopurinol on RBS-HeLa and RBS-MCF7 cells treated with SSe and RBS-MCF7
cells treated with Res. PBS or 100 µM allopurinol was added to cells for 1 hour prior to drug treatment.
RLuc8 and fLuc bioluminescence measurements were acquired and the RLuc8:fLuc ratios were calculated
and reported for (A) RBS-HeLa cells treated with 55 µM SSe for 24 hours, (C) RBS-MCF7 cells treated
with 55 µM SSe for 48 hours, (E) RBS-MCF7 cells treated with 1 mM Res. Intracellular H2O2 levels were
determined using CM-H2DCFDA for (B) RBS-HeLa cells treated with 55 µM SSe for 24 hours, (D) RBSMCF7 cells treated with 55 µM SSe for 48 hours, (F) RBS-MCF7 cells treated with 1 mM Res. All
reported values were normalized to untreated controls. Statistical significance: *(p<0.05), **(p<0.01).
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When RBS-HeLa cells were pretreated with allopurinol for one hour prior to 55
µM SSe treatment for 24 hours, the extent of PCD remained unchanged compared to PBS
pretreatment according to the DNA fragmentation levels reported by the TUNEL assay
(Figure 6.5A). DNA fragmentation percentage remained unchanged between PBS and
allopurinol pretreated RBS-MCF7 cells after the application of 55 µM SSe for 48 hours
(Figure 6.5B). Additionally, allopurinol pretreatment conferred no rescue from cell death
when RBS-MCF7 cells were treated with 1 mM Res, compared to PBS pretreated control
(Figure 6.5C).

Figure 6.5. Extent of DNA fragmentation in RBS cells pretreated with allopurinol prior to the addition of
SSe or Res. PBS or 100 µM allopurinol was used as a pretreatment for 1 hour prior to adding (A) PBS or
55 µM SSe to RBS-HeLa cells for 24 hours, (B) PBS or 55 µM SSe to RBS-MCF7 cells for 48 hours, or
(C) PBS or 1 mM Res to RBS-MCF7 cells for 24 hours. Statistical significance: *(p<0.01).
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6.4 Discussion
Given the disparities seen in previous chapters where caspase-3 activity levels did
not exhibit the same trends as DNA fragmentation levels, it was hypothesized that the
RBS could be used to detect caspase-independent PCD. When both RBS-HeLa and
RBS-MCF7 cells were treated with SSe, the RLuc8:fLuc ratio, percent DNA
fragmentation and intracellular H2O2 levels increased while caspase-3/7 activity levels
remained relatively unchanged. The increase in DNA fragmentation along with the lack
of appreciable caspase activation show that SSe induces caspase-independent PCD and
that this form of cell death can be detected by the RBS sensor in HeLa and MCF7 cells.
Resveratrol application to RBS-MCF7 cells produced results comparable to RBSHeLa and RBS-MCF7 cells treated with SSe, further attesting to the impact the RBS may
have on caspase-independent PCD research. Given the reported effects of resveratrol on
the mitochondria and the associated increase in ROS(4), the RBS may be particularly
useful in studies investigating the targeting of this organelle in cancer therapy(19). In
fact, many compounds that target the mitochondria for this purpose create excessive
amounts of ROS(20-24).
When cells were pretreated with allopurinol for one hour prior to SSe (RBS-HeLa
and RBS-MCF7) or resveratrol (RBS-MCF7), the RLuc8:fLuc ratios were significantly
decreased (p<0.05 for SSe, p<0.01 for resveratrol) compared to cells pretreated with
PBS.

As shown in previous chapters, this decrease corresponds to a decrease in

intracellular H2O2. These results provide strong evidence that the RBS is specifically
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responsive to the increasing H2O2 levels in SSe/Resveratrol-treated cells. However, even
though the RBS is specifically responsive to intracellular H2O2 in cells treated with SSe
and Res, allopurinol pretreatment did not protect these cells from undergoing PCD,
according to the TUNEL assay. Previously, it was reported that these inducers trigger
PCD through ROS in some manner; however, it is likely that H2O2 is not the catalyst
since its removal does not prevent PCD, even in cases of caspase-independent cell death.
This suggests that increasing H2O2 levels are a consequence of cell death. In spite of
these results, we still believe that the RBS will prove to be an informative tool in studies
investigating caspase-independent PCD, given that we and others have shown increases
in intracellular H2O2 levels in wide varieties of cell types and death inducing
conditions(25-27).
Extensive testing of the RBS across different cell lines and with multiple cell
death inducers has shown that the RBS may be a useful tool in the investigation of cancer
therapeutics that focus on either caspase-dependent or caspase-independent PCD. The
consistent correlation between the RLuc8:fLuc ratio and intracellular H2O2 concentration,
along with the reduction in the RLuc8:fLuc ratio by allopurinol strongly indicate that the
RBS detects multiple types of PCD through an ROS (or more specifically, H2O2)
dependent manner. This is not entirely surprising, given the reported increases in ROS in
both caspase-dependent and caspase-independent PCD(1-3, 17, 28). The intracellular
H2O2 trends reported here under all cell death inducing conditions tested suggest that the
RBS will likely perform well in a wide range of PCD-inducing conditions.
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Chapter 7: The RBS detects programmed cell death in vivo
7.1 Abstract
In regards to optical imaging modalities for in vivo research endeavors
investigating cancer therapeutics, bioluminescence imaging (BLI) is an attractive choice
given its simplicity, cost-effectiveness, sensitivity and spatiotemporal imaging abilities.
There are currently only a few bioluminescent sensors designed to detect PCD, and of
these, none can specifically detect caspase-independent PCD. Anticancer drug resistance
and tumorigenesis have been attributed to the evasion of caspase activation, making
caspase-independent PCD a new target for cancer therapeutic development.

In this

chapter, we show that the RBS, which has previously been shown to detect caspasedependent and –independent PCD, can detect PCD in murine tumor models, and that this
detection is related to intracellular levels of H2O2.

7.2 Introduction
Bioluminescence imaging (BLI) has emerged as a powerful molecular imaging
tool to investigate diverse cellular processes non-invasively and in real-time. While its in
vitro utility should not be discounted, its ability to relay physiological information in
animal models makes it an attractive choice for many research endeavors. The optical
properties of some bioluminescent proteins allow for depths of up to a few centimeters to
be imaged in vivo(1, 2). The emission wavelength of fLuc is ~600 nm, making it less
likely to be attenuated in animal tissue. Cancer cells expressing fLuc have been imaged
in rat colon(1) and mouse lungs(2), illustrating the potential of BLI to image beyond
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superficial depths in animal models. Also, the intrinsically low bioluminescence of
tissues allows for greater signal-to-background ratios, as opposed to fluorescence, for
example, where the autofluorescence of tissues causes unwanted background signal,
effectively reducing this ratio.
In addition to its cost-effectiveness, robustness and simplicity, BLI has recently
proven to be quite useful in high-throughput screening (HTS) assays(3-5). An advantage
of using BLI in HTS assays is that lead compounds can be applied to in vivo models that
utilize the same bioluminescent cellular targets originally tested, thus accelerating the
translation from bench to clinic. HTS assays have been employed to identify compounds
that induce programmed cell death (PCD) in many types of cancer cells including
retinoblastoma(6), lymphoma(7) and breast cancer stem cells (8), a subpopulation of
tumor cells that have been shown to drive tumor growth/recurrence (see (9) for review)
and are resistant to many cancer treatments(10). It is envisioned that bioluminescent
probes that detect PCD through cellular and in vivo HTS assays could improve the cancer
therapeutic milieu.
Several bioluminescent sensors for PCD have been developed recently and they
all target caspase-3, a protease critical for certain manifestations of PCD(11). In general,
these sensors have utilized the cleavage of the caspase-3 recognition sequence, DEVD, as
a catalyst for luciferin (substrate) recognition(12, 13), removal of steric hindrance(14), or
protein fragment complementation(15). However, tumorigenesis and anticancer drug
resistance have been attributed to the ability of cancer cells to evade caspase activation
and thus caspase-dependent PCD(16, 17). This phenomenon has led to the investigation
of therapeutics that induce caspase-independent cell death, for example sodium
169

selenite(18), resveratrol(19) and various microtubule stabilizing agents(20, 21). The lack
of caspase activity here deems the aforementioned sensors ineffective in research efforts
involving this mechanism of PCD.
We have shown previously that the Ratiometric Bioluminescent Sensor (RBS) is
capable of detecting caspase-dependent and caspase-independent PCD in multiple cell
lines. Additionally it was shown that the response level of the RBS was directly related
to intracellular hydrogen peroxide (H2O2) levels. In this chapter, we show that the RBS
is capable of detecting PCD in murine tumor models of cervical cancer and that this
detection correlates with H2O2 levels.

7.3 Results
To investigate the capability of the RBS to provide information on cell death in
vivo, RBS-HeLa tumor xenografts were grown in nude mice (n = 3 per group). Tumors
were initially treated with PBS or Allopurinol as an inhibitor, followed by PBS or STS 1
hour later. As seen in Figure 7.1A, control mice that were treated with PBS as an
inhibitor and PBS as treatment (PBS/PBS) exhibited little change in RLuc8
bioluminescence after 24 hours (top panel). Similarly, the fLuc bioluminescence also did
not change significantly in PBS/PBS-treated mice (Figure 7.1A, bottom panel).

In

contrast, in PBS/STS-treated mice, the RLuc8 bioluminescence remained stable (Figure
7.1B, top panel), but the fLuc bioluminescence was significantly diminished after 24
hours (Figure 7.1B, bottom panel).

When mice were treated with inhibitor alone

(Allo/PBS), the tumors again exhibited little change in RLuc8 bioluminescence (Figure
7.1C, top panel), but there was a slight increase in fLuc bioluminescence (Figure 7.1C,
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bottom panel) after 24 hours. Finally, when mice were treated with the inhibitor and the
cell death inducer (Allo/STS), tumors showed little change in bioluminescence for RLuc8
(Figure 7.1D, top panel) and fLuc (Figure 7.1D, bottom panel).

Figure 7.1. Assessment of RBS performance in vivo. Female nude mice bearing RBS-HeLa tumor
xenografts were imaged prior to and 24 hours after the following inhibitor/drug treatment regiment:
(A) PBS/PBS, (B) PBS/STS, (C) Allo/PBS, and (D) Allo/STS. Inhibitors were administered 1 hour
prior to drug treatment.

The bioluminescence values were quantified for each group of animals and the
RLuc8:fLuc ratio values are reported in Figure 7.2. Consistent with previous cell culture
studies, the ratio increased significantly (p < 0.01) between the PBS/PBS and PBS/STS
groups.

The RLuc8:fLuc ratio decreased slightly from the PBS/PBS groups to the

Allo/PBS groups; however, the change was not statistically significant. A significant
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reduction in the RLuc8:fLuc ratio (p < 0.05) was observed between the PBS/STS and
Allo/STS groups.

Figure 7.8. Quantitative analysis of RBS in live animals. RLuc8 and fLuc bioluminescence counts were
obtained from mice bearing RBS-HeLa tumor xenografts and treated with PBS/PBS, PBS/STS, Allo/PBS,
and Allo/STS.

All images were analyzed using Living Image Software.

Following background

subtraction, the RLuc8:fLuc ratios were calculated and normalized to day 1 values. Statistical significance:
* (p<0.05), ** (p<0.01).

7.4 Discussion
The RBS was tested for its ability to detect PCD in murine tumor models using
STS. RBS-HeLa tumors were subjected to one of four conditions: PBS/PBS, PBS/STS,
Allopurinol/PBS or Allopurinol/STS. The inhibitor (or control of PBS) was administered
1 hour prior to drug treatment (or control of PBS). Representative bioluminescence
images of each treatment for RLuc8 and fLuc mimicked in vitro results when the same
cell line (HeLa) and treatment (STS) was investigated (Chapter 3).

The fLuc

bioluminescence was noticeably diminished in the PBS/STS tumor, while the RLuc8
bioluminescence remained stable.

Additionally, when tumors were pretreated with
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allopurinol before STS, little change in either signal was observed after 24 hours.
Interestingly, in the tumors pretreated with allopurinol prior to PBS, an increase in fLuc
bioluminescence was observed after 24 hours that was not seen with RLuc8. This could
be attributed to elevated levels of H2O2 within the hypoxic cores of tumors (see (22) for
review); after 24 hours of allopurinol treatment, H2O2 levels may be reduced, thus
restoring the bioluminescence of fLuc. The quantification of the bioluminescence images
revealed that the RLuc8:fLuc ratio was significantly increased in the PBS/STS group
compared to PBS/PBS (p<0.01) and that this ratio was significantly decreased in the
Allo/STS group compared to PBS/STS (p<0.01). These results were somewhat expected,
given the past performance of the RBS in PCD-inducing conditions, both with and
without allopurinol. These results provide evidence that the RBS is capable of detecting
PCD in vivo in an H2O2-related manner.
We have shown in this body of work that the RBS detects PCD in vitro and in
vivo. Taken together, it is envisioned that the same RBS could be used in HTS assays to
screen for PCD-inducing drugs, in vitro assays to validate lead compounds and in vivo
assays to ensure efficacy with minimal toxicity, which would be necessary prior to
clinical trials. The in vivo imaging capability of the RBS would potentially allow for a
more streamlined transition from the initial screen to animal models, given that it has
been shown to function both in vitro and in vivo.
In addition to screens for PCD-inducing compounds, the RBS could be utilized in
HTS assays that try to identify antioxidant compounds. An example of this involves the
burgeoning area of cancer stem cells (CSCs). This subset of cells within a tumor are
often resistant to chemotherapeutics (10) and ionizing radiation(23, 24). This resistance
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in mammary CSCs has recently been attributed to the lower ROS levels present in these
cells compared to non-tumorigenic cells(25), since ROS are essential elements involved
in ionization-mediated PCD(26, 27).

To increase intracellular ROS levels of the

mammary CSCs, a glutathione (GSH)-depleting agent has been used to decrease
intracellular levels of the antioxidant GSH. After GSH depletion, the mammary CSCs
exhibited higher ROS levels, and thus higher radiosensitization compared to cells with
normal GSH levels(25). It can be imagined that the RBS would prove to be useful in
screens of other compounds that possess the capability of increasing or decreasing
intracellular antioxidant levels in this system.
In summary, we have shown that the RBS is capable of detecting PCD in a
murine tumor model. Inhibition studies using allopurinol demonstrated that the RBS is
likely responsive to intracellular H2O2 levels. Thus it is envisioned that the RBS may be
a useful tool in research endeavors involving caspase-dependent or caspase-independent
PCD as a target for cancer therapeutics.
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Chapter 8: Overall discussion, future directions and
concluding remarks

8.1 Overall Discussion
8.1.1 Development of the Ratiometric Bioluminescent Sensor (RBS) and its response
to cellular stress in HeLa cells
Many optical imaging sensors designed to report on PCD are based on the
specific proteolytic cleavage of the amino acid sequence DEVD by caspase-3, the
cysteine-aspartic protease that is required for apoptotis(1). However, caspases are not the
only proteases that are active during PCD; it has been shown that calpains(2, 3) and
cathepsins(4, 5) are upregulated during this process. Additionally, damaging oxidative
modifications may result from increases in ROS(6-8) that can occur during PCD(9-11).
Thus, information garnered from fluorescent(12-21) and bioluminescent(22-25) sensors
for PCD must be scrutinized carefully, given the many opportunities for damage and/or
modification.
In order to investigate the sensitivity of bioluminescent proteins during PCD, we
began by examining the effects of staurosporine (STS), a PCD-inducing drug(26) that has
also been shown to increase intracellular ROS(9), on HeLa cells transiently expressing
fLuc or RLuc. Throughout 24 hours of 1 µM STS treatment, both fLuc and RLuc
exhibited decreased bioluminescence while a parallel assay indicated that caspase-3
activity was markedly increased over the same time period. The disparity between
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diminished fluc/RLuc bioluminescence and elevated caspase-3 activity confirmed that the
utilization of these proteins in sensors for PCD must be done with caution, as signals
would not only reflect caspase activity, but also other degradation/modification
mechanisms within the cell.
These observations led us to investigate methods of increasing the stabilities of
fLuc and RLuc. The implementation of phenylbenzothiazole (PBT), a chemical reported
to increase the stability of fLuc by preventing its intracellular degradation(27), abrogated
the decrease in fLuc bioluminescence previously seen in STS-treated cells.

While

initially promising, certain limitations prevented PBT from being examined further.
First, it was unknown whether this chemical would interfere with other intracellular
proteins or exogenously applied PCD-inducing compounds. Second, the use of PBT may
not have translated well into in vivo models due to issues related to administration and
pharmacokinetics. Additionally, PBT derivatives have been reported to exhibit antitumor activity(28), which would undoubtedly interfere with both in vitro and in vivo
assays related to PCD. Thus, we investigated two luciferase mutants that have been
reported to exhibit increased stability under various stress conditions, fLuc5(29) and
RLuc8(30). The bioluminescence of fLuc5 remained more stable compared to wild-type
fLuc when transiently expressed in STS-treated HeLa cells.

RLuc8 also exhibited

improved stability when compared to RLuc under the same conditions, and was the more
stable of the two variants tested.
These results led to the hypothesis that if a stable and unstable luciferase were
incorporated

into

one

sensor,

the

resulting

bioluminescence

ratio

(stable

bioluminescence:unstable bioluminescence) could be used to report on the extent of PCD
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and potentially specific molecular processes associated with PCD (e.g., oxidative stress).
RLuc8 was chosen as the stable luciferase element because it possessed the greatest
bioluminescence stability when expressed in HeLa cells undergoing PCD. Wild-type
fLuc was chosen as the unstable luciferase element. Notably, each of these enzymes
utilizes a different substrate, effectively simplifying the distinction between the
bioluminescence of fLuc and RLuc8. The sensor incorporating RLuc8 and fLuc was
termed the Ratiometric Bioluminescent Sensor, or RBS.
Preliminary examination of the RBS using STS-treated HeLa cells demonstrated
that the RLuc8:fLuc ratio, derived from fLuc and RLuc8 bioluminescence measurements,
correlated well with both caspase activation and DNA fragmentation, two hallmarks of
cells undergoing PCD(1, 31). Representative images from STS-treated RBS-HeLa cells
exemplified similar trends to the recorded fLuc and RLuc8 bioluminescence
measurements and ratios. These results suggested that the RBS was capable of detecting
PCD in STS-treated HeLa cells.
When RBS-HeLa cells were plated at a range of 0 – 20,000 cells/well of a 96-well
tissue culture plate, the recorded RLuc8:fLuc ratio was shown to be independent of cell
number. Additionally, there was virtually no increase in the RLuc8:fLuc ratio observed
in RBS-HeLa cells that were incubated (untreated) over a period of 24 hours. These
results highlight the potential transitional use of the RBS, from high-throughput screening
where very small samples are used all the way to animal models, where large numbers of
cells are usually necessary.
While these initial studies regarding the RBS and its response to PCD induction
were promising, the mechanism behind the disparity in fLuc and RLuc8 activity had yet
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to be determined. An initial theory involved the use of the IRES sequence in the plasmid
DNA vector encoding the RBS. This sequence was incorporated into the plasmid such
that it was flanked by RLuc8 and fLuc (RLuc8-IRES-fLuc) in order to allow for protein
translation from a single, bicistronic mRNA(32, 33), effectively eliminating any
unwanted effects related to altered promoter activity. Since it has been reported that in
healthy cells, proteins translated from sequences downstream of the IRES site can be
expressed at lower levels compared with upstream sequences(34), a ‘reverse RBS’ sensor
was created (fLuc-IRES-RLuc8) to determine the effects of the positioning of fLuc and
RLuc8 relative to the IRES sequence. HeLa cells expressing this sensor exhibited an
increase in the RLuc8:fLuc ratio when treated with STS.

While this ratio was

considerably higher than that of the ‘normal’ RBS, this can likely be attributed to the
transient expression of the ‘reverse’ sensor compared to the stable expression of the
‘normal’ sensor, specifically the accelerated loss of fLuc activity owing to, the lack of
genomic integration of the ‘reverse’ RBS plasmid would lead to its dilution through cell
division and/or degradation.
After the elimination of the IRES sequence as a source of the explicit differential
between fLuc and RLuc8 activity, the mechanism behind this difference remained
unknown. There have been various reports indicating that the proteasome(35, 36) and
calpain(2, 3) and cathepsin(4, 5) proteases can play significant roles in PCD.
Additionally, increases in ROS that can occur in cells undergoing PCD broach the
possibility of potentially damaging oxidative modifications to proteins(6-8) and/or
RNA(37). In the subsequent determination of the RBS mechanism, the roles of these
proteases and ROS, among others, were investigated.
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8.1.2 The RBS mechanism relies on ROS, particularly H2O2
In order to determine the mechanism behind the bioluminescence disparity
between fLuc and RLuc8 in the RBS in cells undergoing PCD, an RT-PCR study was
first performed to assess fLuc and RLuc8 mRNA levels in STS treated cells compared to
PBS treated cells. This assay revealed that the relative expression of these mRNAs
within RBS-HeLa cells did not significantly change regardless of PBS or STS treatment.
In contrast, Western blot analysis demonstrated that fLuc protein levels decreased over
the time course of STS treatment, while RLuc8 protein levels remained relatively stable.
Interestingly, some fLuc staining was observed at higher than expected molecular
weights at later time points, which could be indicative of protein cross-links or
posttranslational modifications.

Taken together, these results suggested that the

mechanism of the RBS involved the bioluminescent proteins themselves, rather than
mRNA levels.
Next, various inhibition/scavenging studies were performed on targets known to
play roles in PCD. It was expected that certain inhibitors would rescue fLuc activity,
resulting in a decrease in the RLuc8:fLuc ratio in STS-treated RBS-HeLa cells. Given
that the proteasome is responsible for the majority of intracellular protein degradation, it
was naturally one of the first targets of the inhibition study. The employment of the
proteasome inhibitors MG-132, epoxomicin and lactacystin on STS-treated RBS-HeLa
cells did not rescue fLuc activity and actually caused a slight increase in the RLuc8:fLuc
ratio.

In the case of epoxomicin, this slight increase was statistically significant

compared to uninhibited controls. This result is potentially indicative of increased PCD,
an effect that has been reported to occur during proteasome inhibition using
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epoxomicin(35). Proteasome inhibition has also been shown to increase intracellular
ROS levels(9, 38-40), possibly implicating ROS in the RBS mechanism. Nonetheless,
these results provided strong evidence that enhanced proteasomal degradation was not
likely responsible for the RBS mechanism.
The next group of inhibitors focused on various proteases that are associated with
PCD through various mechanisms: calpains, cathepsins and caspases. When STS-treated
RBS-HeLa cells were pretreated with Calpain Inhibitor III, the RLuc8:fLuc ratio was not
significantly affected compared to PBS pretreated controls. These results suggested that
calpains were not involved in the mechanism of the RBS. Interestingly, an increase in
the ratio was seen in RBS-HeLa cells treated with PBS following Calpain Inhibitor III.
This inhibitor has been shown to decrease the levels of intracellular antioxidant
glutathione (GSH) levels, effectively increasing intracellular ROS(41), again potentially
implicating ROS in the RBS mechanism.
Two inhibitors for cathepsins were employed: Pepstatin A (inhibits aspartyl
proteases) and ammonium chloride (inhibits phagosome-lysosome fustion(42)). Neither
of these inhibitors significantly affected the RLuc8:fLuc ratios in STS-treated RBS-HeLa
cells and hence they were discounted from the mechanism of the RBS.
Arguably, the most thoroughly characterized proteases involved in PCD are the
caspase family of proteases (see (43) for review). To inhibit caspase activity during STS
treatment of RBS-HeLa cells, the pan-caspase inhibitor z-vad-fmk was employed, and
surprisingly the use of this inhibitor did not affect the RLuc8:fLuc ratio. These results
suggested that caspases did not play a significant role in the disparity between fLuc and
RLuc8 activity in STS-treated cells.
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In addition to proteases, various ROS can contribute to the modification, damage
or degradation of proteins in dying cells. Three superoxide (O2•-) scavengers, Tiron,
TEMPOL and MnTMPyP, were tested for their ability to reduce the RLuc8:fLuc ratio in
STS treated cells. None of these scavengers had any significant effect on the RLuc8:fLuc
ratio which led us to conclude that O2•- alone is not responsible for the trends observed in
STS-treated RBS-HeLa cells. This was somewhat expected given the short half-life of
O2•- and its function as a precursor to other oxidizing agents. However, even though the
O2•- scavenging abilities of TEMPOL, Tiron and MnTMPyP were confirmed to be
statistically significant by using a dihydroethidium assay, the intracellular levels of O2•appeared to be reduced by only ~50%. Therefore, further studies on the effects O2•- in
regards to the RBS mechanism may be warranted. Initial experiments could involve the
use of other O2•- scavengers, such as SOD transgenes(44).
Peroxynitrite (ONOO-) is formed as a result of the reaction between O2•- and
nitric oxide (NO)(45) and specific amino acid residues (methionine, cysteine, tyrosine
and tryptophan) are vulnerable to modification by ONOO-(6). To scavenge ONOO-, the
scavenger uric acid was used as a pretreatment on STS-treated RBS-HeLa cells. A slight,
but insignificant, increase in the RLuc8:fLuc ratio was observed compared to PBSpretreated controls which suggested that ONOO- does not play a dominant role in the
mechanism of the RBS. Even though there currently exists no commerical assays to
detect ONOO-, numerous studies have shown that acid is an effective scavenger of
ONOO-(46-48).
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The agents mannitol, a specific scavenger of •OH, deferoxamine (DFO), an iron
chelator, and tetraethylenepentamine (TEPA), a copper chelator, were utilized to examine
the effects of •OH on the RLuc8:fLuc ratio of RBS-HeLa cells treated with STS.
Carbon-centered radical formation via hydroxyl radicals (•OH) serves to initiate the
oxidative attack of protein radicals(6). This carbon-centered radical can give rise to
protein cross-links, peptide-bond cleavage or direct oxidation of amino acids(6). The two
metal chelators, alone and in combination, were used to reduce the amounts of metals
available for the Fenton reaction (Fe2+ + H2O2  Fe3+ + •OH + OH-). None of these
compounds significantly reduced the RLuc8:fLuc ratio, and these results effectively
eliminated the likelihood that •OH as a direct contributor to the loss in fLuc activity. It
may be argued that the slight increase in the RLuc8:fLuc ratio that was observed with
TEPA could be a result of excess H2O2 buildup from the prevention of the Fenton
reaction, however further studies are warranted since the combination of DFO + TEPA
did not yield an additive effect. Additionally, it remains unclear as to the effect of metal
chelation on the Fenton reaction. It has been reported that iron chelation can serve both
antioxidant(49) and prooxidant(50) functions.
Hydrogen peroxide (H2O2) is a powerful oxidizing agent that can directly and
indirectly modify many amino acids, often creating hydroxyl- or carbonyl-derivatives
(see (51) for review). It has been shown that this oxidation can destabilize a protein’s
native structure and result in activity loss(8, 52).

The H2O2 inhibitors/scavengers

catalase, allopurinol and aspirin were tested for their ability to reduce the RLuc8:fLuc
ratio in STS-treated RBS-HeLa cells. The pretreatment of RBS-HeLa cells with these
reagents prior to STS treatment conferred a significant reduction (p<0.01) in the
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RLuc8:fLuc ratio. These findings suggested that fLuc activity could be recovered in
STS-treated RBS-HeLa cells through removal of H2O2. It should be noted that catalase
cannot cross cell membranes, but our results are consistent with previous studies
reporting that extracellularly added catalase is effective at removing intracellular
H2O2(53, 54).
When STS-treated RBS-HeLa cells were subjected to increasing dosages of
catalase, allopurinol and aspirin, the RLuc8:fLuc ratio decreased in a dose-dependent
manner. These results confirmed that fLuc activity could be recovered by reducing H2O2
levels in STS-treated cells.

Additionally, Western blot analysis indicated that fLuc

protein levels in STS-treated RBS-HeLa cells were rescued slightly when pretreated with
each

inhibitor

compared

to

PBS-pretreated

controls.

Therefore,

H2O2

inhibitors/scavengers were able to reduce the degradation of fLuc in STS-treated RBSHeLa cells.
Given that the inhibitors/scavengers of H2O2 significantly affected the
RLuc8:fLuc ratio, additional studies were performed that dealt with H2O2 more directly.
Intracellular H2O2 levels were measured in STS-treated RBS-HeLa cells over a time
course of 24 hours and over a dosing range of 0-50 µM. In both cases intracellular H2O2
levels increased up to nearly three-fold. Additionally, when RBS-HeLa cells were treated
directly with H2O2 in fully supplemented culture medium, the RLuc8:fLuc ratios
exhibited striking increases. These results further supported the intrinsic involvement of
H2O2 in the RBS mechanism.
It may be argued that the concentrations of H2O2 used in both the cellular and in
vitro assays was too high to be biologically relevant.

However, recent studies
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investigating oxidative stress have employed similar concentrations of H2O2(55, 56).
Nonetheless, an immunohistochemical analysis of RLuc8 and fLuc proteins in control
and STS-treated cells may provide insight into any preferential localization of these
proteins to sites of increased ROS (e.g. peroxisomes) during cell death. Peroxisomes
contain ROS and enzymes that generate these species, e.g., xanthine oxidase (see (57) for
review), thus it can be envisioned that localization of proteins to this organelle could be a
source excessive ROS exposure that would subsequently modify/damage fLuc.
The highest level of fLuc rescue in STS-treated RBS-HeLa cells was exhibited
when allopurinol, an XO inhibitor, was employed as a pretreatment. Therefore, RBSHeLa cells were subjected to an HX-XO reaction, which has been shown to produce
H2O2 as the dominant oxidant(58). After 24 hours, a significant (p<0.01) increase in the
RLuc8:fLuc ratio was observed. The magnitude of this increase was above that seen with
STS treatment, but lower than with direct H2O2 treatment, which was expected given that
this reaction produces H2O2 more directly than STS, but is obviously not as harsh as
direct H2O2 application. When purified RLuc8 and fLuc proteins were subjected to the
HX-XO reaction, the RLuc8:fLuc ratio increased significantly (p<0.01). These findings
suggested that the RBS may be specifically responsive to intracellularly produced H2O2
alone, and not other upstream or downstream reactions involving other ROS or enzymes.
We recently measured the amount of H2O2 generated by the HX-XO system we
employed and it was determined that the concentration was ~5 µM. However, when both
RBS-HeLa cells and pure fLuc and RLuc8 proteins were subjected to 5 µM H2O2, no
differences in the RLuc8:fLuc ratio or activity were observed. This could be explained
by degradation of the acutely applied H2O2 at the initial time points of the assays, as
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opposed to the chronic generation of H2O2 via the HX-XO reaction. Alternatively, the
XO enzyme itself contains 4 iron atoms. The reaction of both O2•- and H2O2 with iron
can generate damaging •OH, potentially leading to protein crosslinks, peptide bond
cleavage and amino acid modifications(6).
When RBS-HeLa cells were pretreated with allopurinol prior to STS, no changes
in DNA fragmentation levels were observed.

However, in parallel assays, this

pretreatment significantly (p<0.01) decreased both the RLuc8:fLuc ratio and intracellular
H2O2 levels. This correlation supported earlier findings that the RBS is specifically
responsive to H2O2 during cell death and not other degradation pathways associated with
PCD. Further, the ability of allopurinol to reduce H2O2 levels without affecting cell death
implicated H2O2 production as a consequence of, rather than a catalyst for, cell death.
In order to obtain a more definitive understanding of the role of H2O2 in the RBS
mechanism, purified RLuc8 and fLuc proteins were exposed to a range of H2O2
concentrations.

Analysis of both SDS-PAGE and bioluminescence measurements

indicated that when the proteins were treated with H2O2, fLuc bioluminescence and
protein levels decreased, while RLuc8 bioluminescence and protein levels remained
relatively stable over the time course for all doses tested. Additionally, smearing of the
fLuc protein was observed for most H2O2 concentrations, indicative of possible
modifications or degradation. Interestingly, fLuc bioluminescence appeared to decay
more rapidly and to a greater extent than fLuc protein levels at all concentrations tested.
These observations indicate that H2O2 may have oxidatively modified or damaged the
fLuc proteins, rendering them inactive, prior to degradation/protein loss. This conclusion
would also support the Western blot analysis where fLuc protein levels were rescued by
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the H2O2 inhibitors/scavengers. Since oxidatively modified/damaged proteins are often
targets for proteasomal degradation(59, 60), it can be hypothesized that the H2O2
inhibitors scavengers prevented oxidative modifications of fLuc that would normally
trigger proteasomal degradation of the protein.
H2O2 may modify the fluc protein through carbonylation; protein carbonylation is
irreversible(61), can cause protein aggregates to form(51, 62) and targets damaged
proteins for degradation(63). When STS-treated RBS-HeLa cells were analyzed for
protein carbonylation, a substantial increase in this phenomenon was seen when
compared to PBS treated controls. Furthermore, when H2O2-treated purified fLuc and
RLuc8 proteins were subjected to the carbonylation assay, fLuc became extensively more
carbonylated versus RLuc8, compared to PBS-treated controls. These results implicated
protein carbonylation as one of the potential modifications to fLuc in STS-treated RBSHeLa cells, especially since it has been shown that H2O2 can cause protein
carbonylation(51).
Investigation into the crystal structures of fLuc and RLuc8 may provide insight
into the activity disparity between fLuc and RLuc8 in stressed cells as well. Given that
certain amino acid residues, namely lysine, arginine, proline, methionine, cysteine and
tyrosine are preferentially oxidatively modified(6, 64, 65), the relative locations of these
residues (i.e. on the surface or buried) might explain the differential in oxidative
modifications leading to fLuc protein activity loss.
While the precise mechanism behind the ROS-mediated activity of the RBS has
yet to be determined, we have shown that it is primarily responsive to intracellular H2O2
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levels. Thus, it is envisioned that the RBS will be useful as a sensor for PCD, since many
instances of PCD are accompanied by ROS production(11, 66-74).
8.1.3 The RBS can detect caspase-dependent PCD in multiple cell lines using
multiple inducers
Many therapies that have been developed to treat cancer involve inducing
apoptosis, a type of PCD, that is mechanistically characterized by a proteolytic cascade
involving caspases (See (43) for comprehensive review).

Accordingly, a variety of

sensors have been developed to image and monitor apoptosis, or more specifically
caspase-3 activity, to further assist in the discovery, development, and evaluation of
apoptosis-inducing agents.

These sensors detect caspase-3 by the recognition and

cleavage of the amino acid sequence DEVD and are either fluorescent(12-21) or
bioluminescent(22-25) in nature. However, we have shown caspase-3 activity is not
always elevated in apoptotic cells (Chapter 3). Another confounding factor in regarding
sensors for caspase-3 is that caspase-7 recognizes and cleaves the same amino acid
sequence (DEVD) as caspase-3.

Thus, sensors designed specifically for caspase-3

activity as a biomarker for apoptosis may not accurately report on the extent of cell death.
As shown in chapter 3, the RBS is responsive to cell death induced by STS in
HeLa cells. To begin to investigate the span of cell types in which the RBS could
function, RBS-MCF7 cells were treated with a dosage range of STS (0 – 50 µM) for 6
hours. Here, fLuc bioluminescence decreased by up to 90% while RLuc8 remained
relatively insensitive to the treatment and only decreasing by 20%. Accordingly, the
RLuc8:fLuc ratio increased with increasing STS dose. Additionally, intracellular H2O2
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levels, caspase-3 activity and DNA fragmentation levels all increased with STS dosage in
RBS-MCF7 cells, consistent with the notion that the RBS detects PCD through a H2O2related mechanism. When RBS-293T/17 cells were treated with the same STS dosage
range for 6 hours, increases were also seen in the RLuc8:fLuc ratio, intracellular H2O2
levels, caspase-3 activity and DNA fragmentation levels. The ability of the RBS to relay
information on cell death in MCF7 and 293T/17 cells in addition to HeLa cells indicates
its versatility and potential for utilization over a wide range of cellular research
endeavors.
The treatment of RBS-MCF7 and 293T/17 cells with allopurinol for 1 hour prior
to 10 µM STS for 6 hours effectively reduced the RBS ratio and intracellular H2O2 levels,
while leaving caspase-3 activity and DNA fragmentation unchanged. The trends in
RLuc8:fLuc ratio and intracellular H2O2 reduction with allopurinol pretreatment further
supported the theory that the RBS is specifically responsive to H2O2 during cell death.
Also, these results further confirm that H2O2 elevation is a consequence of cell death,
rather than a catalyst for cell death in STS-treated RBS-MCF7 cells.
The STS studies on RBS-MCF7 cells were expanded to a time course of 24 hours
using 10 µM STS. Under these conditions, the RLuc8:fLuc ratio increased dramatically
compared to PBS-treated controls. The intracellular H2O2 levels also increased under this
conditions while the caspase-3 activity actually peaked at the 6 hour time point and
returned to control levels by 24 hours.

The TUNEL assay revealed that DNA

fragmentation remained elevated throughout the entire time course.

These results

introduced an interesting disparity between caspase-3 activity and DNA fragmentation,
RBS ratio and intracellular H2O2 levels; namely, caspase-3 activity returned to near191

control levels while the remaining three parameters remained elevated. These results
highlighted how the use of caspase-3 activity as a biomarker for cell death could
potentially lead to ambiguous findings, due to the transient nature of its activation. Here,
the RBS may hold an advantage over traditional cell death assays, since it is capable of
detecting cell death when caspase activity assays cannot and possesses real-time and in
vivo capabilities that are not characteristic of the TUNEL assay.

Additionally, the

correlation between the TUNEL assay and the RBS, even in the absence of caspase
activity, suggests that the RBS may be able to provide insight on cells undergoing
caspase-independent PCD. This would not be entirely surprising considering that many
previous studies have shown that caspase-independent cell death pathways can involve
ROS(11, 68, 69, 74-76).
Even though caspase-independent PCD research is gaining in popularity, caspasedependent cell death remains a prominent area of interest regarding cancer therapeutics,
whether by inducing PCD on their own(77-79) or in combination with other drugs(80,
81). Two drugs that induce apoptosis in HeLa cells are doxorubicin (DOX, (82)) and
camptothecin (Cpt, (83)). When RBS-HeLa cells were treated with 1 µM DOX or 10 µM
Cpt over the course of 48 hours, the RLuc8:fLuc ratio increased compared to PBS-treated
controls.

In addition, the intracellular H2O2 levels increased compared to untreated

control and the RLuc8:fLuc ratio was significantly decreased when the cells were
pretreated with 100 µM allopurinol (DOX, p<0.05, Cpt, p<0.01).

Parallel caspase

activity and DNA fragmentation assays indicated that PCD was occurring under DOX
and Cpt treatment. The overall increasing trend in RLuc8:fLuc ratio, DNA fragmentation
and H2O2 levels following DOX- and CPT-treatment suggests that the RBS will likely
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detect cell death under a vast array of induction methods, since many are accompanied by
an increase in H2O2 levels. For example, it has been shown that murine epidermal cells
treated with vanadate undergo apoptosis and exhibit an increase in intracellular H2O2
cells(84). Similarly, apoptosis induced by erbstatin(85), vinblastine and inostamycin(86)
in human small cell lung carcinoma cells is also accompanied by increased intracellular
H2O2 levels.
While the ability of the RBS to detect caspase-dependent PCD should not be
discounted, it would be interesting to determine whether it would be responsive in
oxidatively stressed cells that are not undergoing PCD. This could be accomplished by
treating RBS-cells with tumor necrosis factor (TNF) alpha or various antioxidant
inhibitors. Additionally, expressing the RBS in immune cells, such as neutrophils, that
exhibit a characteristic ‘oxidative burst’ may provide more insight into the response of
the RBS to oxidative stress induction.
8.1.4 The RBS can detect caspase-independent PCD through pathways involving
ROS

production,

Bcl-2

downregulation

and

mitochondrial

membrane

permeabilization
Anticancer drug resistance and tumorigenesis have been attributed to the ability of
certain cancers to evade caspase activation(87, 88).

It is envisioned that cancer

therapeutics that induce PCD through a caspase-independent mechanism could have
widespread impact. The therapeutic need for agents that induce caspase-independent
PCD gives rise to the necessity of assays that can detect this phenomenon; thus, the RBS
was examined for its potential to report on caspase-independent PCD.
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When RBS-HeLa cells were treated with a dosage range (0-55 µM) of sodium
selenite (SSe), a compound that has been shown to induce caspase-independent PCD in
HeLa cells through oxidative stress mediated activation of p53 and p38(89), the
RLuc8:fLuc ratio increased. Under the same conditions, caspase-3 remained relatively
inactive, while intracellular H2O2 and DNA fragmentation levels increased. RBS-MCF7
cells were subjected to the same SSe dosage conditions for 48 hours. The exact pathway
by which SSe induces caspase-independent PCD in MCF7 cells is unknown, however it
has been shown to decrease viability in this cell type(90). Similarly to RBS-HeLa cells,
the RLuc8:fLuc ratio, intracellular H2O2 levels and DNA fragmentation levels increased,
while caspase activity remained unchanged, as the SSe dosage increased. In both of these
studies, the increase in DNA fragmentation along with the lack of appreciable caspase
activity show that SSe induces caspase-independent PCD and that it can be detected by
the RBS. Also, the correlation between levels of intracellular H2O2 and the RLuc8:fLuc
ratio suggested that the RBS was responsive to H2O2 in these instances of PCD.
To further investigate the detection of caspase-independent PCD by the RBS,
resveratrol was used as a PCD inducer in RBS-MCF7 cells. Resveratrol has been shown
to induce PCD in MCF7 cells through Bcl-2 downregulation, mitochondrial membrane
permeabilization and ROS production without caspase-3 activation, PARP cleavage or
cytochrome c release(91). With increased resveratrol dosage (0-1 mM), the RLuc8:fLuc
ratio increased, while caspase activity remained unchanged. Additionally, intracellular
H2O2 and DNA fragmentation levels increased as the resveratrol dose increased. Taken
together, the studies that used SSe and Res further attested to the impact the RBS may
have on research endeavors involving caspase-independent PCD. The RBS may be
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particularly useful in studies involving the targeting of mitochondria in cancer therapy,
given the reported effects of resveratrol on the mitochondria and the associated increase
in ROS(91). In fact, many compounds that target the mitochondria for this purpose
generate excessive amounts of ROS(92-96).
To examine the role of H2O2 in these caspase-independent PCD processes,
allopurinol was used as an inhibitor for one hour prior to the application of SSe (RBSHeLa and RBS-MCF7) and resveratrol (RBS-MCF7). RBS-HeLa and RBS-MCF7 cells
pretreated with 100 µM allopurinol for 1 hour prior to treatment with 55 µM SSe
exhibited significant decreases (p<0.05) in the RLuc8:fLuc ratio and intracellular H2O2
levels, compared to cells pretreated with PBS. Similarly, allopurinol pretreatment for 1
hour prior to 1 mM resveratrol application for 24 hours on RBS-MCF7 cells conferred
significant (p<0.01) reductions in the RLuc8:fLuc ratio and levels of intracellular H2O2.
These results provided strong evidence that the RBS is specifically responsive to the
increasing H2O2 levels seen in SSe/resveratrol-treated cells.
Allopurinol pretreatment did not protect either of the cell types from PCD
compared to PBS pretreatment, as indicated by a TUNEL assay. Previous reports have
indicated that the mechanisms of PCD induced by SSe and resveratrol involve ROS in
some manner(89, 91); however, it is unlikely that H2O2 is the catalyst because its removal
does not prevent PCD. These results suggested that increasing levels of H2O2 are thus a
consequence of cell death.
We have shown through extensive testing of multiple compounds on multiple cell
lines that the RBS may be a useful tool in the development and testing of cancer
therapeutics designed to induce caspase-independent PCD.

There was a consistent
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correlation between the RLuc8:fLuc ratio and levels of intracellular H2O2. Further, the
RLuc8:fLuc ratio was reduced in drug-treated cells when pretreated with allopurinol.
The trends reported here suggest that the RBS will likely perform well in a wide range of
PCD-inducing conditions.
8.1.5 The RBS detects programmed cell death in vivo
We have acquired evidence that the RBS is capable of detecting caspasedependent and caspase-independent PCD in multiple cell lines. Additionally it was
shown that the response level of the RBS was directly related to intracellular H2O2 levels.
To test the in vivo imaging capability of the RBS, a murine tumor model was employed.
Nude mice bearing RBS-HeLa tumors (n = 3 per group) were imaged at time 0
hours to obtain fLuc and RLuc8 bioluminescence images. Immediately following the
second imaging session, tumors were treated with either PBS or allopurinol as inhibitors
for one hour prior to PBS or STS administration. After 24 hours, the animals were
imaged again. The animals treated with PBS as an inhibitor and as a drug treatment
(PBS/PBS) exhibited little change in either RLuc8 or fLuc bioluminescence after 24
hours.

The group treated with PBS followed by STS (PBS/STS) retained RLuc8

bioluminescence after 24 hours, while fLuc bioluminescence diminished considerably.
When tumors were treated with allopurinol followed by PBS (Allo/PBS), the RLuc8
bioluminescence did not change and fLuc demonstrated a slight increase in
bioluminescence after 24 hours.

Finally, STS treatment following allopurinol

pretreatment (Allo/STS) conferred little change in RLuc8 bioluminescence and a slight
decrease in fLuc bioluminescence after 24 hours. Following bioluminescence image
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quantification, it was found that the RLuc8:fLuc ratio increased significantly (p<0.01) for
the PBS/STS group compared to the PBS/PBS control.

Additionally, the ratio

significantly decreased (p<0.05) for the Allo/STS group compared to the PBS/STS group.
These results indicated that the RBS was capable of detecting PCD in vivo.
After 24 hours, the tumors treated with Allo/STS exhibited an increase in fLuc
bioluminescence that was not observed with RLuc8. This could be attributed to the
elevated levels of H2O2 within the hypoxic cores of tumors (see (97) for review).
Intrinsically high levels of H2O2 levels within these tumors were likely reduced after 24
hours of allopurinol treatment, thus restoring fLuc bioluminescence.
In summary, we have shown that the RBS is capable of detecting PCD in vivo
through a murine tumor model. Using allopurinol as an inhibitor demonstrated that the
RBS is likely responsive to intracellular H2O2 levels. Together with previous in vitro
results, it is envisioned that the RBS will be a useful tool in research endeavors involving
caspase-dependent and caspase-independent cell death.

8.2 Future Directions
Intracellular H2O2 levels are generally accepted to lie in the nM-µM range,
depending on health status. However, the levels of exogenously applied H2O2 in our
studies were in the mM range. Thus, this concentration discrepancy should be further
examined. When we treated both RBS-HeLa cells and purified proteins with the HX-XO
reaction, we also observed that fLuc activity decreased significantly, while the RLuc8
activity remained stable. Interestingly, when the H2O2 concentration generated by this
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HX-XO reaction was measured using Amplex Red, it was found to be ~5 µM. The HXXO reaction generates H2O2 in a continuous manner, until the compounds are exhausted.
Conversely, the exogenously applied H2O2 could be degraded over time, which could
account for the mM levels of H2O2 used to activate the RBS. It has been shown that
exogenously applied H2O2 can decrease by ~67% after 20 minutes in fully supplemented
cell culture medium(98). To explore this further, additional studies could be performed
to more accurately quantify H2O2 levels as a function of time during both the HX-XO
reaction and acute H2O2 application on both cells and purified proteins.
The SDS-PAGE and bioluminescence assays performed on purified proteins
demonstrated that, when treated with H2O2, the fLuc protein exhibited activity loss at a
higher rate and to a greater extent than protein degradation. This suggests that the
oxidative modification of the fLuc protein may be primarily responsible for its activity
loss and that degradation only occurs at a later stage. This would be consistent with
current observations that oxidatively modified/damaged proteins are targeted for
proteasomal degradation(59, 60, 99). In order to further examine these processes, a
Western blot could be performed on PBS and STS-treated RBS-cells that were pretreated
with PBS or proteasome inhibitors. It would be expected that the inhibitor pretreated
STS-treated RBS-cells would exhibit higher fLuc protein levels even if cells under the
same treatment conditions exhibited low bioluminescence activity. These blots may also
reveal altered band staining accounting for damage/modification. The lysates from these
cells could also be subjected to a protein carbonylation assay to assess the levels of
carbonyl-derivative formation. Presumably, these proteins would be carbonylated, but
not degraded due to proteasome inhibition. To specifically investigate carbonylation
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levels of fLuc and RLuc8 in these cells, the carbonylation assay could be performed on
immunoprecipitated fLuc and RLuc8 proteins.
While many commercial assays for ROS are unable to be used in animal models
of disease, they often possess high in vitro sensitivity. To improve the sensitivity of the
RBS, additional luciferases (e.g. gaussia, cbRed, cbGreen) or randomly mutated fLuc
could be examined for their sensitivity to inactivation in stressed cells. It also may be
worthwhile to investigate fLuc variants that are engineered to be even less stable than
wild-type fLuc. For example, a fLuc variant containing a ‘PEST’ sequence from mouse
ornithine decarboxylase targets the protein for proteolytic degradation, effectively
reducing its half-life to less than 1 hour, compared to ~3.5 hours for wild-type fLuc(100).
The use of this fLuc variant in the RBS could result in a faster stress response given the
higher rate of protein turnover.
Intriguingly, the wild-type fLuc sequence from the popular pGL3 basic vector
(also used in this dissertation) was actually engineered to remove a peroxisomal targeting
sequence(101) (discovered to be the C-terminal sequence -Ser-Lys-Leu(102)). It was
thought the peroxisomal targeting of fLuc could interfere with normal cell functions,
contribute to its degradation and/or reduce cofactor availability. With the exception of
interfering with basic cellular processes, the remaining two consequences could prove to
be beneficial in the context of the RBS.
Additionally, many in vivo assays for PCD in regards to cancer therapeutic
development occur over many weeks. Thus if the wild-type fLuc of the RBS was
replaced with a slightly more stable variant of fLuc, the resulting sensor may prove to be
more useful in studies of this nature. We have shown that the fLuc variant, fLuc5,
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exhibits improved stability over wild-type fLuc, but not to the extent of RLuc8.
Although further testing is warranted, the combination of fLuc5 and RLuc8 could
improve upon the functional lifespan of the RBS.
Even though RLuc8 is 4 times brighter than native RLuc, its emitted wavelength
of light (480 nm) is greatly attenuated in animal tissue, resulting in low bioluminescence
signal measurements during in vivo imaging studies. The RBS sensor may be improved
by incorporating red-shifted luciferase variants.

Recently, a variant of RLuc8 was

developed, RLuc8.6, that exhibits a red-shifted bioluminescence compared to both wildtype RLuc and RLuc8(103). It is envisioned that this variant could be utilized in the RBS
in two ways. First, it could be combined with wild-type fLuc to create essentially a redshifted RBS, wherein the bioluminescence signals from fLuc and RLuc8.6 would be
distinguished by their different substrates, but the RLuc8.6 would likely exhibit less
signal attenuation in vivo. A second RBS variant could involve wild-type RLuc and
RLuc8.6.

In this case, emission filters would be absolutely required in order to

distinguish the bioluminescence signals from each enzyme as they catalyze the same
substrate,

coelenterazine.

However,

the

need

for

only

one

substrate

administration/imaging session could save considerable time, reagents and financial
resources.

8.3 Concluding remarks
This

body

of

work

involved

the

development,

characterization

and

implementation of an ROS-responsive Ratiometric Bioluminescent Sensor (RBS). It was
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hypothesized that the RBS could serve as a metric for intracellular stresses involved in
PCD, as many instances of PCD are associated with elevated levels of ROS. While the
exact mechanism behind the disparity in bioluminescence activity between RLuc8 and
fLuc has yet to be elucidated, we have shown that ROS, namely H2O2, play a significant
role. The RBS was implemented in various models of PCD, both in vitro and in vivo and
proved to be responsive in any instances of PCD that involved increased ROS levels. It
is envisioned that the RBS could prove to be quite useful in research endeavors
investigating PCD, and its related molecular processes (e.g. oxidative stress). Ultimately,
the RBS could have widespread impact in the development, evaluation and/or
improvement of therapeutics intended to combat many, often devastating pathologies
related to these molecular processes, such as cancer, Alzheimer’s disease, autoimmune
disorders, type-2 diabetes and AIDS.
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